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 Bcl-2 is best known for its ability to prevent the outer mitochondrial 
membrane permeabilization through interaction with pro-apoptotic family members 
leading to inhibition of apoptotic execution. Recently, an alternative paradigm has 
surfaced that describes Bcl-2 as a redox regulator, conferring survival advantage of 
cancer cells with Bcl-2 overexpression as compared to their normal counterparts. We 
have previously demonstrated that a mild but chronic elevation of intracellular O2.- 
levels induced by Bcl-2 overexpression in cancer cells would promote a pro-oxidant 
milieu rendering those cells resistant towards conventional anti-cancer 
chemotherapies, and a functional involvement of the small GTPase Rac1 was 
suggested. Here we confirmed that the elevated O2.- levels at mitochondria are indeed 
mediated through the activation of Rac1 induced by overexpression of Bcl-2 in 
chronic myeloid leukaemia cell line model. We also confirmed the existence of a 
physical interaction between Rac1 and Bcl-2 at the mitochondrial membranes 
corroborating our previous findings. A further characterization on the binding 
domains/residues identified five parameters critically required for the interaction, 
namely 1) the geranylgeranylation of Rac1; 2) the activation of Rac1; 3) the Switch 1 
effector loop region (in particular the residue 37) of Rac1; 4) the BH3 domain groove 
of Bcl-2; 5) the phosphorylation of the flexible loop region (in particular at the residue 
Ser70) of Bcl-2. In addition, the crosstalk between these parameters where Rac1 
activation could induce Bcl-2 phosphorylation at Ser70 through JNK and redox 
changes, suggests a possible positive feedback loop in enhancing the interaction levels 
in malignancies with oncogenic Bcl-2. Disruption of the interaction through either the 
pharmacological inhibitor of Rac1 or siRNA mediated silencing of Rac1 as well as 
the synthetic Bcl-2 BH3 domain peptides led to a remarkable decrease in O2.- levels 
x 
 
and sensitized the Bcl-2-overexpressing cancer cells to routine chemotherapeutic 
agents including etoposide, vincristine and daunorubicin in chronic myeloid 
leukaemia and cervical cancer models, indicating that this interaction is contributing 
towards Bcl-2-mediated pro-oxidant state and chemoresistance. Further assessment on 
the functional relevance of this interaction through computer simulation driven 
predictive experiments in collaboration with ™CELLWORKS Group Inc., confirmed 
the pro-oxidant and tumorigenic nature of Rac1-Bcl-2 pathway, corroborating our wet 
lab experimental data. Interestingly, the transcription factor, STAT3, was identified to 
positively correlate with the expression levels of Rac1 and Bcl-2. Subsequent 
preliminary wet lab experiments identified that STAT3 activation as marked by 
phosphorylation at Tyr705 could be induced by Bcl-2-overexpression, which was 
mediated through Rac1 activation and O2.- production, suggesting that STAT3 
activation could be a functional readout for Rac1-Bcl-2 interaction leading to 
transcription of downstream target genes involved in proliferation and survival. These 
novel findings in understanding the molecular basis for Bcl-2-induced pro-oxidant 
state has opened a new avenue for future therapeutic design to overcome Bcl-2-
mediated chemoresistance, through agents that either disrupt the interaction between 
Rac1 and Bcl-2 or target their downstream signal transducer STAT3. Indeed, the 
observations that the Rac1-Bcl-2 interaction was only observed in cancerous cells but 
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CHAPTER 1: INTRODUCTION 
 
1.1. Cancer 
1.1.1 Cancer Epidemiology: The No.1 Killer in Singapore 
Cancer, a group of heterogeneous diseases which result from unregulated 
expansion of cells, is one of the world’s leading causes for deaths. In Singapore, it is 
the No. 1 killer. Every day, 12 people die from cancer and 28 people are diagnosed 
with cancer; During 2005-2009, 49,412 incident cancers are diagnosed among the 
whole resident population; Eventually, 1 in 4 Singaporeans dies of cancer[1]. With 
such astonishing figures, it is no wonder that research studies aiming at understanding 
the heterogeneity of cancer at the cellular level, biochemical level, chromosomal level, 
and molecular level, hoping to find better treatments or even cures for cancer have 
been increasing exponentially over the past two decades[2-4].  
 
1.1.2 Carcinogenesis: Shifting the Equilibrium 
Human bodies are made up of billions of cells. Normal healthy cells grow and 
multiply at a steady controlled rate and their death is also highly regulated 
establishing equilibrium between cell proliferation and cell death. Despite the 
complexity of the various command and control pathways implicated in oncogenic 
transformation of cells with different origins, the common denominator in all forms of 
neoplasia is the dysregulated or defective ratio between cell proliferation and cell 
death[5]. Any disturbance of this ratio due to either enhanced proliferation signals or 
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defective death circuits would result in an abnormal accumulation of cells leading to 
carcinogenesis. 
 
1.1.3 Fighting Cancer: Hurdles and Hopes 
Conventional chemotherapies for cancer are usually limited to general 
cytotoxic or cytocidal pharmaceutical agents, which have evolved over half a century 
to be the major weapon against most forms of cancer[6], including alkaloids[7, 8], 
taxanes[9, 10], alkylating agents, antibiotics and antimetabolites[11-15], etc. 
Etoposide and vincristine are two forms of alkaloids, the former of which inhibits 
topoisomerase II and blocks replication of DNA leading to strand breaks[16], while 
the latter inhibits microtubule assembly and arrests mitosis in metaphase[17, 18]. 
Vincristine is commonly used in the management of acute lymphocytic and non-
lymphocytic leukaemias, Hodgkin’s and non-Hodgkin’s lymphomas, non-small cell 
lung cancer, Kaposi’s sarcoma and testicular cancer, while etoposide is more 
restricted to small cell lung cancer and testicular cancer[2].  Another example of drugs 
is daunorubicin, a member of the antibiotics group, which intercalates into DNA 
strands resulting in the failure of DNA replication and transcription[19]. However, 
one of the drawbacks for conventional chemotherapies is a lack of desirable 
selectivity. A majority of the existing compounds do not distinguish between cancer 
cells and their rapidly dividing normal counterparts resulting in severe side effects 
such as myelosuppression[20], haemorrhagic cystitis, acute and chronic 
cardiotoxicities, gastrointestinal mucositis, renal toxicity[2] and peripheral and central 
neuropathy[21]. In addition, drug resistance is also a problematic issue, especially 
when a single agent is used extensively over a sustained period of time[22], although 
this can be somewhat circumvented by the routine employment of a cocktail of 
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multiple drugs administered either simultaneously or sequentially in the clinic. The 
urgent need to develop novel therapeutic agents specifically catered for cancer cells, 
to be used either alone or in a combination strategy aiming at improved efficacy and 
reduced toxicity, has always been the stimulus behind research efforts. With our 
understanding of the genomic aberrations that underlie the malignant transformation 
of normal cells being greatly improved over the past 5 to 10 years[23], there has been 
a conceptual revolution in the therapeutic management of this disease. Bearing in 
mind the heterogeneity and complexity of the disease, a strategy that is aimed at 
targeting the critical circuit that is common and essential to all cancers irrespective of 
their origins and types would be a smart choice[2]. One common denominator, as we 
discussed in the previous section, is the dysregulated or defective ratio between cell 
proliferation and cell death. The intracellular milieu of cancer cells is non-conducive 
for efficient death signalling as compared to normal cells and one hypothesis that 
explains this difference in the process of oncogenic transformation and  has been 
supported by abundant evidence over the past couple of years, places the redox status 
of cancer cells in the centre of this picture[2, 24-32]. 
 
1.2. Role of Reactive Oxygen Species (ROS) in Carcinogenesis 
1.2.1 What is ROS? 
Reactive oxygen species or ROS in short, are a collective term referring to 
oxygen derived radicals, which contain one or more unpaired electrons, as well as 
non-radicals. Superoxide anion (O2.-), hydroxyl radical (.OH), peroxy radical and 
singlet oxygen are all examples of free oxygen radicals while hydrogen peroxide 
(H2O2) belongs to the category of non-radicals. 
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1.2.2 Where is ROS Generated? 
There are many sources of ROS within a cell, which can be broadly 
categorized into two types: 1) those biological processes that release ROS as by-
products or waste products along with essential biochemical reactions[33]; 2) those 
that intentionally produce ROS as part of a cell defense mechanism or a signal 




An example from the first category is the mitochondria, which are among the 
major intracellular sources of ROS production since about 1-3% of the oxygen 
consumed by the respiratory chain can be converted to ROS in isolated 
mitochondria[34]. Partial reduction of molecular oxygen by the unpaired electrons 
that are generated in the process of oxidative phosphorylation leads to the production 
of O2.- which is readily converted to H2O2 by magnesium superoxide dismutase 
(MnSOD) residing in the mitochondria matrix. H2O2 can be converted subsequently to 
the highly reactive oxygen species .OH, through the iron-dependent Fenton 
reaction[35]. .OH is the most reactive among the three species and is the cause for 
most of the oxidative damage[36]. In addition, O2.- will react with another freely 
membrane diffusible radical .NO to form the much more reactive radical species 
peroxynitrite (ONOO-). Due to its ability to diffuse across the mitochondrial 
membranes, ONOO- can result in oxidative damage of critical components throughout 
the mitochondria via oxidation, nitration and/or nitrosation. The oxidants derived 
from .NO are collectively named as reactive nitrogen species (RNS)[37], and the 
detailed description of each species are beyond the scope of this thesis. 
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 Although it is well known that ROS can be generated as by-products of 
oxidative phosphorylation, the question as to the specific site(s) along the electron 
transport chain (ETC) responsible for ROS generation has always been a hotly 
debated topic. It is traditionally believed that under physiological conditions, 
Complex I (NADH dehydrogenase) is the main site for mitochondrial ROS 
production, where O2.- is produced on the matrix side and rapidly dismutated to 
H2O2[38, 39]. In addition, Complex III (ubiquinol cytochrome c reductase) has also 
been reported as a site for O2.- production[40, 41]. It is demonstrated that under 
ischemic and apoptotic conditions, O2.- production is triggered at Complex III. This 
may happen through inhibition of Complex IV (cytochrome c oxidase or COX) as 
well as over-reduction of the ETC in the event of mounting hypoxic stress[42]. In a 
more recent review, the relative contribution of each complex towards O2.- production 
has been clearly quantitated with Complex I and Complex III (producing O2.- to both 
the matrix and intermembrane space) having the greatest maximum capacities while 
Complex II having normally negligible rates[43]. 
 
 Apart from the ETC, several other sites in the mitochondria have also been 
reported to generate O2.-, including pyruvate dehydrogenase, α-ketaglutarate 
dehydrogenase, glycerol-3-phosphate dehydrogenase[44] and fatty acid β-
oxidation[43]. Recently, new findings that support the concept of mitochondrial O2.- 
flashes have gained much interest and reveal several previously unknown aspects of 
mitochondrial dynamics. Transient quantal O2.- flashes were observed in excitable 
cells such as muscle cells and neurons in vivo and they were associated with 
mitochondrial permeability transition pore (mPTP) opening, which presents a new 
facet in physiological ROS production[45, 46]. 
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1.2.2.2 NADPH oxidase 
The NADPH oxidase (Nox) family proteins belong to the second category, 
which intentionally produce ROS as part of a cell defense mechanism or a signal 
transduction pathway. They are membrane-associated, multi-unit enzyme complexes 
catalysing the electron transfer from NADPH to molecular oxygen, generating O2.- 
and H2O2. The phagocytic isoform Nox2 (gp91phox where phox stands for 
phagocytic oxidase), being the one that is firstly identified in the family, robustly 
produce O2.- as a defense mechanism in the face of pathogen infection and the O2.- is 
converted by superoxide dismutase (SOD) and myeloperoxidase into hypochlorous 
acid (HOCl) that acts as a potent microbicide. The whole process is known as the 
phagocytic respiratory burst. Over the past decade, other Nox isoforms have also been 
characterized in many other cell types although the ROS production is to a lesser 
extent, which include Nox1[47, 48], Nox3[49, 50], Nox4[51-53], Nox5[54, 55] and 
Duox1/Duox2[56-58] apart from Nox2[59, 60]. Various stimuli (including 
angiotensin II, thrombin, platelet-derived growth factor and transforming growth 
factor β) are known to alter the activity or expression levels of Nox proteins and their 
subunits, ultimately influencing the amount of ROS generated. Of particular note is 
the requirement of the small GTPase Rac in a GTP-bound form for Nox1, Nox2 and 
Nox3 activation while Nox4 is constitutively active when associated with the 
cytosolic p22phox subunit[59]. Similar to the role of Nox2 in phagocytes, Nox1 and 
Duox1/Duox2 have also been implicated in the host defense of the colon and the lung, 
respectively[61]. Apart from host defense mechanisms, Nox family proteins are 
largely involved in signal transduction pathways as well. Nox-derived O2.- and H2O2 
can specifically and reversibly react with proteins, altering parameters such as enzyme 
activity, subcellular localization and half-life. Although the ROS species produced by 
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different Nox isoforms are the same (either O2.- or H2O2), they often play distinct roles 
partly due to the different compartmentalization of different isoforms within the cell. 
For example, Nox2 is found in phagosomes and on the leading edge of lamellipodia 
as well as in redoxisomes of nonphagocytic cells[62-64] while Nox4 has been 
identified in the nucleus[65], the endoplasmic reticulum (ER) [66], the 
mitochondria[67-70] as well as focal adhesions[71], therefore interacting with distinct 
kinases, phosphatases and transcription factors involved in discrete signalling 
pathways. 
 
The relative quantitative contribution of mitochondria and Nox family proteins 
in cellular ROS production is expected to vary greatly from one cell type to another. 
In certain cells including the phagocytic neutrophils as well as non-phagocytic 
fibroblasts, vascular smooth muscle cells and endothelial cells, cellular ROS 
production is largely contributed by NADPH oxidases[43, 72, 73].  
 
1.2.3 How is ROS Regulated: Their Scavenger System 
Since there are a number of intracellular sources of ROS production, it is not 
surprising that the cells are well equipped with a myriad of antioxidant defence 
systems to keep the levels of ROS in check. In the mitochondria alone, there are 
SODs and two major antioxidant systems: the thioredoxin (TRX) system and the 
glutaredoxin (GRX) system, where the former include TRX, NADPH, TRX reductase 
(TrxR), TRX-dependent TRX peroxidase and peroxiredoxin (PRX) while the latter 
include GRX, NADPH, glutathione (GSH), glutathione reductase (GR), and GRX-
dependent glutathione peroxidase (GPX)[74-76]. Unlike H2O2, O2.- does not diffuse 
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that readily across the membrane and thus for O2.- produced in the mitochondria 
matrix, the activity of MnSOD is critical to prevent the mitochondrial matrix 
components from oxidative damage. In certain cell types, the other isoform of the 
superoxide dismutase Cu/ZnSOD is also present in the mitochondrial intermembrane 
space apart from its cytosolic residence[77, 78]. The dismutated product H2O2 can be 
either further metabolized by mitochondria isoforms of both the TRX and GRX 
systems including Trx-2, Grx-2a, Grx-5, Prx III/V and GPX4[76] or diffuse into 
cytosol where it can be combatted by the cytosolic antioxidant defense machinery. 
  
 Although excessive levels of ROS will lead to protein oxidation, lipid 
peroxidation and DNA damage, lower levels of ROS have been demonstrated to be 
essential signalling molecules[35, 79, 80]. Indeed, the intracellular redox milieu has a 
great impact on signal transduction and gene expression and over the past decade, 
more and more evidences are surfacing to suggest that mild oxidative stress is a 
contributing factor to carcinogenesis[27, 29, 31, 81]. 
 
1.2.4 Pro-oxidant Theory of Carcinogenesis 
In a variety of cell types, exposure to low concentrations of ROS, in particular 
O2.- and H2O2, triggers growth response by stimulating the activation of early growth 
related genes such as c-fos and c-jun[82-84]. The mitogenic activity of ROS comes 
from their ability to alter the activities of a plethora of intracellular signalling targets: 
activation of transcription factors, oxidative inhibition of phosphatases and 
modulation of protein kinases[85], which all in turn switch on the downstream  
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effectors for proliferation. Examples of redox regulated targets include the 
transcription factors NF-κB and AP-1, tyrosine kinases such as Janus kinase 2 (JAK2) 
and tyrosine kinase 2 (TYK2)[86, 87], c-Jun N-terminal kinases (JNKs), p38 mitogen-
activated protein kinases (MAPKs), phosphatidylinositol 3-kinases (PI3Ks)[88], low 
molecular weight-protein tyrosine phosphatase (LMW-PTP)[89] and the list goes 
on[90]. The underlying molecular mechanisms for ROS-induced signalling vary from 
target to target. For example, NF-κB activation is achieved either by enhanced 
phosphorylation of IκBα through oxidation or enhanced proteasome-mediated IκB 
degradation[91, 92]. Inactivation of protein tyrosine phosphatases is achieved through 
oxidation of their cysteine residues by ROS which renders them unable to counteract 
the activity of protein tyrosine kinases[93] and results in constant autophosphorylation 
and activation of the cell-surface receptors such as EGFR (epidermal growth factor 
receptor) upon ligand induction[94]. Enhanced membrane recruitment of PI3K to the 
substrate site is achieved through tyrosine phosphorylation of its catalytic subunit by 
H2O2 therefore maximizing its catalytic efficiency enhancing the downstream 
activation of AKT[88]. In addition to all the targets mentioned above, ROS has also 
been demonstrated to positively regulate the activity of a number of ion channels[84, 
85], in particular Na+/H+ exchanger (NHE) which has been shown to influence cell 
division through the maintenance of an alkaline intracellular milieu[95]. Further 
evidences to support the notion of ROS being proliferative signals come from the 
observations that in certain systems, addition of ROS scavengers such as SOD or 





Low levels of ROS not only serve as mitogenic signals during normal cellular 
growth and proliferation but also during tumour transformation and progression. The 
earliest observations that link ROS and carcinogenesis were reviewed in 1985 where 
increased concentrations of ROS were observed to cause chromosomal damage and 
promote initiated cells to neoplastic growth in a number of hereditary disorders[96]. It 
is now well known that a number of cancers exhibit a chronic pro-oxidant intracellular 
milieu through either constitutive ROS production in substantial amounts or defective 
antioxidant systems, favouring proliferation and survival as compared to their normal 
counterparts[82, 83], suggesting a causal relationship between pro-oxidant state and 
carcinogenesis. Indeed, NIH3T3 fibroblasts with Nox1 overexpression and enhanced 
O2.-  generation exhibited transformed appearance, anchorage-independent growth and 
were able to induce tumours in athymic mice providing direct evidence for the 
hypothesis[47]. Studies in prostate cancers also revealed that ROS generation through 
the NADPH oxidase system is critical for the migratory/invasive phenotypes observed. 
Blocking of ROS production reversed cell invasion and increased cell death[97]. In 
addition, the expression of an important antioxidant enzyme in the mitochondria, 
MnSOD, has been shown to be down-regulated in a variety of cancer cells, thus 
creating a constitutive pro-oxidant milieu. The reduction in the MnSOD levels has 
been demonstrated to enhance the invasiveness of these cells, while reintroduction of 
MnSOD resulted in a suppression of the malignant phenotypes and favouring of 
differentiation[98-102]. Further evidence that supports the hypothesis that pro-oxidant 
cellular status contributes to cancer progression comes from the observation that colon 
carcinomas showed much greater levels of oxidative damage than colon adenomas 
and that addition of the antioxidant N-acetylcysteine dramatically impaired the 
proliferative capacity of the former. 
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As mentioned in section 1.1.2, carcinogenesis results from the shift in the 
equilibrium between cell proliferation and cell death. It has been recognized that pro-
oxidant state also impairs death signalling pathways while on the contrary, a reduced 
intracellular milieu facilitate the execution in tumours[24, 47, 103-110]. Two 
members of the ROS family that are particularly important in this picture and will be 
the focus of the following section are O2.- and H2O2. 
 
1.2.5 Onco-ROS vs. Onco-suppressor-ROS 
Although the prevailing opinions had been that ROS participate in the 
apoptotic induction and invariably accompany the death execution, more and more 
pieces of evidence are surfacing to demonstrate that the exact regulatory roles ROS 
play in cell fate determination depend very much on the concentrations or rather the 
ratio of respective species involved. It is understood that there are a number of 
different cell death mechanisms described in the literature such as necrosis, apoptosis, 
necroptosis, autophagy and most recently ferroptosis[111]. However, detailed 
discussion on the roles of ROS in other forms of death is beyond the scope of this 
thesis and apoptosis will be placed as the prime focus here. 
 
Recent findings from our own laboratory as well as other groups demonstrated 
that a mild increase in the intracellular ROS levels resulted in an inhibition of the 
apoptotic pathways in cancer cells, irrespective of the triggers[28, 103-105, 107, 110, 
112-114]. A closer look at the actual species of ROS led to the identification of O2.- 
being the culprit. The first observation on the death inhibitory role of O2.- was made in 
a FAS-mediated apoptotic model in human melanoma cells[104]. Subsequently it was 
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shown by our group that in the absence of cytotoxic amount of H2O2 production, an 
increase in the intracellular O2.- levels resulted in an inhibition rather than an 
activation of apoptosis, as opposed to what has been conventionally perceived, while 
overexpression of the cytosolic O2.- scavenger Cu/ZnSOD reversed the death 
inhibitory effect sensitizing the human melanoma M14 cells to chemotherapeutic 
agents including etoposide and daunorubicin. Inhibition of one major intracellular 
source of O2.-, NADPH oxidase, also resulted in a significant increase in the 
sensitivity to drug-induced apoptosis[104, 107]. Similar observations were made by 
another group showing that elevated levels of intracellular O2.- functioned as a pro-
survival signal and that death execution could be facilitated by decreasing O2.- in a 
virus-induced apoptotic model[115]. 
 
Interestingly, on the contrary, another ROS species, H2O2, seems to function 
as a death facilitator in certain systems. Although lower doses of H2O2, similar to 
what O2.- does, could activate mitogenic signalling as discussed in the previous 
section, slightly elevated levels of H2O2 (lower than the 500 μM threshold that could 
result in necrosis) lead to a decrease in O2.- levels, an increase in reduced GSH to 
oxidized GSSG ratio, a marked drop in intracellular pH, thus creating a reduced 
intracellular milieu favouring apoptotic execution[28, 105].  
 
The underlying molecular mechanisms that govern the opposing effects of 
these two ROS species can be attributed to two main aspects: 1) the activity of 
caspases, the mediators and executioners of apoptosis; 2) intracellular pH. Firstly, the 
catalytic domain common to the caspase family (QARCG) has a thiol-containing 
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cysteine residue that is susceptible to oxidative inhibition in an oxidative intracellular 
milieu[116-119]. Increased levels of O2.- significantly suppressed the activity of 
caspase 3 and a decrease in O2.- restored the activity[107]. On the other hand, H2O2 
has been demonstrated to directly activate caspase 3 and 9[120]. Secondly, O2.- 
production via the NADPH oxidase system results in the oxidation of NADPH to 
NADP+ and the extrusion of H+ leading to an increase in the intracellular pH[85]. In 
addition, it has also been shown that increased levels of O2.- could induce the 
promoter activity of the Na+/H+ exchanger 1 (NHE-1) gene resulting in an alkaline 
pH[121]. On the contrary, H2O2 has been shown to inhibit the NHE-1 promoter 
activity and gene expression resulting in an acidic milieu[121, 122].The cytosolic 
acidification in turn leads to the mitochondrial recruitment of Bax, the pro-apoptotic 
member of the Bcl-2 family for apoptotic induction[25]. 
 
The ratio between these two ROS species, O2.- and H2O2, is therefore critical 
in cell fate determination. Under homeostatic growth condition, the intracellular ratio 
between these two is in a tight control by antioxidant systems to keep a balance 
between cell proliferation and cell death. However, in many cancer cells, this balance 
is tilted in favour of O2.- creating a pro-oxidant intracellular milieu that promotes cell 
proliferation as well as survival indirectly through inhibition of apoptosis, which are 
two hallmarks for cancer. On the contrary, when the ratio tilts in favour of H2O2, this 
creates a reductive milieu that is permissive for death execution. As such, we term O2.- 
as Onco-ROS and H2O2 as Onco-suppressor-ROS[123]. In this regard, manipulating 
the cellular redox status would serve as a promising strategy for enhancing the 
sensitivity of cancer cells to conventional chemotherapeutic drugs. Over the past 
decade, our group, with the impetus of identifying the druggable intracellular targets 
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responsible for redox regulation, have been working intensively on this subject and 
one of the novel targets that we have discovered is the anti-apoptotic protein Bcl-2. 
 
1.3. Role of Bcl-2 Family in Carcinogenesis 
1.3.1 Bcl-2 in the Conventional Picture: Guardians for Mitochondrial Membrane 
Integrity 
1.3.1.1 Bcl-2 portrait: Discovery, structure and localization 
Bcl-2 is the acronym for the B-cell lymphoma/leukaemia 2 gene. As its name 
implies, this gene was first discovered in B-cell malignancies[124] where the Bcl-2 
gene, normally localized to chromosome 18q21, was fused with the immunoglobin 
heavy chain gene promoter and enhancer on chromosome 14q32 [t(14,18) 
chromosomal breakpoint], thereby its transcription gets excessively deregulated 
inducing aberrant overexpression[125]. This observation was associated with drug 
resistance due to the inherent pro-survival function of Bcl-2 through its ability to keep 
pro-apoptotic proteins at bay and thereby inhibiting mitochondria-dependent apoptotic 
signalling[126]. 
 
 Structurally, Bcl-2 possesses four Bcl-2 homology (BH) domains as well as a 
carboxyl terminal hydrophobic transmembrane domain (TM), which is responsible for 
its membrane localization. With the use of immunofluorescence and electron 
microscopic analyses as well as subcellular fractionation studies, Bcl-2 has been 
identified in the nuclear envelope, ER, and outer mitochondrial membranes[127]. The 
three-dimensional structure of Bcl-2 contains two central helices that are mostly 
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hydrophobic, surrounded by four amphipathic α-helices. A hydrophobic groove that 
consists of BH1, BH2 and BH3 domains is present on the surface of the protein and is 
essential in its heterodimerization with pro-apoptotic family members[128]. In 
addition, a putative unstructured loop is also present in Bcl-2 between the first and 
second helix based on X-ray crystallographic and nuclear magnetic resonance (NMR) 
spectroscopic studies on Bcl-xL[129], another anti-apoptotic member of the Bcl-2 
family, offering ample opportunities for post-translational modifications[130-134]. 
 
1.3.1.2 Bcl-2 and its pro- and anti-apoptotic family members 
Bcl-2 belongs to the Bcl-2 family of proteins, which can be classified into 
three sub-groups according to the BH domains that they possess and their regulatory 
functions on apoptosis. Members that contain all four BH domains (BH1, BH2, BH3 
and BH4), which include Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and A1, are classified under 
anti-apoptotic or pro-survival category[123]. Overexpression of each of these 
members has protective effects against apoptosis, while genetic knocking down of 
them shows that they are essential for cell survival. Members that contain BH1, BH2 
and BH3 domains but not BH4 domain such as Bax, Bak and Bok are classified under 
pro-apoptotic category. Bax and Bak are ubiquitously expressed in various tissues 
while Bok is mainly present in reproductive organs. There is a third divergent class of 
pro-apoptotic members which only share sequence homology in the BH3 domain. 
These proteins are called BH3-only proteins, which consist of Bad, Bid, Bim, Bmf, 




Being regulators of apoptosis, the balance between the pro- and anti-apoptotic 
members of the Bcl-2 family clearly governs the yes or no answer in the death 
execution pathways, as their name implies. In response to stress signals, such as 
exposure to radiation, hypoxia, deprivation of nutrients, heat shock, viral infection 
and DNA damage, the pro-apoptotic members are activated, resulting in their 
localization to the mitochondria where they form oligomers and induce mitochondrial 
outer membrane permeabilization (MOMP), thereby facilitating the release of 
apoptogenic factors such as cytochrome C, Smac/DIABLO and apoptosis-inducing 
factor (AIF) from the mitochondria, activating downstream effector caspases. This is 
the classical type II or the intrinsic pathway of apoptosis, a genetically programmed 
process with an orchestrated series of events leading to the death of a cell in the end. 
However, in the event where the anti-apoptotic proteins are overexpressed, which is 
invariably observed in drug-resistant cancers, they can antagonize the effect of pro-
apoptotic Bax, Bak and/or Bok by forming homo- and heterodimers and preventing 
oligomerization of these pro-apoptotic members[137]. The BH3-only proteins, on the 
other hand, can act as either antagonists of anti-apoptotic members or direct activators 
of pro-apoptotic members.  
 
The first elucidation of the three dimensional (3D) structure of human Bcl-xL 
revealed that it is reminiscent of pore forming proteins[129] and subsequently other 
members in the family such as Bcl-2 and Bax as well as Bcl-xL itself are all found to 
be capable of forming pores in artificial membranes[138-140].  It was not until 2001 
that the 3D structure of Bcl-2 was resolved with its unstructured loop region being 
replaced by that of Bcl-xL. Although they share a similar overall helical fold and 
function, they differ in the highly flexible unstructured loop region, which contributed 
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to the different solubilities of these two proteins[128]. Another key structural 
difference lies in the amino acid residues and the size of the hydrophobic groove 
formed by the BH1, BH2 and BH3 domain, which is the important interaction site 
with pro-apoptotic members such as Bax and Bak[141] and this probably explains the 
different binding affinities observed between Bcl-2 and Bcl-xL towards them. The 
BH3 domain is critical in the functions of the Bcl-2 family proteins, because not only 
is this domain of Bcl-2 responsible for interacting with and antagonizing the pro-
apoptotic members but also is the domain used by the pro-apoptotic Bax and Bak to 
antagonize Bcl-2 mediated protection against apoptosis. Deletion of this domain from 
Bax and Bak results in impairment of their pro-apoptotic property and binding 
towards Bcl-2 and Bcl-xL while transfection of this domain alone can lead to 
apoptosis acting similarly to BH3-only proteins. 
 
A few mechanistic models have been proposed as in how exactly the pro- and 
anti-apoptotic Bcl-2 family proteins regulate MOMP. The pro-apoptotic Bax and Bak 
are capable of forming pore-like channels upon oligomerization[142] or alternatively 
they are also able to regulate the adenine nucleotide translocase (ANT)[143] and 
voltage-dependent anion channel (VDAC) causing the former to open and the latter to 
close resulting in matrix swelling and outer mitochondrial membrane disruption[144]. 
The anti-apoptotic Bcl-2 and Bcl-xL, on the other hand, in addition to their ability to 
bind and sequester the pro-apoptotic members, have been shown to directly interact 
with VDAC1[145] or alternatively function as an ionophore dissipating the electrical 
transmembrane potential[146], both of which prevent the closure of this channel and 
maintaining the exchange of ATP/ADP therefore inhibiting the hyperpolarisation, 
swelling and rupture of the mitochondria[147, 148].  
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As to the third class of the Bcl-2 family, the BH3-only proteins, they act 
upstream of the pro-apoptotic Bax and Bak since they cannot induce cell death in 
Bax-/-Bak-/- double knockout mice[149]. They function as sensors or mediators of 
apoptosis and different individual BH3-only protein responds to different stimuli. For 
example, PUMA and Noxa can be transcriptionally induced by p53 upon sensing 
DNA damage[150, 151]. Another BH3-only protein Bad is regulated through 
phosphorylation/dephosphorylation. Upon cytokine withdrawal, Bad is 
dephosphorylated and released from the sequestration by the scaffold protein 14-3-3. 
It can then bind and neutralize Bcl-2, Bcl-xL and Bcl-w and activates Bax and 
Bak[152]. Similarly, Bim and Bmf are also kept in sequestration by cytoskeleton 
proteins without stimuli[153, 154]. The proposed mechanisms of action for the BH3-
only proteins can be classified into: 1) Direct activation model; 2) Indirect activation 
model. Bim and tBid (the truncated form of Bid cleaved by caspase 8 upon apoptotic 
stimuli), which directly activate Bax and Bak, can be classified into the first category. 
Apart from these two direct activators, Bad and Bmf are also classified under the first 
category and they are called sensitizers since they bind to and displace the sequestered 
Bim and tBid from pro-survival Bcl-2, Bcl-xL and Bcl-w leading to activation of Bax 
and Bak[155, 156]. However, recent evidences have challenged this model and 
suggest that this needs not to be a necessary physiological event since Bax is not able 
to bind Bim or Bid in physiological conditions[157] and also Noxa and Bad BH3 
peptides have been found to induce apoptosis even in the absence of Bim, Bid and 
PUMA[158]. In the indirect activation model, it is suggested that all BH3-only 
proteins will bind to pro-survival members thus indirectly liberating Bax or Bak from 
their sequestration, promoting their homo-oligomerization. However, BH3-only 
proteins are selective in their pairing with pro-survival members. Bim and PUMA 
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have been shown to be able to bind Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and A1, while Bad 
and Bmf bind to Bcl-2, Bcl-xL and Bcl-w as mentioned above, and Noxa binds only 
Mcl-1 and A1[159].  
 
1.3.1.3 Post-translational modifications of Bcl-2 and their implications on apoptosis 
Bcl-2 is frequently regulated through post-translational modifications 
including proteolytic cleavage, ubiquitination, proteosomal degradation and in 
particular phosphorylation through its interaction with kinases and phosphatases. 
These modifications alter its folding and conformation, stability and half-life, 
subcellular localization, protein-protein interactions as well as activity[160, 161]. In 
this section, phosphorylation/dephosphorylation will be the prime focus. As 
mentioned in earlier section, Bcl-2 possesses a non-structured loop that lies in-
between its BH3 and BH4 domains and certain residues within that flexible loop, to 
be specific Thr56, Thr69, Thr74, Ser70 as well as Ser87, are subjective to 
phosphorylation in response to a variety of stimuli. The significance of Bcl-2 
phosphorylation on its anti-apoptotic activity is controversial, depending very much 
on 1) the extent of phosphorylation: single site or multi-site phosphorylation; 2) the 
exact subcellular localization where the phosphorylation takes place[131, 162, 163]. 
 
There are two opposing models of Bcl-2 phosphorylation initially proposed: 
“Taxol-induced” model and “Interleukin-3 (IL-3)-induced” model. In the first model, 
microtubule-active drugs including Vinca alkaloids and paclitaxel (Taxol) that lead to 
mitotic arrest[164] are found to induce Bcl-2 phosphorylation and inhibit its anti-
apoptotic function[165-167]. However, phosphorylation of Bcl-2 and initiation of the 
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apoptotic program are only observed following drug treatment in the cycling cancer 
cells but not in Bcl-2-overexpressing chronic lymphocytic leukaemia cells that are 
blocked at G0-G1 phase[168] indicating the significance of cellular context (mitotic 
cells or interphase cells). In addition, Bcl-2 phosphorylation is also observed in 
normal mitosis therefore it probably functions as a guardian of chromosome 
segregation[167-170]. On the contrary, in the “IL-3-induced” model, Bcl-2 
phosphorylation leads to an enhancement of its anti-apoptotic function in IL-3-
depedent hematopoietic cell lines. It might seem to be a paradox at first glance; 
however, a closer examination on the specific residues in the loop region being 
phosphorylated revealed that multi-site phosphorylation (including Thr69, Ser70 and 
Ser87) occurs in the “Taxol-induced” model[171] while only single site 
phosphorylation on Ser70 accounts for the “IL-3-induced” model[172, 173]. Indeed, a 
non-phosphorylatable mutant of Bcl-2, S70A, has been shown to be unable to support 
prolonged cell survival whereas the mutant S70E that mimics a phosphate group by 
having the negative charge suppressed apoptosis much more potently than the wild 
type Bcl-2[172]. Taken together, this indicates that single site phosphorylation on 
Ser70 enhances Bcl-2’s anti-apoptotic function while multi-site phosphorylation on 
Thr69, Ser70 and Ser87 leads to inactivation of Bcl-2. However, a study based on a 
series of serine/threonine (S/T) to glutamate/alanine (E/A) mutants, that mimic or 
abrogate either single site or multi-site phosphorylation, clearly demonstrated that all 
of the phosphomimetic E mutants potently enhanced cell survival upon apoptotic 
stress induced by paclitaxel and retarded G1/S cell cycle transition after IL-3 addition 
or treatment with paclitaxel in the presence of IL-3 with the T69E/S70E/S87E (EEE) 
triple mutant being the most potent as compared to non-phosphorylatable A mutants 
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stressing the importance of cellular context when deciphering the functions of Bcl-2 
phosphorylation[174]. 
 
Multiple kinases have been implicated in phosphorylating Bcl-2, including 
cyclin-dependent kinase 1 (CDK1)[175], JNK[171, 176], mTOR[177], PKA[178] and 
Raf-1[167] in “Taxol-induced” model and MEK/MAPK kinase, extracellular signal-
regulated kinase (ERK)/MAPK[179] and protein kinase C (PKC)[172, 173, 180, 181] 
in “IL-3-induced” model. In addition to these two models, mitochondria PKCα is also 
implicated in other studies to be responsible for phosphorylating Bcl-2 at Ser70 and 
enhances its anti-apoptotic activity in drug-treated myeloid cells[180-182]. 
Interestingly, JNK is repeatedly indicated by various groups as a Bcl-2 kinase and has 
been shown to phosphorylate four sites within the flexible loop region including 
Ser70 that is common to both models (the rest three residues would be Thr56, Thr74 
and Ser87)[171, 176, 183-185]. Since so many kinases are implicated, it is very likely 
that there are certain levels of redundancy and their activation would depend on 
specific cellular context. As always emphasized, phosphorylation event is determined 
not only by kinases but also by phosphatases and sometimes it is the inhibition of 
phosphatases, as what happens during mitotic arrest, that results in the increased 
phosphorylation and kinases are not necessarily activated[162]. Indeed the 
serine/threonine phosphatase, protein phosphatase 2A (PP2A), has been shown to 





Clearly, apart from the residue site of phosphorylation, the role of 
phosphorylated Bcl-2 also differs in different subcellular localizations. 
Phosphorylated Bcl-2 is found to be localized to nuclear structures during mitosis[169] 
while in mitotic arrested cells following paclitaxel treatment it is the mitochondrial 
Bcl-2 that is phosphorylated by JNK[190]. PKCα-induced Bcl-2 phosphorylation on 
Ser70 that enhances its anti-apoptotic activity and PP2A-induced dephosphorylation 
of Bcl-2 that inhibits its activity are also at the mitochondria. Interestingly in one 
study on the “IL-3-induced” model a minor but distinct cytosolic pool rather than the 
more predominant mitochondrial pool of Bcl-2 is phosphorylated[191]. In addition, 
multi-site phosphorylation of Bcl-2 in the ER renders it unable to bind to pro-
apoptotic BH3-only proteins and inhibits its protective role against Ca2+-dependent 
death stimuli[130]. 
 
1.3.1.4 Bcl-2 and its interaction network with non-homologous proteins: Modulation 
of its anti-apoptotic function 
We have discussed in the earlier section for the interaction of Bcl-2 with its 
homologous family members in the mitochondria. In fact, there is a whole list of other 
non-homologous proteins that also interact with Bcl-2 in a wider variety of cellular 
pathways modulating its anti-apoptotic property and a few examples from the 
overwhelming list would be illustrated here in this section including Ras, Raf-1, 




1.3.1.4.1 Interaction to synergise Bcl-2’s anti-apoptotic property: Ras, Raf-1 
and FKBP38 
Ras -- The oncogene Ras, whose mutation has been witnessed in 30% of 
cancers, is well known to interact with Bcl-2[192]. The mutagenic Ras will activate 
survival pathways in the cancer cells; however under certain conditions, Ras can also 
trigger apoptosis[193]. In lymphocytes, activated Ras can trigger Fas mediated 
apoptosis and when Bcl-2 is overexpressed, this form of apoptosis is inhibited through 
the association of the BH4 domain of Bcl-2 with mitochondrial Ras. The CAAX motif 
required for farnesylation at the C-terminus of Ras is demonstrated to be essential for 
its apoptotic signalling and Bcl-2 association[194]. 
 
Raf-1 – Raf-1, a signal transducing serine/threonine kinase in the Ras pathway, 
has been shown to interact with Bcl-2 as well leading to apoptotic inhibition[195]. 
Upon phosphorylation by p21-activated kinase 1 (PAK1), Raf-1 is targeted to the 
mitochondria through its interaction with the BH4 domain of Bcl-2. Mitochondrial 
Raf-1 then phosphorylates Bad and releases Bcl-2 from Bad-Bcl-2 complex, 
promoting cell survival[196]. 
 
FKBP38 – Another protein that is known to regulate Bcl-2’s anti-apoptotic 
function is the immunosuppressant FK-506 binding protein 38 (FKBP38). Once 
bound to calcium and calmodulin, FKBP38 becomes active and chaperones Bcl-2 to 
the mitochondria, where it probably interferes with Bcl-2’s ability to bind to its targets 
by physically interacting with the BH2 domain as well as the loop region of Bcl-2. As 
discussed in the previous section on post-translational modifications, the loop region 
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of Bcl-2 offers ample opportunities for phosphorylation whose status is critically 
linked to its anti-apoptotic property. Indeed, from deletional mutant analysis, sites in 
the flexible loop region of Bcl-2 that contain or surround Ser70 and Ser87 appear to 
be critical for the physical interaction with FKBP38 where phosphorylated Bcl-2 
showed a significant reduction in its binding affinity towards FKBP38. Therefore 
FKBP38 is likely to play a role in regulating apoptosis through modulating the 
phosphorylation status of Bcl-2 although there are controversies in whether it exerts 
pro- or anti-apoptotic functions[197-199]. 
 
1.3.1.4.2 Interaction to abrogate Bcl-2’s anti-apoptotic property: p53, PP2A 
and Nur77 
P53 – The tumour suppressor activity of p53 is primarily explained by its 
ability to induce cell cycle arrest, repair of the genome and apoptosis under genotoxic 
stress through its transcriptional activities. Apart from that, a non-transcriptional 
mechanism of p53 induced apoptosis was also elucidated. Studies showed that p53 is 
able to localize to mitochondria upon DNA damage in cancer cells and directly bind 
to Bcl-2 thus displacing bound Bax and inducing MOMP and cytochrome c 
release[200]. In addition, upon binding to p53, a conformational change of Bcl-2 
occurs and the BH3 domain is exposed correlating with the abrogation of its anti-
apoptotic property[201]. Both a negative and a positive regulatory region exist at the 
flexible loop of Bcl-2 where deletion of the negative regulatory region (amino acid 
residues 32-68) disrupted the interaction with p53 enhancing Bcl-2’s anti-apoptotic 
property. On the contrary, the multi-site phosphorylation on Thr69, Ser70 and Ser87, 
as mimicked by the triple mutant T69E/S70E/S87E (EEE), at the positive regulatory 
region (amino acid residues 69-87) resulted in reduced interaction levels.  
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PP2A– The serine/threonine phosphatase, PP2A, as mentioned earlier, has 
been shown to dephosphorylate Bcl-2 on Ser70 leading to an increase in apoptotic cell 
death[186-189]. It has been demonstrated that it is the BH4 domain of Bcl-2 that 
PP2A directly binds to and utilizes as a docking site to potentially reach out to the 
target residue Ser70 located at the adjacent flexible loop region. The inhibitory effects 
of PP2A on Bcl-2 not only come from the dephosphorylation of Bcl-2 itself but also 
from an enhanced binding between p53 and dephosphorylated Bcl-2[186]. 
 
Nur77 – Although Bcl-2 is well known as an anti-apoptotic protein, recently it 
has been shown to be able to induce programmed cell death as well. The loop region 
of Bcl-2 mediates its interaction with orphan nuclear receptor Nur77 and targets it to 
the mitochondria. The interaction results in a conformational change in Bcl-2 leading 
to exposure of its otherwise hidden BH3 domain. The exposed BH3 domain, in turn, 
blocks the function of Bcl-xL, thus converting Bcl-2 from a protector to a killer[202]. 
 
As discussed above, it is well known that Bcl-2 serves as a guardian for the 
mitochondria membrane integrity and its anti-apoptotic function can be modulated 
through post-translational modifications especially phosphorylation and interaction 
with both homologous Bcl-2 family members and other non-homologous proteins. 
However, recent evidences have been accumulating to indicate that the anti-apoptotic 
property of Bcl-2 can be attributed to its role in redox regulation as well, shedding 




1.3.2 Bcl-2 as a Non-canonical Redox Regulator 
Instead of being mere by-products, mitochondrial ROS production is likely to 
be highly regulated as a part of physiological functions or even pathological 
conditions and the underlying molecular mechanisms are being gradually 
uncovered[35]. One of the proteins identified by our laboratory and other groups over 
the past couple of years to function as a redox regulator particularly in the 
mitochondria is Bcl-2[26, 70, 123, 203, 204]. 
 
1.3.2.1 Bcl-2: An anti-oxidant or pro-oxidant? 
The involvement of Bcl-2 in redox regulation was first demonstrated by 
Hockenbery et al. that Bcl-2 overexpression protected against ROS-induced apoptosis. 
This is attributed to Bcl-2’s function as an anti-oxidant by the group since 
overexpression of Bcl-2 completely suppressed the lipid peroxidation induced by 
H2O2 and menadione (a quinone that transfers electrons to oxygen leading to 
production of free radicals) [112]. Soon after other studies also revealed the protective 
capacity of Bcl-2 against various ROS triggers[205-209] including prevention of 
oxidant-mediated lipid peroxidation[210, 211] as well as inhibition of NO2- 
production and carbonyl formation[212]. In addition, phenotypes with increased 
oxidative stress were also observed in Bcl-2-deficient mice[213, 214]. However, Bcl-
2 itself was later found out to possess no intrinsic antioxidant ability[215] implying 
that rather its overexpression indirectly induces an enhancement in antioxidant 
capacity of the cells when they undergo overt oxidative stress[123, 216]. This is 
supported by the findings that Bcl-2-mediated protection is associated with up-
regulation of the cellular enzymatic and non-enzymatic antioxidant defense 
machineries including the glutathione system, NAD(P)H, catalase and 
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Cu/ZuSOD[212, 215, 217-221]. The enhanced glutathione system has been attributed 
to the increase in the transcription of γ-glutamylcysteine ligase induced by elevated 
levels of NF-κB in Bcl-2-overexpressing cells, which leads to an increase in GSH 
levels protecting cells from H2O2-induced death[222]. In addition, recent evidence has 
demonstrated that Bcl-2 is able to regulate the mitochondrial GSH pool as well[223].  
 
A direct physical interaction has been shown between Bcl-2 and GSH-
conjugated agarose in vitro, which could be disrupted by the Bcl-2 inhibitor, HA14-1, 
that binds to the BH3 domain groove of Bcl-2, and by another structurally distinct 
BH3 mimetic as well as a recombinant BH3-only protein, Bim-L. The availability of 
the BH3 domain groove is clearly essential for Bcl-2 to interact with GSH and the 
physical tethering probably serves as a means to sustain the mitochondrial pool of 
GSH by Bcl-2. Supporting this further, GSH was displaced from the mitochondria in 
intact neurons when its interaction with Bcl-2 was abolished with the use of BH3 
mimetics[223]. However, there is no evidence that Bcl-2 has active transport 
properties for GSH; thus how the physically tethered GSH contributes to the 
mitochondrial antioxidant capacity remains elusive, but at least physically tethered 
GSH would likely decrease the susceptibility of oxidation of the proteins at the 
mitochondrial membranes[224]. Nonetheless, these observations provide further 
evidence that Bcl-2 is able to counteract excessive oxidative stress in the 
mitochondria through regulation of the GSH pool, thereby serving as a safety valve in 




However, all these evidences only supported the notion that Bcl-2 confers 
protection against oxidative stress without elucidating its intrinsic property until the 
study highlighted by Steinmann’s group where they examined the physiological 
intracellular milieu upon Bcl-2 overexpression and realized that Bcl-2 was inducing 
basal levels of oxidative stress that led to increased oxidative damage as measured by 
8-hydroxyguanine and a subsequent boost in the antioxidant system such as catalase 
providing the first piece of evidence that Bcl-2 is functioning as a pro-oxidant[225]. 
Indeed, subsequently more and more studies all pointed out and established that Bcl-2 
serves as a definite pro-oxidant under normal physiological states[114, 203, 218, 226, 
227]. Based on this pro-oxidant property of Bcl-2, it implies that the enhanced 
antioxidant capacity that was observed with Bcl-2 overexpression could be an 
adaptive response to the chronic but mild oxidative intracellular milieu[206, 215, 217, 
220, 227] and this serves as a first-line defense in the event of acute oxidative insults 
maintaining the ROS levels within a threshold optimal for cell survival[123, 203, 204, 
216]. 
 
1.3.2.2 Molecular mechanisms of Bcl-2-induced pro-oxidant state 
The underlying mechanisms on how Bcl-2 exerts its pro-oxidant activity, 
however, have not been fully elucidated. It was first hypothesized that the pro-oxidant 
milieu in Bcl-2-overexpressing mitochondria resulted from altered dynamics of the 
oxidative phosphorylation. An increase in the mitochondrial size and associated 
matrix content was observed with Bcl-2 overexpression and this indicates an increase 
in the number of electron donors and a subsequent increase in the electrons leaking 
out of the ETC to form O2.-[218, 228]. However, the exact mechanism linking Bcl-2 
expression levels to the mitochondrial size and matrix content was not addressed in 
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the above mentioned studies. More recently, our group has discovered that one of the 
mechanisms for Bcl-2 to generate intra-mitochondrial O2.- is through the engagement 
of mitochondrial respiration in cancer cells. 
 
1.3.2.2.1 Interaction with COX 
An increased mitochondrial oxygen consumption rate and Complex IV 
activity was observed in Bcl-2-overexpressing cancer cells[114, 203, 204, 229]. It is 
plausible that the increased mitochondrial respiration rate results in an increased 
electron flux across the ETC and an increased probability of leakage of electrons onto 
molecular oxygen thus leading to an increase in the by-production of O2.-. Indeed, 
either silencing of Bcl-2 with siRNA or functional inhibition of Bcl-2 with the BH3 
mimetic, HA14-1, in those cells, reversed both the oxygen consumption rate as well 
as the O2.- levels[203]. This is further supported by the observation that mitochondrial 
respiratory rate and O2.- levels both correlated with Bcl-2 expression levels across 
different cancer cell lines with varying amounts of endogenous Bcl-2[204]. 
Subsequently, it was revealed that Bcl-2 overexpression promoted the mitochondrial 
localization of COX Va and Vb, the nuclear encoded subunits of Complex IV, which 
could explain for the significantly increased Complex IV activity in these cells[204] 
since it has been previously shown that mitochondrial level of COX Vb correlated 
with the COX holoenzyme activity[230]. In addition, evidence was presented to 
demonstrate a physical interaction between COX Va and Bcl-2 through the BH2 
domain of Bcl-2. In the events of early oxidative stress induced through either serum 
withdrawal, glucose deprivation or hypoxia, Bcl-2 could function as a redox regulator 
by decreasing the COX activity accordingly, through adjustment of the COX subunits, 
thereby maintaining the ROS levels within a non-detrimental threshold[203, 204]. 
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Of particular note, the increased O2.- release as induced by increased oxygen 
consumption observed with Bcl-2 overexpression might seem contradictory to the 
notion that inhibition of ETC also results in O2.- release. However, as explained earlier, 
the former occurs as a result of increased electron flux across the ETC and an 
increased probability of leakage of electrons onto molecular oxygen while the latter is 
the result of inhibition of the reduction steps along ETC leading to promotion of the 
reaction of oxygen with accumulated reductants[231]. 
 
1.3.2.2.2 Potential involvement of Rac1 
Apart from COX, an additional functional player in Bcl-2-mediated pro-
oxidant state has been identified by our group, which is the small GTPase Rac1. The 
first evidence indicating the involvement of Rac1 comes from the study that a 
dominant negative form of Rac1, N17, decreased the levels of O2.- in Bcl-2-
overexpressing cancer cells sensitizing them to either receptor or drug-induced 
apoptosis[114]. Indeed, preliminary results from our laboratory suggested a direct 
physical interaction between Bcl-2 and Rac1. This leads us to hypothesize that Rac1 
could be a critical regulator in Bcl-2 mediated pro-oxidant state and the work 
presented in this thesis provide evidences in support of this hypothesis. In the next 
proceeding section, the physiological roles of Rac1 and its contribution to 




1.4. Role of Small GTPase Rac1 in Carcinogenesis 
1.4.1 The Small GTPase Rac1: A Molecular Switch 
Ras-related C3 botulinum toxin substrate 1, or commonly known as Rac1, 
belongs to the Rho (Ras homologues) subfamily of the Ras superfamily, which are 
monomeric G proteins with molecular mass ranging from 20 to 30 KDa comprising of 
more than 100 members identified so far[232]. Rho subfamily can be classified into 
six groups including: 1) the Rho proteins (RhoA, RhoB and RhoC); 2) the Rac 
proteins (Rac1, Rac2, Rac3 and the splice variant Rac1b); 3) the Cdc42-like proteins 
(Cdc42, TC10, TCL, Wrch1 and Chp); 4) the Rnd proteins (Rnd1, Rnd2 and 
Rnd3/RhoE); 5) the RhoBTB proteins (RhoBTB1, RhoBTB2 and RhoBTB3); 6) the 
Miro proteins (Miro1 and Miro2)[233, 234]. Among them, RhoA, Rac1 and Cdc42 
are the most extensively studied and their first identified functions are involved in 
actin cytoskeleton regulation: RhoA induces stress fibres and focal adhesions; Cdc42 
regulates filopodia formation; Rac1 mediates lamellipodia formation and membrane 
ruffles[235]. In addition, Rac1 is known to function in a variety of other cellular 
functions including gene transcription, regulation of cell cycle and survival as well as 
ROS production[236].  
 
Rac1, was first identified together with Rac2 in 1989, which bears 58% 
homology to Rho proteins and 20-30% homology to Ras proteins[237]. Subsequently, 
other forms of Rac proteins, namely Rac3 and Rac1b were discovered. The tissue 
distributions vary among different forms, with Rac1 ubiquitously found all over the 
body, Rac2 mainly in hematopoietic cells, Rac3 highly enriched in the brain but 
expressed in other tissues as well at lower levels and the splice variant Rac1b 
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minimally expressed in normal cells but highly enriched in cancers such as breast and 
colorectal cancers[238-241].  
 
1.4.1.1 Structure of Rac1 
Rac1, being a small GTPase, its activity is tightly regulated through GTP/GDP 
cycling. In order to better understand the structure-function relationship, the 3D 
structure of Rac1 complexed with a non-hydrolysable analogue of GTP, guanosine-5’-
(βγ-imino) triphosphate (GMPPNP) was resolved through X-ray crystallography 
[242]. Rac1 contains a central β-sheet made up of six strands (denoted as β1- β6), six 
α-helices and two short 310- helices.  
 
There are two effector regions in Rac1, named as Switch 1 (resides 29-40) and 
Switch 2 (resides 59-74) which are critical regulatory sites for GTP/GDP cycling. The 
nucleotide binding pocket consists of: 1) the two guanine recognition loops (including 
residues 116-119 which is the NKXD motif, and residues 158-160); 2) the two 
phosphate-binding loops (including residues 10-17 which is called the P-loop, and 
residues 57-61 containing part of the Switch 2); 3) the Switch 1 effector loop region 
that interacts with the ribose and the magnesium ion (Mg2+). The Mg2+ stabilizes not 
only the binding of guanine nucleotides but also the intrinsic GTPase activity within 
Rac1, therefore the Switch 1 effector loop is of particular importance since it is 
involved in the hydrolysis of GTP, the binding of GTPase-activating proteins (GAP) 
and downstream signal transduction. In addition, if compared with other members of 
the Rho family, there are several hydrophobic to charged substitutions as underlined 
in the following sequence: 28PGEYIPTVF, which render the exposed chain of Switch 
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1 less stable and possibly more flexible and this is reflected in the density map of the 
X-ray crystal structure as well with residues 32YIPTV being poorly defined. Since 
Rac1’s interaction with the guanine nucleotide exchange factors (GEFs) is mapped to 
a groove formed by Switch 1, Switch 2 and β1- β3 strands, the flexibility of the 
Switch 1 effector loop is probably important for specificity towards different GEFs to 
signal distinct downstream functions. In addition, flexible loop also offers greater 
opportunities for interaction with other proteins and in turn alters the conformation of 
Rac1 and modulates its activity[242, 243]. 
 
The conserved polybasic region (PBR) comprised of multiple lysines or 
arginines that immediately precedes the C-terminal CAAX sequence motif common 
to many small GTPases, is important for their subcellular targeting and interaction 
with other proteins. A unique PBR sequence is the main distinguishing feature of 
some small GTPases, including the three isoforms of Rac, Rac1, Rac2 and Rac3, 
stressing the importance of PBR in signalling, subcellular localization and tissue 
distribution. Nuclear localization signal (NLS) sequence is found in the PBR of Rac1 
that directs it to the nucleus where it participates in signalling pathways and is 
ultimately targeted for degradation[244, 245]. In addition, the basic residues in the 
PBR have been demonstrated to interact electrostatically with the acidic 
phospholipids in the plasma membrane promoting the membrane localization of Rac1. 
Rac1 mutants with mutated or deleted PBR showed reduced interactions with 
membranes[246, 247]. Furthermore, the trafficking of Rac1 to different membrane 
compartments is also dependent on the post-translational modifications of the C-
terminus. The CAAX motif (where C denotes cysteine, A represents any aliphatic 
amino acid and X may be any amino acid) is a substrate for post-translational 
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modification with the covalent attachment of a non-sterol isoprenoid. In the case of 
Rac1, it is the addition of geranylgeranyl pyrophosphate (GGPP) to the cysteine 
residue catalysed by geranylgeranyltransferase I (GGTase I) and the whole process is 
named as geranylgeranylation. This targets Rac1 to the ER where it undergoes further 
modifications with the three terminal amino-acid residues removed and the carboxyl 
group of the terminal cysteine methyl esterified. Rac1 then binds to Rho guanine 
nucleotide dissociation inhibitor (GDI) which keeps it in a soluble state (through 
recognition of the geranylgeranyl moiety) in the cytosol for shuttling to various 
membrane compartments to exert its functions[248]. Apart from geranylgeranylation, 
Rac1 can also be palmitoylated with the reversible addition of fatty acid palmitate at 
cysteine residue upstream of CAAX motif, which regulates its oligomerization state 
and activity as well as the partitioning and stabilization into ordered cholesterol-rich 
membrane microdomains[249]. 
  
1.4.1.2 Regulation of the small GTPase Rac1 through GTP/GDP cycling 
Being a guanosine triphosphatase, the activation status of Rac1 depends on the 
binding status of nucleotide, regulated by the joint activities of a series of GEFs, 
GAPs and RhoGDI. Upon triggers from diverse signals that are sensed by cell surface 
receptors[250, 251], Rac1 dissociates from RhoGDI in cytosol and translocates to 
membranes where the GEFs promote its activation by stimulating the release of GDP 
thus allowing the binding of GTP[252]. The interaction of GEFs with Rac1 
destabilizes the binding of nucleotide and Mg2+ resulting in the formation of a 
nucleotide free intermediate. GTP is present in a much higher intracellular 
concentration as compared to GDP, thus it gets bound by Rac1 much more easily. 
GEFs function as a catalyst here to promote the equilibrium between GDP- and GTP-
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bound Rac1. The change in bound nucleotide from GDP to GTP alters the 
conformation in the Switch 1 and Switch 2 allowing Rac1 to bind downstream 
effector proteins including scaffold proteins (such as p67phox and IQGAPs), 
serine/threonine kinases (such as MEKKs: mitogen activated protein kinase kinase 
kinase and PAKs), lipid kinases (such as PI3K) and lipases (such as PLD: 
phospholipase D and PLC-β2), etc.[253]. After the transient activation to signal 
downstream pathways, GTP is hydrolysed to GDP with the stimulation from GAPs 
since the intrinsic GTPase activity is slow. The inactive GDP-bound Rac1 is then 
extracted from the membranes and sequestered in cytosol by RhoGDI[251].  
 
The signalling specificity (i.e. activation of which Rho GTPase pathway) is 
governed in part by GEFs since the specificity of GEFs towards the GTPases varies. 
For example, Tiam1 is a specific activator of Rac1[254] while Vav promiscuously 
bind RhoA, RhoG, Rac1 and Cdc42[255]. The structure mapping of Rac1 complexed 
with its GEFs showed that the groove formed by Switch 1, Switch 2 and β1-3 strands 
of Rac1 is important in binding with GEFs[256], as mentioned earlier. In particular, 
the residue Trp56 in β3 region is critical in discriminating the binding of GEFs 
including Trio and Tiam1[243, 257, 258]. 
 
1.4.2 Implications of Rac1 in Carcinogenesis: Redox Regulation 
Deregulation of Rac1 functions has been implicated in various disorders, one 
of which that is of particular interest here in this thesis is carcinogenesis. Many of the 
cellular processes that Rac1 regulates as mentioned above, including proliferation and 
apoptosis[259], cell migration and invasion[260] as well as redox regulation, are all 
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pertinent to malignant tumour initiation and progression[261]. This has been 
attributed to Rac1-induced enhancement of mitogenic signals such as activation of 
ERK1/2, JNK, PI3K and AKT as well as transactivation of genes mediated by AP-1, 
NF-κB, CRE and STAT3, etc.[259, 261]. From the perspective of “Pro-oxidant theory 
of carcinogenesis”, the ability of Rac1 to activate NADPH oxidase for ROS 
production will be an indispensable contributing factor for carcinogenesis. Indeed, as 
a downstream target for Ras oncogenes, Rac1 activation and ROS production have 
been demonstrated to contribute to Ras-induced mitogenic signalling in 
fibroblasts[262, 263]. Therefore, a detailed discussion on the mechanisms of Rac1-
induced ROS production would be necessary here. 
 
One of the first effector proteins of Rac1 identified was p67phox, a subunit of 
the NADPH oxidase complex[264]. Upon trigger, Rac1 gets activated in GTP-bound 
form, binds to cytosolic p67phox associated with p47phox and p40phox and then 
recruits them to the membranes where they bind to the integral membrane 
components gp91phox (Nox2) and p22phox for the assembly and activation of the 
multimolecular NADPH oxidase complex for O2.- production through one electron 
reduction using NADPH as a substrate[265-267]. In addition to the binding of Rac1 to 
its effector p67phox, direct binding between Rac1 and gp91phox at the membranes 
has also been demonstrated to be essential in activation of electron transport through 
the heterodimeric flavocytochrome b558 comprised of gp91phox and p22phox[268]. 
Based on site-directed/deletional mutagenesis and peptide walking studies, regions in 
Rac1 that have been demonstrated to be critical in NADPH oxidase activation lie in 
the Switch 1 effector loop, the insert domain as well as the C-terminal basic motif[242, 
264, 269-271]. As discussed in earlier section, although this activation model was first 
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described for phagocytic isoform Nox2-based NADPH oxidase, Rac1 has been shown 
to activate Nox1 and Nox3-based complexes in non-phagocytic cells as well[272, 273] 
and the modulatory activity is achieved through Rac1-binding proteins Noxa1 
(homolog of p67phox) and Noxo1 (homolog of p47phox)[274, 275].  
 
1.4.3 Preliminary Evidences from Our Laboratory: Involvement of Rac1 in Bcl-2 
Mediated Pro-oxidant State and Apoptotic Resistance  
The oncogenic potential of Rac1 mediated through ROS  production in cancer 
cells was further demonstrated by our laboratory where we showed constitutively 
active mutant of Rac1, V12, increased intracellular O2.- production in human 
melanoma M14 cells leading to their resistance towards various chemotherapeutic 
drugs while transient introduction of the dominant negative mutant N17 decreased 
O2.- levels and greatly enhanced the sensitivity of those cells. In addition, inhibition of 
Rac1 in T24 bladder carcinoma cells with mutant Ras also significantly decreased O2.- 
levels and increased their sensitivity to both receptor and drug mediated apoptosis. On 
the contrary, the effect could be reversed with inhibition of the cytosolic O2.- 
scavenger Cu/ZnSOD indicating that the apoptotic resistance of oncogenic Ras-
expressing cancer cells could be associated with increase in the steady state levels of 
intracellular O2.- mediated through Rac1 activation[103]. 
 
As discussed in earlier section that Bcl-2 overexpression leads to a pro-oxidant 
intracellular milieu conferring resistance to apoptotic execution, interestingly, 
transient transfection of the dominant negative mutant Rac1N17 compromised the 
pro-oxidant status thus bypassing the resistance. This resulted in a remarkable 
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increase in the sensitivity of Bcl-2-overexpressing CEM (chronic myeloid leukaemia) 
cells to receptor or drug-induced apoptosis[114]. Intrigued by these findings, we set 
out to investigate the possibility of a physical interaction between these two proteins 
which could explain their functional relevance. Indeed, preliminary results from our 
laboratory showed that Rac1 and Bcl-2 interacted at the mitochondria providing hint 
that this interaction might possibly contribute towards the pro-oxidant state and 
apoptotic resistance induced by Bcl-2 overexpression. Interestingly, although Rac1 is 
found to be associated with membranes, its predominant membrane residence reported 
in the literature is plasma membrane and little is known about its mitochondrial 
membrane association except for a few reports published so far. Boivin and Beliveau 
reported in 1995 that Rac1 was found in the pure mitochondria from rat kidney cortex 
using sucrose gradient centrifugation[276]. Another group also reported in 2003 that 
Rac1 co-localized with Mitotracker, a mitochondrial marker, by confocal microscopic 
analysis. In addition, Rac1 was observed in the mitochondria-enriched fractions 
obtained through differential centrifugation[277]. More recently, Heather et al. 
reported the presence of Rac1 in the intermembrane space of mitochondria where the 
fraction was obtained following digitonin treatment of mitochondria fractions[278]. 
Indeed, previous results from our group also demonstrated the existence of Rac1 in 
the mitochondria through: 1) electron microscopic analysis[70]; 2) confocal 
microscopic analysis on the co-localization of Rac1 with Mitotracker (data not shown); 
3) western blot analysis of mitochondria-enriched fractions through differential 
centrifugation[70]. As such, in view of the mitochondrial localization of Rac1 and its 
interaction with Bcl-2, further investigations in establishing the interaction and 
characterizing the binding domains as well as elucidating the functional relevance of 
the complex in the mitochondrial redox status from a cancer context would be of great 
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significance for therapeutic management of cancers where Bcl-2 overexpression 
presents a major hindrance in the clinic.  
 
1.5. Therapeutic Targeting of Bcl-2 in Cancers 
1.5.1 Clinical Significance of Targeting Oncogenic Bcl-2 
The carcinogenic potential of Bcl-2 was first demonstrated in 1988 where 
mice injected subcutaneously with the NIH3T3 cells having a stably transfected Bcl-2 
resulted in tumour formation[126]. This was supported later by another group where 
they showed that transgenic mice with stable Bcl-2 overexpression led to massive 
lymphadenopathy as compared to their normal counterparts due to delayed apoptosis 
of B-cell lymphocytes resulting in the expansion of those cells in the follicular 
centre[279]. Further understanding of the oncogenic role of Bcl-2 came from the 
study in 1991 where genetically engineered Bcl-2-knockout mice demonstrated the 
importance of Bcl-2 for the survival of T-lymphocytes through protection against 
radiation-induced cell death[280]. These earlier findings laid the foundation for the 
subsequent studies to identify Bcl-2’s role in apoptotic inhibition through the 
prevention of MOMP and more recently the new facet of Bcl-2 biology in redox 
regulation that also contributes to its anti-apoptotic property, is being gradually 
revealed. The pro-oxidant state induced by Bcl-2 overexpression not only creates an 
intracellular milieu non-permissive for death execution and stimulates proliferative 
signals but also promotes genomic instability due to the mild but chronic oxidative 




It is now well established that overexpression of Bcl-2 is one of the intrinsic or 
acquired mechanisms for chemoresistance in a great number of cancers, which has 
been associated with poor disease prognosis[123]. The list of Bcl-2 dysregulation 
includes hematologic cancers such as B-cell chronic lymphocytic leukaemia (CLL), 
acute myeloid leukaemia (AML), follicular lymphoma and multiple myeloma[282] as 
well as solid tumours such as melanoma[283], head and neck cancers[284], 
breast[285], lung[286], pancreatic[287], colon[288] and prostate cancers[289], which 
stress the significance of targeting Bcl-2 therapeutically in the clinical settings. 
However, conventional strategies which aim at counteracting Bcl-2 by either antisense 
oligonucleotides to reduce its expression or BH3 mimetics that sit in the BH3 domain 
groove and inhibit its activity, have showed limited success to be used as a single 
agent based on experimental and clinical evidences. The emerging role of Bcl-2 as a 
redox regulator as well as the significance of ROS in cell fate decision have 
highlighted the potential of a novel approach that combines the targeting of pro-
oxidant Bcl-2 with conventional chemotherapies[123, 290].  
 
1.5.2 Current Strategies in Overcoming Bcl-2 Mediated Apoptotic Resistance 
1.5.2.1 Antisense oligonucleotides 
Since Bcl-2 is overexpressed in many cancers, the first strategy that is logical 
to think of would be to target it through down-regulation of its expression levels. This 
could be achieved through antisense strategy which utilizes short stretches of 
chemically modified oligodeoxynucleotides (18-21-mer) that are complementary to 
specific regions of the target mRNA. DNA binding to the sequence specific mRNA 
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results in the inhibition of gene expression by blocking the translation of the mRNA 
or targeting the mRNA for RNase H mediated degradation.  
 
G3139, an 18-mer oligonucleotide named as oblimersen (Genasense™), 
targets the first six codons of Bcl-2 mRNA. The phosphothiorate modification renders 
the oligonucleotide more stable in vitro and can efficiently down-regulate Bcl-2 
expression, for example, by more than 80% in human breast cancer cells and the 
reduction in protein levels was associated with 80-95% loss of cell viability due to 
induction of MOMP and caspases. The breast cancer cells with down-regulated Bcl-2 
expression were also observed to be more sensitive towards cytotoxic drugs[291]. 
Furthermore, Bcl-2 down-regulation by Genasense, followed by the administration of 
rituximab is an efficient anti-tumour strategy associated with improved survival in 
lymphoma-bearing severe combined immunodeficiency (SCID) mice, corroborating 
the in vitro data[292]. In another mouse xenograft model of B-cell lymphoma, the 
treatment of Genasense before addition of the proteosomal inhibitor bortezomib and 
cyclophosphamide enabled the eradication of B-cell lymphoma from the mice[293]. 
Genasense was first used in clinical trial to treat Non-Hodgkin’s lymphomas (NHL) 
which mostly overexpress Bcl-2[294]. Although only modest results were observed, 
due to its limited toxicity, Genasense has been approved for evaluation of its 
effectiveness in several other cancers such as small cell lung cancer, prostate 
cancer[295] and renal cell carcinoma[296]. Genasense has also been used with a 
variety of conventional anticancer treatments as a combination approach, some of 
which have been very promising. A phase II trial combining Genasense with 
rituximab in NHL was completed in 2010 and the results demonstrated the safety of 
the combination treatment and it seems to be most beneficial in patients with indolent 
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NHL[297]. A Phase III trial involving the combination of Genasense with fludarabine 
plus cyclophosphamide for the treatment of patients with refractory or relapsed CLL 
increased the complete response rate as compared to fludarabine/cyclophosphamide 
alone[298]. Results from another phase III clinical trial on the combination of 
Genasense with dacarbazine for patients with advanced melanoma also showed 
significantly improved multiple clinical outcomes and increased overall survival[299]. 
However, the results from myeloma and AML patients have not been too successful. 
This could be due to the overexpression of other pro-survival Bcl-2 family members 
and also the hindrance can come from the lack of efficient delivery and stability in 
vivo[300]. 
 
Interestingly, the phosphorylation status of Bcl-2 at the flexible loop region, in 
particular, on the residue Ser70 is critical in the Bcl-2 antisense sensitization model. 
Non-phosphorylatable mutant S70A showed greater sensitivity towards the combined 
treatment of a Bcl-2 antisense oligodeoxynucleotide (although the exact target site 
was not revealed) and vitamin E analogue α-tocopheryl succinate (α-TOS) whereas 
the phosphomimetic S70E was remarkably resistant to apoptosis in human acute 
lymphocytic leukaemia Jurkat cells. Computational modelling revealed that a unique 
hairpin conformation that resembles a BH3 mimetic was adopted by α-TOS to dock 
onto the hydrophobic BH3 domain groove of Bcl-2[301]. 
 
1.5.2.2 BH3 domain peptides 
Apart from down-regulating the expression levels of Bcl-2, another approach 
is to interfere with Bcl-2’s function by blocking its activity. Based on the BH3 
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domains of Bax and Bad, Shangary and group synthesized peptides that bind to the 
hydrophobic groove of Bcl-2 and displace pro-apoptotic members and they showed 
that these peptides were able to induce cytochrome c release and thus apoptosis in 
Bcl-2-overexpressing cells indicating the potential of BH3 domain peptides to be used 
as anti-cancer therapeutics[155, 302]. BH3 peptides have also been shown to trigger 
oligomerization of Bax and Bak resulting in MOMP[156]. However, the use of BH3 
peptides as therapeutics is limited due to their poor solubility, metabolic stability, 
bioavailability and cell permeability in vivo. Nonetheless, several approaches have 
been taken to address these problems, such as tagging the peptides with protein 
transduction domain from Drosophila antannepedia protein or alternatively from HIV 
TAT (Human Immunodeficiency Virus trans-activator of transcription) protein as well 
as chemical modification by synthesizing hydrocarbon stapled BH3 helices to 
improve cell permeability and resistance to protease digestion[303]. These approaches 
have enabled several groups to use BH3 peptidomimetics to trigger apoptosis in 
several cancers including leukaemia[304], neuroblastoma[305] and head and neck 
cancer[306]. 
 
1.5.2.3 BH3 mimetics  
More recently, based on computational modelling, structure-based design or 
high throughput screening, several groups have discovered small molecule 
compounds that mimic the action of pro-apoptotic BH3 proteins by binding 
specifically to the BH3 domain groove of pro-survival Bcl-2 family proteins. As such, 
they are named as BH3 mimetics. For cancer cells that overexpress the pro-survival 
members of the Bcl-2 family, they tend to be more sensitive towards BH3 mimetics as 
compared to their normal counterparts.  
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One of the first bona fide BH3 mimetics is a benzenesulfonyl derivative 
designed on the structure basis of a naturally occurring cottonseeds-derived Bcl-2 
inhibitor, gossypol, which is named as TW-37[307]. It has been shown to induce 
apoptosis in many malignancies including diffuse large B-cell lymphoma, ALL, 
mantle cell lymphoma[308, 309] and pancreatic cancer[310]. In addition, TW-37 has 
been demonstrated to increase sensitization of the cancer cells to a range of 
conventional drugs[311]. Interestingly, synergistic effects were also observed 
combining TW-37 with the MEK inhibitor U0126 in melanoma cells. The killing 
effects were mediated through selective p53 activation which was induced by ROS 
production sparing normal cells. The intrinsic vulnerability of the melanoma cells 
with dysregulated redox buffering capacity to handle ROS suggests the potential use 
of this combination regimen in the clinical management of this disease.  
 
ABT-737 is another extensively studied BH3 mimetic, which is also derived 
from gossypol as an analogue by Abbott (Abbott Laboratories, Abbott Park, IL, USA). 
As compared to previously reported compounds, it has a significantly enhanced 
potency with two to three orders of magnitude higher binding affinity towards Bcl-
2[312]. Konopleva and group showed that ABT-737 acts as a Bad BH3-only molecule 
which binds to Bcl-2 displacing Bax and in addition, Bak is also required for efficient 
killing in mouse embryonic fibroblast (MEF) cells[313]. Enhanced sensitivity to 
chemotherapeutic agents has also been observed with ABT-737. Numerous studies 
have demonstrated that primary cells from patients were extremely sensitive to ABT-
737 in the nanomolar range, including ALL, lymphocytic leukaemia[314-316], 
follicular lymphoma and marginal zone lymphoma[313]. The drug is now in the phase 
II clinical trial[311]. A modified version of ABT-737, ABT-263, with higher oral 
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availability, is now in the phase I/II clinical trial as well to treat various malignancies 
including CLL, lymphoma and small cell lung cancer[311, 317-319]. The extremely 
high binding affinity to Bcl-2 (less than 100 picomolar) makes ABT-737/ABT-263 
much more promising therapeutic candidates as compared to other small molecules 
discussed above[320].  
 
However, ABT-737 only binds Bcl-2, Bcl-xL and Bcl-w but not Mcl-1, thus it 
is inactive in those cancer cells with Mcl-1 overexpression unless a combination 
treatment is used which reduces the expression levels or inhibits the activity of Mcl-1. 
In addition, the phosphorylation status of Bcl-2 also affects the efficacy of this 
compound.  Inhibition of Bcl-2 phosphorylation either by using a MEK1 inhibitor or 
introduction of a non-phosphorylatable mutant on the three phosphorylation sites 
within the flexible loop region of Bcl-2 has been demonstrated to restore the 
sensitivity in vitro[312, 314]. Interestingly, inhibition of Bcl-2 function with ABT-
737 resulted in a significant depletion of cellular GSH levels in human cervical cancer 
HeLa cells and Jurkat cells. This has been accounted for the subsequent increase in 
intracellular ROS levels, caspase activation and finally apoptosis[321] stressing the 
significance of Bcl-2 as a redox regulator to maintain the ROS levels within an 
optimal threshold and suggesting the potential of combination treatment with Bcl-2 
targeting and ROS-inducing agents[123].  
 
 In that regard, further understanding of Bcl-2 function in redox regulation and 
elucidation of other players involved that could serve as potential druggable targets 
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This work originated from the attempts to elucidate the source(s) of O2.- 
induced by Bcl-2 overexpression, and how this contributes to its carcinogenic 
property from a novel perspective. Preliminary results indicated the involvement of 
Rac1 in this pathway probably through a physical interaction as mentioned in earlier 
section. Intrigued by these findings, this thesis aims to confirm and establish the 
functional involvement of Rac1 in pro-oxidant status induced by Bcl-2, to confirm 
and establish the physical interaction, to characterize the binding domains involved 
and to elucidate the functional relevance and potential downstream players of this 
interacting complex in the cancer context with specific focus on redox regulation and 
chemoresistance. 
 
1.6.1 Establishing the Regulatory Role of Rac1 in Bcl-2 Mediated Pro-oxidant State 
 To test the hypothesis that Bcl-2 (but not another pro-survival Bcl-2 family 
member Bcl-xL) is able to induce a pro-oxidant status in cancer cells with a 
specific focus on mitochondria O2.- levels. 
 To assess the functional involvement of Rac1 in Bcl-2 mediated pro-oxidant 
state through 1) measurement of Rac1 activation status across cancer cell lines 
with differential Bcl-2 expression levels as well as upon transient Bcl-2 
overexpression; 2) measurement of mitochondrial O2.- levels upon 
pharmacological inhibition of Rac1. 
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1.6.2 Establishing the Physical Interaction between Rac1 and Bcl-2 
 To assess the co-localization of Rac1 and Bcl-2 through fluorescence 
microscopic analysis in cancer cells transiently transfected with both mCherry-
Rac1 and GFP-Bcl-2. 
 To assess the physical interaction of Rac1 and Bcl-2 through co-
immunoprecipitation assay across cancer cell lines with different Bcl-2 
expression levels.  
 To assess the cancer specificity of the interaction through checking the 
presence of the interaction by co-immunoprecipitation assay in peripheral 
blood mononuclear cells (PBMCs) obtained from normal healthy donors. 
 
1.6.3 Establishing the Localization of the Interacting Complex 
 To assess the mitochondrial localization of Rac1 through subcellular 
fractionation studies in cancer cell lines as well as human fibroblast cell lines, 
which differ in Bcl-2 expression levels. 
 To check for the requirement of post-translational geranylgeranylation in the 
mitochondria targeting of Rac1 (through subcellular fractionation study) as 
well as its involvement in Rac1-Bcl-2 interaction (through co-





1.6.4 Identifying the Critical Functional Elements and Binding Domains/Residues 
for the Interaction 
 To investigate whether the activation status of Rac1 is essential for its 
interaction with Bcl-2 through co-immunoprecipitation assay upon: 1) crude in 
vitro loading of  either the non-hydrolysable GTP analogue GTP-γS or GDP to 
manipulate its activation status; 2) transient transfection of either the 
constitutively active Rac1V12 or the dominant negative Rac1N17 mutants; 3) 
pharmacological inhibition of Rac1 activity. 
 To investigate whether Nox family proteins are involved in the interaction 
through:1) checking the interaction levels upon general pharmacological 
inhibition of Nox proteins followed by co-immunoprecipitation analysis; 2) 
identifying the presence of Nox subunits in mitochondria through subcellular 
fractionation study. 
 To identify the specific residue(s) of Rac1 involved in the interaction 
preliminarily through transient transfection of different Rac1 point mutants 
followed by co-immunoprecipitation analysis. 
 To identify the specific domain(s)/region(s) of Bcl-2 critical for its interaction 
with Rac1 through co-immunoprecipitation analysis upon 1) blocking of its 
BH3 domain with Bcl-2 BH3 peptides; 2) blocking of its BH4 domain with 
Bcl-2 BH4 peptides; 3) transient transfection of either non-phosphorylatable 





1.6.5 Establishing the Link between Two of the Parameters Critical for the 
Interaction: Rac1 Activation and Bcl-2 Phosphorylation Status 
 To investigate whether active Rac1 can induce Bcl-2 phosphorylation on the 
particular residue Ser70 located at the flexible loop region through 1) transient 
introduction of Bcl-2 into cancer cells with stably transfected constitutively 
active Rac1V12 or dominant negative Rac1N17; 2) transient transfection of 
Rac1V12 or Rac1N17; 3) pharmacological inhibition of Rac1. 
 To identify the kinase(s) involved in active Rac1-induced Bcl-2 
phosphorylation at residue Ser70 as well as to further confirm its/their 
involvement in the interaction through pharmacological inhibition of the 
kinase(s). 
 
1.6.6 Studying the Functional Implication(s) of the Interaction 
 To investigate the redox regulatory ability of Rac1-Bcl-2 interaction through 
measurement of mitochondrial O2.- levels upon disruption of the interaction 
through 1) Bcl-2 BH3 peptides; 2) pharmacological inhibition of Rac1. 
 To investigate whether disruption of this interaction, through 1) Bcl-2 BH3 
peptides; 2) pharmacological inhibition of Rac1; 3) siRNA-mediated silencing 
of Rac1 expression levels, can sensitize Bcl-2-overexpressing cancer cells to 
conventional chemotherapeutic drugs based on assessment of the cell 
proliferation/viability as well as cell cycle profile analysis. 
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1.6.7 Identifying Additional Downstream Players Involved in the Rac1-Bcl-2 
Interaction Pathway through ™CELLWORKS In Silico Modelling 
 To confirm the tumorigenic properties of Rac1 and Bcl-2 through 
manipulation of their expression levels in the modelled HCT116 human 
colorectal carcinoma cells based on phenotypic indexes such as angiogenesis, 
proliferation, viability, metastasis and tumour volume as well as O2.- levels 
and apoptotic markers. 
 To identify the downstream players whose protein levels are affected upon 
virtual manipulation of Rac1 and/or Bcl-2 expression levels. 
 To investigate through wet lab experiments whether STAT3 is a downstream 
target of Rac1-Bcl-2 interaction pathway as predicted by 1) checking the 
mitochondrial localization of STAT3; 2) studying whether Bcl-2 
overexpression can induce STAT3 activation as marked by the 
phosphorylation on Tyr705; 3) investigating whether Bcl-2-induced STAT3 
activation is dependent on Rac1 activity with the use of the pharmacological 
inhibitor of Rac1; 4) investigating whether Bcl-2-induced STAT3 activation is 
redox regualted with the use of the general Nox inhibitor; 5) investigating 
whether there are physical interactions between each of these three proteins: 









CHAPTER 2: MATERIALS AND MATHODS 
 
2.1. Chemicals 
Acrylamide/bis-acrylamide (30% solution), Coomassie Plus Protein Assay 
Reagent, Stable Peroxide Solution and SuperSignal West Pico Luminol/Enhancer 
Solution were obtained from Pierce, IL, USA.  
 
Ammonium persulfate (APS), bovine serum albumin (BSA), daunorubicin 
hydrochloride, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
diphenyleneiodonium chloride (DPI), dithiothreitol (DTT), ethylenediaminetetraacetic 
acid (EDTA), ethylene glycol tetraacetic acid (EGTA), 4-(2-hydroxyethyl) 
piperazine-1-ethanesulfonic acid (HEPES), isopropanol, leupeptin, magnesium 
chloride (MgCl2), Nickel-enhanced 3, 3 diaminobensidine tetrahydrochloride (DAB) 
solution, pepstatin A, phenylmethanesulfonyl fluoride (PMSF), potassium chloride, 
propidium iodide (PI), sodium chloride (NaCl) and SP600125 were obtained from 
Sigma-Aldrich, LO, USA.  
 
Benzyloxycarbonyl-Val-Ala-Asp (OMe)-fluoromethylketone (Z-VAD-FMK) 
was obtained from ALEXIS, San Diego, USA. 
 




Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), L-
glutamine, penicillin & streptomycin (PS), phosphate buffered saline (PBS) and 
Roswell Park Memorial Institute Medium (RPMI 1640) were obtained from HyClone, 
UT, USA.   
 
EHT1864 was obtained from Tocris Bioscience, Bristol, United Kingdom. 
 
GGTI-2147 and NSC23766 were obtained from Calbiochem, CA, USA.  
 
100X Guanosine 5’-O-[gamma-thio] triphosphate (GTP-γS), 100X guanosine 
diphosphate (GDP) and p21-activated kinase 1 p21-binding domain (PAK1 PBD) 
conjugated with agarose were obtained from Millipore, MA, USA. 
 
G418 and hygromycin B were obtained from Roche Diagnostics Corporation, 
IN, USA. 
 
Hoechst 33342, MitoSox, and N,N,N,N-tetramethylethylenediamine (TEMED) 
were obtained from Invitrogen, CA, USA.  
 




 Methanol, ribonuclease A (RNase A), and sodium dodecyl sulphate (SDS) 
were obtained from AppliChem, Darmstadt, Germany.  
  
MitoTracker was obtained from Molecular Probes, Eugene, OR, USA. 
 
Precision Plus Protein Standards and Tween-20 were obtained from Bio-Rad, 
CA, USA.   
 
Protein A agarose and glutathione agarose were obtained from Santa Cruz 
Biotechnology, CA, USA. 
 
SuperFect Transfection Reagent was obtained from QIAGEN, Hilden, 
Germany. 
 
Triton X-100 was obtained from USB, OH, USA. 
 





Alexa Fluor® 488 goat anti-mouse IgG and Alexa Fluor® 568 goat anti-rabbit 
IgG were obtained from Molecular probes Invitrogen, CA, USA. 
 
Biotinylated secondary mouse and rabbit secondary antibodies were obtained 
from Vector Laboratories, Burlingame, CA, USA. 
 
Clean-Blot IP Detection Reagents were obtained from Thermo Scientific, IL, 
USA. 
 
 Goat anti-mouse IgG horseradish peroxidase (HRP) and goat anti-rabbit IgG 
HRP were obtained from Pierce, IL, USA. 
 
Goat polyclonal anti-Flotillin, rabbit polyclonal anti-Nox2 and rabbit 
polyclonal anti-Nox4 were obtained from Abcam, Cambridge, UK. 
 
Goat polyclonal anti-p22phox, goat polyclonal anti-VDAC, mouse 
monoclonal anti-myc-tag, mouse monoclonal anti-p-JNK (Thr183/Tyr185), mouse 
monoclonal anti-STAT3, rabbit monoclonal anti-PARP, rabbit monoclonal anti-p-
Bcl-2 (Ser70), rabbit monoclonal anti-p47phox, rabbit polyclonal anti-c-Jun, rabbit 
polyclonal anti-Cu/Zn SOD, rabbit polyclonal anti-p-c-Jun (Ser63) and rabbit 
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polyclonal anti-p-STAT3 (Tyr705) antibodies were obtained from Cell Signalling 
Technology, MA, USA.  
 
Mouse control IgG, mouse monoclonal anti-β-actin, mouse monoclonal anti-
Bax, mouse monoclonal anti-Bcl-2, mouse monoclonal anti-Bcl-xL, mouse 
monoclonal anti-pan-Ras, rabbit polyclonal anti-Bcl-2, rabbit polyclonal anti-Rac1 
and rabbit polyclonal anti-STAT3 antibodies were obtained from Santa Cruz 
Biotechnology, CA, USA. 
 
 Mouse monoclonal anti-Rac1 antibody was obtained from Upstate, NY, USA. 
 
 Rabbit control IgG was obtained from ProSci Incorporated, CA, USA. 
 
2.3. Chemical Synthesis of Peptides 
The Bcl-2 BH3 (PVVHLTLRQAGDDFSR), Bcl-2 BH4 
(TGYDNREIVMKYIHYKLSQRGYEW) and control peptides with no homology to 
human protein sequence (ALILTLV) were fused with an internal sequence of HIV 
TAT (Human Immunodeficiency Virus trans-activator of transcription) protein 
(KKKRRQRRR) to ensure cell permeability. The peptides were synthesized by 1st 
BASE (Science Park II, Singapore), dissolved in sterile distilled H2O and kept as 10 




2.4. cDNA Plasmids 
Bcl-2 and its control vector pcDNA3, Bcl-xL and its control vector pBabe 
plasmids were a kind gift from Dr. Elizabeth Yang (Vanderbilt University, USA). 
Bcl-2 single non-phosphorylatable mutant S70A and phosphomimetic mutant S70E 
were generated by our laboratory using QuikChange®Site-Directed Mutagenesis Kit 
(Stratagene, CA, USA). Bcl-2 triple non-phosphorylatable mutant T69A/S70A/S87A 
(AAA) was obtained from Addgene, MA, USA. Green fluorescent protein (GFP) 
tagged Bcl-2 and GFP tagged Bcl-xL plasmids were kindly provided by Dr. Victor Yu 
(Institute of Molecular and Cell Biology, Singapore). The empty vector GFP-C1 was 
a kind gift from Dr. Tang Bor Luen (National University of Singapore, Singapore). 
mCherry tagged Rac1 plasmid (cloned in SacI and NotI sites of pCAG vector 
backbone) was constructed by Quek Shuwen Alan from our laboratory and the control 
mCherry plasmid was kindly provided by Dr. Tapan (Genome Institute of Singapore, 
Singapore). The constitutively active Rac1 mutant V12, dominant negative Rac1 
mutant N17 and control vector pIRES plasmids were a kind gift from Dr. Clément 
Marie-Veronique (National University of Singapore, Singapore). The red fluorescent 
protein tagged Rac1 (RFP-Rac1) and control RFP plasmids were kindly provided by 
Dr. Edward Manser (Institute of Medical Biology, Singapore). 
 
2.5. Buffers 
2.5.1 Buffers for Western Blot Analysis 
RIPA lysis buffer for total cell lysate preparation: 50 mM Tris HCl (pH 7.5), 
150 mM NaCl, 1% Nonidet P40, 1 mM EDTA. Protease and phosphatases inhibitors 
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(10 μg/ml aprotinin, 10 μg/ml leupeptin, 20 μg/ml pepstatin A, 1 mM NaF, 1 mM 
Na3VO4, 1 mM PMSF) were added fresh before each lysis. 
 
1X Lammeli loading buffer:  50 mM Tris-HCl (pH 6.8), 50 mM DTT, 2% SDS, 
0.1% bromophenol blue, 10% glycerol. 
 
12% Resolving gel for SDS-PAGE (polyacrylamide gel electrophoresis):  30% 
acrylamide/bis-acrylamide, 1.5 M Tris (pH8.8), 10% SDS, 10% APS, TEMED. 
 
5% Stacking gel for SDS-PAGE:  30% acrylamide/bis-acrylamide, 1.0 M Tris 
(pH 6.8), 10% SDS, 10% APS, TEMED. 
 
Running buffer for SDS-PAGE:  25 mM Tris base (pH 8.3), 250 mM glycine, 
0.1% SDS. 
 
Wet transfer buffer: 39 mM glycine, 48 mM Tris base, 20% methanol. 
 
Tris-buffered saline with Tween20 (TBST):  137 mM NaCl, 20 mM Tris-HCl 




Blocking buffer: 5% non-fat milk in TBST. 
 
2.5.2 Mg2+ Lysis/Wash Buffer (MLB) for Rac1 Activation Assay 
5X MLB: 125 mM HEPES (pH 7.5), 750 mM NaCl, 5% Igepal CA-630, 5 
mM EDTA, 50 mM MgCl2, 10% glycerol. Dilute to 1X by adding 4 mL sterile, 
distilled water containing 10% glycerol to each ml of 5X MLB used. Protease 
inhibitors (10 mg/mL Leupeptin, 10 mg/mL aprotinin) and phosphatase inhibitors (1 
mM NaF, 1 mM Na3VO4) were added fresh before each lysis.  
 
2.5.3 Buffer for Co-immunoprecipitation (Co-IP) 
50 mM Tris (pH 7.6), 150 mM NaCl, 0.5% Nonidet P-40, 1 mM EDTA. 
Protease and phosphatase inhibitors (10 μg/ml aprotinin, 10 μg/ml leupeptin, 20 μg/ml 
pepstatin A, 1 mM NaF, 1 mM Na3VO4, 1 mM PMSF) were added fresh before each 
lysis. 
 
2.5.4 Buffers for Subcellular Fractionation 
Extraction buffer A for mitochondrial fractionation:  50 mM PIPES-KOH (pH 
7.4), 50 mM KCl, 220 mM mannitol, 68 mM sucrose, 5 mM EGTA, 1mM DTT, 2 
mM MgCl2. Protease and phosphatase inhibitors (10 μg/ml aprotinin, 10 μg/ml 
leupeptin, 20 μg/ml pepstatin A, 1 mM NaF, 1 mM Na3VO4, 1 mM PMSF) were 




Buffer for subcellular fractionation of heavy membrane (HM), light membrane 
(LM) and cytosol:  25 mM HEPES KOH (pH 7.6), 0.5 M KCl, 0.5 mM EDTA, 1 mM 
DTT, 5 mM MgCl2, 10% glycerol, 0.5% Tween-20. Protease and phosphatase 
inhibitors (10 μg/ml aprotinin, 10 μg/ml leupeptin, 20 μg/ml pepstatin A, 1 mM NaF, 
1 mM Na3VO4, 1 mM PMSF) were added fresh before each use. 
 
2.6. Cell Lines and Culturing of Cells 
The human chronic myeloid leukaemia CEM cells stably transfected with 
pcDNA3 vector containing either the neomycin gene (CEM/Neo) or the human Bcl-2 
gene (CEM/Bcl-2) were generously provided by Dr. Roberta A Gottlieb (Scripps 
Cancer Centre, USA). CEM cells were cultured in RPMI 1640 medium supplemented 
with 5% FBS, 1% L-glutamine and 1% PS at 37°C in a humidified incubator with 5% 
CO2. The stable clones were maintained in 20 μg/ml of selective antibiotics G418. 
 
The human cervical carcinoma HeLa cells were obtained from American Type 
Culture Collection (ATCC, MD, USA). HeLa stably transfected with pcDNA3 vector 
containing either the neomycin gene (HeLa/Neo) or the human Bcl-2 gene (HeLa/Bcl-
2)  as well as HeLa (ATCC) cells were cultured in DMEM medium supplemented 
with 10% FBS, 1% L-glutamine and 1% PS. The stable clones were maintained in 20 




The human B cell lymphoma Raji and human T cell lymphoma Jurkat cells 
obtained from ATCC were cultured in RPMI 1640 medium supplemented with 10% 
FBS, 1% L-glutamine and 1% PS. 
 
The human lung fibroblast MRC5 and IMR90 cells were kindly provided by 
Dr. Manoor Prakash Hande (National University of Singapore, Singapore). 
 
The human melanoma M14 cells stably transfected with pIRES vector 
containing the hygromycin gene or the constitutively active mutant of human Rac1 
gene (V12) or the dominant negative Rac1N17 gene were cultured in DMEM medium 
supplemented with 5% FBS, 1% L-glutamine and 1% PS. The stable clones were 
maintained in 0.5% of selective antibiotics hygromycin B. 
 
 Trypsin (0.25%) was used to detach adherent cells from culture flasks and the 
cells were then pelleted by centrifugation at 1200 rpm for 5 mins at 22°C followed by 
resuspension in DMEM medium. The number of cells was counted by a 
haemocytometer before seeding of cells onto culture well plates followed by 




2.7. Clinical Human Samples 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood 
using Ficoll-PaqueTM kit (GE Healthcare Bio-Sciences, Singapore) and kindly 
provided by Dr. Wang Binbin (National University of Singapore, Singapore). 
 
2.8. Amplification and Purification of Plasmids 
Plasmids (1 μg each) were mixed gently with 100 μl of competent E. coli cells 
and the mixture was incubated on ice for half an hour. After that, the mixture was 
incubated at 37°C in a water bath for 45 secs for a heat shock and was then transferred 
back to ice for 2 mins followed by transfer to 0.9 ml lysogeny broth (LB) with either 
ampicillin or kanamycin and incubated in a shaker at 200 rpm, 37°C for half an hour. 
After the incubation, the bacteria broth culture was spread on an LB plate (with either 
ampicillin or kanamycin) and kept in a bacteria incubator for 16 hrs at 37°C. On the 
following day, one colony was picked from each bacteria agar plate by a sterile 
pipette tip and thrown into LB broth (with either ampicillin or kanamycin) in a 
miniculture tube for incubation in a shaker at 200 rpm, 37°C for 16 hrs. After that, 
1ml of each miniculture was added into 250 ml LB broth (with either ampicillin or 
kanamycin) and again incubated in a shaker at 200 rpm, 37°C for 16 hrs to get a 
maxiculture.  
 
 After amplification of plasmids, they were then purified with PureYieldTM 
Plasmid Maxiprep System (Promega, WI, USA). The transformed E. coli cells were 
first centrifuged at 5,000 g for 10 mins and the pellet was resuspended in 12 ml Cell 
Resuspension Solution followed by addition of 12 ml Cell Lysis Solution. The 
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mixture was then inverted 3-5 times gently and incubated for 3 mins at room 
temperature followed by addition of 12 ml Neutralization Solution and again inverted 
for 10-15 times to mix. The bacteria cell lysate was then centrifuged at 14,000 g for 
20 mins and the supernatant was passed through the PureYieldTM Clearing Column 
and Maxi Binding Column on a vacuum manifold. After that, 5 ml of Endotoxin 
Removal Wash was added to the PureYieldTM Maxi Binding Column followed by 
another 20 ml of Column Wash. The column membrane was then dried for 5 mins by 
applying vacuum followed by addition of 1.5 ml of Nuclease-Free Water and 
centrifugation at 2,000 g for 5 mins at room temperature. The eluate that contained the 
DNA was then collected. In order to increase the DNA concentration, ethanol 
precipitation was carried out by adding 1/10 volume of 3 M sodium acetate (pH 5.2) 
and 2.5 volumes of 95% ethanol followed by incubation on ice for 15 mins. The DNA 
was then pelleted at 14,000 g for 10 mins, washed with 70% ethanol, mixed well and 
again centrifuged at 14,000 g for 2-5mins. Finally the pelleted DNA was resuspended 
in water and kept in -20°C.  
 
2.9. Transient Transfection  
HeLa cells (0.25 x 106 cells/well/2ml of DMEM medium for 6-well plates) 
were seeded one day prior to transfection. On the day of transfection, 2 μg plasmid 
was mixed with 200 μl of plain DMEM medium and 8 μl of SuperFect reagent. The 
mixture was vortexed for 10 secs and incubated at 37°C for 10 mins. The mixture was 
then topped up with 300 μl of DMEM medium and added drop by drop into the wells 
and incubated at 37°C for 3 hrs. The cells were then washed three times with 1X PBS 
and incubated in fresh DMEM medium for 48 hrs at 37°C. 
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2.10. siRNA Mediated Silencing  
siRNA for endogenous Rac1 was purchased from Ambion, CA, USA. As a 
negative control, the scrambled siRNA, a perfectly unique sequence which does not 
match to any sequence in the human genome, was used as recommended by the 
manufacturer. Transient transfections were carried out using siPORT™ NeoFX™ 
Transfection Agent (Ambion, CA, USA) and 30nM of Rac1 siRNA. The expression 
levels of Rac1 were analysed by western blot using anti-Rac1 antibody 48 hrs after 
the transfection. 
 
2.11. Protein Assay 
Protein concentration of cell lysate was determined using Coomassie Plus 
Protein Assay Reagent. 5 μl of lysate was added to 150 μl of the reagent and loaded 
into a 96-well plate. Absorbance was measured at 595 nm using a microplate reader 
(GENios Plus, Tecan, Männedorf, Switzerland). BSA of different concentrations was 
used as protein standards. 
 
2.12. Western Blot Analysis 
Cells were lysed using RIPA lysis buffer containing protease and phosphatase 
inhibitors. After boiling at 100°C for 5 mins on a heat block, an average of 60 μg of 
total protein per sample was subjected to 12% SDS-PAGE at 120 V for 1 hr. Precision 
Plus Protein Standards were used as molecular weight markers for the resolved 
protein bands. Following wet transfer of the resolved proteins, the polyvinylidene 
fluoride (PVDF) membrane was incubated with blocking buffer for 1hr on a shaker. 
After that, the membrane was washed with TBST three times (10 mins each) and 
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probed with desired primary antibody in TBST overnight on a shaker at 4°C. On the 
following day, the membrane was again washed three times and incubated with the 
respective secondary antibody in TBST with 1% non-fat milk on a shaker for 1 hr. 
Finally, after three washes the membrane was exposed to SuperSignal West Pico 
Luminol/Enhancer Solution and Stable Peroxide Solution for the protein bands to be 
visualized (Medical X-ray Processor, Kodak, NY, USA). 
 
2.13. Measurement of Mitochondrial Superoxide Anion Levels 
MitoSox is a live-cell permeable dye with hydroethidine (HE) covalently 
linked to a triphosphonium cation through a hexyl carbon chain and is selectively 
targeted to mitochondria due to the positive charge on the phosphonium group. The 
dye exhibits red fluorescence once it is oxidized by superoxide anion (O2.-). 
 
 CEM cells (1.0 x 106 cells per sample) were washed once with 1X PBS and 
spun at 1200 rpm at 22°C for 5 mins. Pellet was then resuspended in 100 μl plain 
RPMI medium with 10 μM MitoSox dye and incubated in dark at 37°C for 15 mins. 
Excess dye was then washed away twice with 1X PBS and the pellet was resuspended 
in 500 μl plain RPMI medium. At least 10,000 events were analysed by flow 
cytometry (Epics Elite EPS, Beckman Coulter, FL, USA) and data was further 




2.14. Measurement of Intracellular Superoxide Anion Levels 
The cells were lysed with 400 µl of 1X somatic cell ATP releasing reagent 
(Sigma-Aldrich, MO, USA). Next 100 µl of 850 µM lucigenin solution was injected 
automatically before the reading. Chemiluminescence was measured using a Berthold 
Sirius Luminometer (Berthold detection systems GmbH, Pforzheim, Germany) for 20 
secs. 
 
2.15. Quantification of Rac1 Activation Levels 
2.15.1 Rac1 G-LISA™ Kit  
The kit (Cytoskeleton Inc., CO, USA) contains a Rac-GTP-binding protein 
linked to the wells of a 96-well plate and only active, GTP-bound Rac1 in cell lysate 
will bind to the wells while inactive GDP-bound Rac1 is removed during washing 
steps. The bound active Rac1 is then detected with a Rac1 specific antibody by 
luminescence.  
 
 CEM cells were seeded onto 6-well plates (2.0 x 106 cells/well). After 
treatment, the cells were washed with ice old 1X PBS, lysed in 100 μl of ice cold Cell 
Lysis Buffer and immediately clarified by centrifugation at 14,000 rpm, 4°C for 2 
mins. The cell lysate was then diluted with Lysis Buffer to equalize protein 
concentration in each sample (not higher than 2.0 mg/ml or below 0.3 mg/ml). The 
powder in the 96-well plate was dissolved with 100 μl ice cold water and the solution 
was completely removed just before the addition of cell lysate (25 μl lysate + 25 μl 
cold Binding Buffer) or blank control (25 μl Lysis Buffer + 25 μl cold Binding Buffer) 
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or positive control (5 μl Rac1 Control Protein + 45 μl cold Binding Buffer), 
accordingly. The plate was immediately placed on an orbital microplate shaker (400 
rpm) at 4°C for exactly 30 mins. After 30 mins, the solution was flicked out and 
washed twice with 200 μl Wash Buffer at room temperature. Room temperature 
Antigen Presenting Buffer (200 μl) was immediately added into each well and 
incubated at room temperature for exactly 2 mins and washed three times with 200 μl 
each of room temperature Wash Buffer. Diluted anti-Rac1 primary antibody (50 μl) 
wash then added to each well and the plate was placed on the orbital microplate 
shaker (400 rpm) at room temperature for 45 mins and washed again three times with 
200 μl each of room temperature Wash Buffer. Diluted secondary antibody (50 μl) 
was added after that to each well and the plate was placed on the orbital microplate 
shaker (400 rpm) at room temperature for 45 mins and washed again three times with 
200 μl each of room temperature Wash Buffer. After the wash, 50 μl of HRP 
Detection Reagent was added and the luminescence signal was detected using a 
microplate reader (GENios Plus, Tecan, Männedorf, Switzerland). 
 
2.15.2 Rac1 Activation Assay through Immunoprecipitation with PAK-1 PBD 
Agarose 
Cell culture and extract preparation:  Cells were pelleted by gentle 
centrifugation (500 g) and then rinsed twice with ice-cold TBS. Ice-cold MLB was 
added to the cell pellet (0.5-1 ml per 1.0 x 107 cells) to lyse cells by repeated (4-5 
times) pipetting. If nuclear lysis occurs, the extract may be very viscous (and difficult 
to pipette) due to released genomic DNA. In that case, DNA may be sheared by 
passing the lysate through a 26-gauge syringe needle 3-4 times. The cell lysate was 
then precleared by adding 100 ml of glutathione agarose per 1 ml of lysate and 
67 
 
rocking for 10 mins at 4°C. The agarose beads were collected by pulsing for 5 secs in 
the microcentrifuge at 14,000 g. The supernatant was removed and aliquots were 
stored on ice (for immediate use) or snap frozen in liquid nitrogen and stored at -80°C 
(for long term).  
 
In vitro GTP-γS/GDP loading for positive and negative controls: 0.5 ml of 
each cell extract was aliquoted to two microfuge tubes. To each tube, 20 ml of 0.5 M 
EDTA (to 10 mM final concentration) was added. For the positive control tube, 5 ml 
of 100X GTP-γS (to 100 mM final concentration) was added while 5 ml of 100X 
GDP (to 1 mM final concentration) was added to the negative control tube. The tubes 
were incubated at 30°C for 15 mins with agitation. 
 
Rac1 pull-down assay: 10 ml (10 mg) of PAK-1 PBD agarose (Millipore, MA, 
USA) was immediately added per 0.5 mL of cell lysate. The reaction mixture was 
then gently rocked at 4°C for 60 mins (30 mins for GTP-γS and GDP loaded lysates). 
The agarose beads were collected by pulsing for 5 secs in the microcentrifuge at 
14,000 g followed by 3 washes with 0.5 ml of MLB. After that, the agarose beads 
were resuspended in 40 ml of 2X laemmli reducing sample buffer, boiled for 5 mins 
and loaded onto SDS-PAGE for western blot analysis. 
 
2.16. Cell Viability Assay  
MTT can be reduced to a purple formazan by an active mitochondrial 
reductase, which only takes place in living cells. Since this conversion reaction is a 
68 
 
direct readout for the number of viable cells, the MTT reduction assay is commonly 
utilized to determine cell viability.  
 
 CEM cells were plated onto 12-well plates (1.0 x 106 cells/well) and after drug 
exposure, 50 μl of MTT (3 mg/ml in plain RPMI) was added to 50 μl of cells and 
followed by incubation for 2 hrs at 37°C in the dark. After that, the plate was spun at 
3000 rpm for 5 mins. The supernatant was then removed and the crystal in each well 
was dissolved in 200 μl DMSO and 10 μl Sorenson’s glycine buffer (0.1 M Glycine, 
0.1 M NaCl, pH 10.5). Cell viability was assessed by dye absorbance measured at 570 
nm with the microplate reader (GENios Plus, Tecan, Männedorf, Switzerland). 
 
2.17. Immunofluorescence Microscopic Analysis  
HeLa cells transfected with fluorescent protein tagged Bcl-2 or Rac1 plasmids 
were washed once with 1X PBS, fixed with paraformaldehyde (4% w/v) for 20 mins 
and permeabilized with 0.5% Triton X-100 for 5 mins. Washing with 1X PBS was 
done after fixing and permeabilization, respectively, for three times (5 mins each). 
Cells were then incubated with 10 μM Hoechst 33342 for 10 mins and washed three 
times with 1X PBS, after which cells were mounted onto slides and examined with a 
fluorescence microscope. The fluorescence of GFP was excited with 488nm laser line 
and fluorescence of mCherry was excited with 568-nm laser line. Pictures were taken 





For HeLa cells that were not transfected with fluorescent protein fusion 
plasmids, after fixing and permeabilization, they were blocked with 1% BSA (in 1X 
PBS) for 1 hr to prevent non-specific binding followed by incubation with respective 
primary antibodies for 2 hrs at room temperature. The cells were washed three times 
with 1X PBS (5 mins) and incubated with Alexa-fluo-conjugated IgG based 
secondary antibodies for fluorescent labelling followed by another three washes of 1X 
PBS (5 mins) before mounting onto glass slides for fluorescence microscopic analysis. 
 
2.18. Co-immunoprecipitation 
Cells (10 x 106) were pelleted, washed in 1 X PBS and incubated on ice with 
Co-IP lysis buffer for 20 mins. Subsequently, 4 µg of anti-Rac1 or anti-Bcl-2 or anti-
STAT3 antibodies were added to 1000 µg of cell lysate and the mixture was incubated 
on a rotator overnight at 4˚C where interacting proteins could be co-
immunoprecipitated. 40 µl of either protein A or protein G agarose beads were then 
added to the mixture rotating for 4 hrs at 4˚C to capture the immunocomplexes. The 
beads were washed three times with 1 ml of Co-IP lysis buffer, resuspended in 30µl of 
laemmli loading buffer and boiled for 15 mins to release the immunocomplexes. After 
that, the mixture was centrifuged at 14,000 g and the supernatant that contained the 
released immunocomplexes were loaded onto a 12% SDS-PAGE gel. Clean-Blot IP 
Detection Reagents were used in the follow-up western blot analysis to minimize the 




For co-immunoprecipitation done on subcellular fractions, 60 x 106 cells were 
used for fractionation followed by subsequent incubation of different fractions with 
Co-IP lysis buffer. 
 
2.19. Subcellular Fractionation by Differential Centrifugation 
2.19.1 Mitochondrial Fractionation 
20 x 106 cells were washed with ice-chilled 1 x PBS at 1200 g. Cell pellets 
were resuspended in 500 µl of extraction buffer A and incubated at 4°C for 20 mins, 
followed by Dounce homogenization. The homogenate was centrifuged at 300 g for 
10 mins at 4°C. The supernatant was additionally centrifuged at 20000 g for 30 mins 
(fractions enriched with intact mitochondria). The supernatant from the last 
centrifugation was spun again at 100000g for 45 mins to get the cytosolic fraction. 
Immunoblotting with VDAC and Cu/Zn SOD antibodies was carried out to show the 
purity of mitochondria and cytosolic fractions, respectively. 
 
2.19.2 Subcellular Fractionation of HM, LM and Cytosol   
20 x 106 cells were washed with ice-chilled 1 x PBS at 1200 g. Cell pellets 
were resuspended in 600 µl of fractionation buffer and incubated at 4°C for 20 mins, 
followed by Dounce homogenization (20 strokes). The homogenate was centrifuged at 
1000 g for 10 mins at 4°C. The supernatant was additionally centrifuged at 20,000 g 
for 20 mins to get the HM pellet (fractions enriched with intact mitochondria). The 
supernatant from the last centrifugation was spun again at 100,000 g for 1 hr to get the 
LM (pellet) and cytosolic fractions (supernatant). The HM purity was shown by 
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immunoblotting with VDAC antibody. The purity of LM and cytosolic fractions were 
checked by probing for Flotillin and Cu/ZnSOD, respectively. 
 
2.20. Immunohistochemical staining and Transmission Electron 
Microscopy 
HeLa/Neo and HeLa/Bcl-2 cells were washed with 1X PBS twice. The cells 
were then fixed with 0.2% glutaraldehyde in 2% paraformaldehyde in phosphate 
buffer, pH 7.4 solution for 1 hr.  For immunostaining, the fixed cells were blocked 
with 5% BSA to block nonspecific binding for 1 hr. Cells were then incubated with 
anti-Rac1 and anti-Bcl-2 respectively for 2 hrs. After 3 washes with 1 X PBS, 
biotinylated secondary mouse and rabbit secondary antibodies were used to stain the 
cells for 1 hr.  Following 1 hr incubation with Avidin-Biotin Peroxidase complex and 
2 washes with 1 X PBS, the peroxidase activity was demonstrated by Nickel-
enhanced 3, 3 DAB solution in Tris buffer containing 0.05% hydrogen peroxide. The 
chemical reaction was stopped with several washes of Tris buffer and then the 
samples were post-fixed in 1% osmium tetroxide in 0.1M PBS, pH7.4, for 1 hr at 
room temperature and dehydrated in graded series of ethanol. The samples were then 
embedded in araldite mixture. Ultra thin sections were stained in lead citrate and 
viewed in an EM208S electron microscope. Some sections were treated 




2.21. Cell Cycle Profile Analysis by Flow Cytometry  
Cell cycle profile was determined using PI staining by measuring the DNA 
content of the cells. PI (0.5 mg) was reconstituted in 1ml 38mM sodium citrate buffer 
(pH 7.0) to give a 50X stock solution while RNase A (10mg) was reconstituted in 1 
ml of 10 mM Tris-HCl buffer (pH 7.5) with 15 mM NaCl, boiled for 15min, and 
cooled to room temperature (40X stock solution). Following treatment, CEM cells 
(1.0 x 106 cells/well) were harvested by washing with 2 ml of 1X PBS with 1% FBS, 
then spinning at 1200 rpm for 5 mins at 22°C and the pellet was resuspended in 1ml 
of 1X PBS with 1% FBS, then immediately fixed with 70% ethanol and incubated on 
ice for 30 mins. After incubation, the cells were again washed twice with 1X PBS 
with 1% FBS and the pellet was resuspended with 0.5 ml of 1X PI : RNase A (10 μg 
PI and 250 μg RNase A) in sodium citrate solution and incubated for 30 mins at 37°C 
in the dark. At least 10,000 events were analysed by flow cytometry using an 
excitation wavelength of 488 nm and emission wavelength of 610 nm (Epics Elite 
EPS, Beckman Coulter, FL, USA). Data was further analysed using WINMDI 
software. 
 
2.22. ™CELLWORKS In Silico Modelling 
In an attempt to study the functional implication(s) of Rac1-Bcl-2 interaction, 
computer simulation driven virtual predictive experiments were carried out based on 
the protein pathway dynamic network created by ™Cellworks Group Inc., CA, USA. 
The ™Cellworks Oncology Platform was customized to create a system aligned to 
HCT116 human colorectal cancer cell line with K-Ras mutation, PI3K overexpression 
(OE), CDKN2A deletion, β-catenin OE and an additional Bcl-2 OE. A variant cell 
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line was also created with Rac1 OE based on the above baseline and either Rac1 or 
Bcl-2 down-regulation (target expression inhibition by 70%) was then tested on the 
above two modelled cell lines to study the effects on phenotypic indices and key bio 
markers on tumorigenesis. 
 
2.23. Statistical Analysis 
The statistical analysis for the data obtained was performed by Student’s t-test 
assuming equal variances with SPSS software. Means were only considered 













CHAPTER 3: RESULTS 
 
3.1. Bcl-2 Induces a Slight Pro-oxidant Intra-mitochondrial Milieu in 
Cancer Cells 
3.1.1 Overexpression of Bcl-2 in Cancer Cells Increased Mitochondrial O2.- Levels 
Previous results from other groups[225] as well as our group demonstrated a 
pro-oxidant nature of the anti-apoptotic protein Bcl-2 where its overexpression led to 
a slightly but constitutively elevated  O2.- levels both intracellularly as well as intra-
mitochondrially[70, 114, 203, 322]. In order to confirm this point and establish a 
working model of Bcl-2-induced pro-oxidant status with the focus on mitochondria 
for the subsequent experiments in this thesis, the basal levels of mitochondrial O2.- 
from two cell lines: the stable Bcl-2-overexpressing human chronic myeloid 
leukaemia CEM cells (CEM/Bcl-2) and the control vector matched CEM/Neo cells, 
were measured using MitoSox dye as described in Materials and Methods. MitoSox 
red, being a live-cell-permeable dye with hydroethidine (HE) covalently linked to a 
triphosphonium cation, is selectively targeted to mitochondria due to the significantly 
lower trans-mitochondrial membrane potential as compared to trans-plasma 
membrane potential. The redox sensitive dye is then oxidized by O2.- produced in the 
mitochondria of living cells and the oxidation product exhibits red fluorescence upon 
binding to nucleic acids, which can be detected by Fluorescence-activated cell sorting 
(FACS) using a flow cytometry. The specificity of this mitochondria-targeted probe 
for O2.- but not other ROS or reactive nitrogen species (RNS) makes it a reliable 














































































3.1.2 Transient Overexpression of Bcl-xL in Cancer Cells Did not Affect 
Intracellular O2.- Levels 
In order to explore whether the pro-oxidant property is specific to Bcl-2 only 
but not other pro-survival Bcl-2 family member such as Bcl-xL, the intracellular O2.- 
levels were examined upon transient Bcl-xL overexpression in human cervical cancer 
HeLa/Neo cells. The intracellular O2.- levels were determined using a lucigenin-based 
chemiluminescence assay as described in Materials and Methods. The lucigenin is 
first reduced by one electron to lucigenin cation radical (probably by the same 
biological system(s) that produce(s) O2.-) that can then react with O2.- to yield the 
unstable dioxetane intermediate, followed by decomposition and relaxation to the 
ground state emitting a photon which can be sensitively captured[323]. Indeed, 48 hrs 
post transient introduction of the Bcl-xL plasmid into HeLa/Neo cells, there was no 
change observed in the intracellular O2.- levels (Figure 2B), unlike Bcl-2, which has 
been reported previously by our group to induce a constitutively elevated production 
of intracellular O2.- upon overexpression, be it transiently or stably in HeLa cells[114, 
203]. The transfection efficiency of Bcl-xL was confirmed by western blot analysis 
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3.2. Bcl-2 Overexpression Induces Rac1 Activation in Cancer Cells 
3.2.1 Cancer Cells with Higher Bcl-2 Expression Levels Have Higher Rac1 
Activation Levels 
Since the discovery of the pro-oxidant property of Bcl-2, extensive studies 
have been carried out in our laboratory to identify the exact source(s) for the elevated 
O2.- production as observed upon Bcl-2 overexpression. One hypothesis is that Bcl-2 
engages mitochondrial respiration and this is supported by the evidences that activity 
of the rate limiting enzyme of the mitochondrial electron transport chain (ETC), 
cytochrome c oxidase (COX or Complex IV), got enhanced upon Bcl-2 
overexpression, which led to increased oxygen consumption rate and an overall 
increased probability of electron leakage onto molecular oxygen producing O2.-[203, 
204]. In addition, preliminary results suggested an involvement of Rac1 as well, 
which is known to activate NADPH oxidases for O2.- production upon GTP 
loading[264, 272, 273]. Transient transfection of the dominant negative mutant 
Rac1N17 significantly decreased the intracellular O2.- levels in CEM/Bcl-2 cells[114]. 
Intrigued by this finding, the activation levels of Rac1 were examined across four 
cancer cell lines with differential Bcl-2 expression levels including Raji (the human B 
cell lymphoma), Jurkat (the human T cell leukemia) as well as CEM/Neo and 
CEM/Bcl-2, using an affinity precipitation method as described in Materials and 
Methods. GST-agarose beads bound to PBD (p21 binding domain), the N-terminal 
regulatory region of Rac1’s downstream effector protein PAK1 (p21-activated kinase 
1) were used to pull down GTP-loaded Rac1 only and thus the levels of active Rac1 
can be quantitatively assessed through subsequent western blot analysis. Indeed, 
cancer cells with relatively higher Bcl-2 expression levels such as Jurkat and 
CEM/Bcl-2 as shown in the input (Figure 3B), showed significantly higher Rac1 
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activation levels indicating a direct correlation between Bcl-2 expression and Rac1 
activation levels. Cells loaded with either a non-hydrolysable GTP analog GTP-γS or 
GDP followed by PAK-1 PBD pull downs served as a positive or negative control, 
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3.2.2 Transient Bcl-2 Overexpression in Cancer Cells Induced Rac1 Activation 
In order to study whether there is a direct causal relationship between Bcl-2 
expression and Rac1 activation levels, the amount of active Rac1 was assessed upon 
transient manipulation of Bcl-2 expression levels, using the same affinity precipitation 
method mentioned in the previous section. Upon transient overexpression of green 
fluorescent protein tagged Bcl-2 (GFP-Bcl-2) in HeLa cells with relatively low 
endogenous expression of Bcl-2 (Figure 4B), there was a significant increase in the 
amount of active Rac1 compared to the control vector GFP-C1  transfected cells 
(Figure 4A) suggesting the transiently introduced Bcl-2 probably either directly or 
indirectly activated the endogenous Rac1. Interestingly, this was not observed with 
transient transfection of GFP tagged Bcl-xL (GFP-Bcl-xL) (Figure 4A) corroborating 
with the previously discussed data in section 3.1.2 that overexpression of Bcl-xL in 
cancer cells did not affect intracellular O2.- levels (Figure 2) and suggesting that Rac1 




































































































3.3. Rac1 Regulates Mitochondrial O2.- Levels in Bcl-2-overexpressing 
Cancer Cells 
For a better justification of the direct involvement of Rac1 in Bcl-2-induced 
pro-oxidant state, the mitochondrial O2.- levels were measured using MitoSox 
following the inhibition of Rac1 activity upon exposure to a cell permeable 
pharmacological inhibitor NSC23766. This is a first generation small molecule 
inhibitor that specifically targets Rac, identified through a computer based Virtual 
Screening on over 140,000 small chemical compounds available in the National 
Cancer Institute database. It was found based on the criteria to interact with residue 
Trp56 and to be able to dock onto the pocket created by Lys5, Val7, Trp56 and Ser71 
of Rac1 according to the structure of Rac1-Tiam1 monomer complex[256]. Trp56 has 
been demonstrated to be the critical determinant of Rac1 for its ability to discriminate 
within a subset of Rac1-specific GEFs (guanine nucleotide exchange factors) such as 
Tiam1 and Trio. As such, any molecule that interacts with Trp56 and occupies the 
pocket could potentially inhibit the interaction between Rac1 and its GEFs thus 
blocking its activation[257]. Indeed, the inhibitory effect of NSC23766 was 
determined using a complex formation assay where it specifically inhibited the 
binding of TrioN to Rac1 in a competitive manner with an inhibitory concentration-50 
(IC50) of about 50 μM in vitro but not with Intersectin to Cdc42 (where Intersectin is a 
Cdc42-specific GEF)[243, 258]. Further investigation revealed that NSC23766 could 
inhibit Tiam1 binding to Rac1 as well thus inhibiting Rac1 activation but had no 
detectable inhibitory effect on RhoA. There is also no inhibitory effect observed with 
Rac1 binding to its effector such as PAK1 or to GAP (GTPase-activating protein) 
such as BcrGAP indicating that NSC23766 is a specific inhibitor for Rac1-GEF 
interaction. In the computer simulated model, NSC23766 is able to bind to a surface 
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cleft that is formed by residues Lys5, Asp38, Asn39, Trp56, Thr58, Leu70 and Ser71 
which correspond to the groove between β1-β3 regions, Switch 1 and Switch 2. The 
inhibitory effect could result from: 1) steric hindrance so that GEFs can no longer 
bind to Rac1; 2) prevention of the conformational change of loop L4, that is formed 
with residues 60-64; 3) prevention of the displacing of the Mg2+ ion by Ala59. Both 2) 
and 3) prevent the switch from GDP-bound conformation to a nucleotide free open 
conformation to allow the loading of GTP onto Rac1[243].  
 
The inhibitory effect of NSC23766 was further validated in our model of 
CEM/Bcl-2 cells using the Rac1 G-LISA™ Kit as described in Materials and 
Methods. Only active Rac1 will be captured by the Rac-GTP affinity wells and 
probed with Rac1 antibody that can be detected with a 96-well plate luminometer. 
Indeed, dose-dependent inhibitory effect on Rac1 activity was observed upon 
exposure to increasing doses of NSC23766 with IC50 of about 50 μM (Figure 5A) 
which corroborates with previously published results based on in vitro complex 
formation assay mentioned above. The constitutively activated Rac1 recombinant 
protein was used as a positive control while the blank that contained only the buffers 
was used as a negative control (Figure 5B). Upon 2 hrs exposure of NSC23766 that 
blocks the interaction of Rac1-GEFs, mitochondrial O2.- levels were measured in both 
CEM/Neo and CEM/Bcl-2 cells. As shown in Figure 6A, significant dose-dependent 
reduction in mitochondrial O2.- levels was observed with Rac1 activity inhibited in 
Bcl-2-overexpressing CEM cells compromising its pro-oxidant state as compared to 
the basal levels without any drug exposure. Minimum effect was observed in 
CEM/Neo cells with relatively lower Bcl-2 expression levels. In order to confirm that 
the reduction of O2.- levels in CEM/Bcl-2 cells comes from the mitochondria, both 
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whole cells as well as isolated mitochondria were measured for their mitochondrial 
O2.- levels upon inhibition of Rac1 activity. Indeed, similar reduction was observed in 
both whole cells and isolated mitochondria (Figure 6B) indicating that mitochondria 
is a significant contributing organelle site to the pro-oxidant state in CEM/Bcl-2 cells. 
 
 
To provide evidences that the reduction in mitochondrial O2.- levels upon 
NSC23766 treatment in CEM/Bcl-2 cells was due to inhibition of Rac1 activity but 
not other effects, changes in cell viability and protein expression levels of Rac1 and 
Bcl-2 were determined, if there are any, using MTT cell viability assay and western 
blotting, respectively, as described in Materials and Methods. Only viable cells harbor 
the reductase enzymes which can reduce MTT to formazan dyes, giving a purple color 
that can be captured by spectrophotometer[324]. Although it is not a direct 
measurement for cell death, any changes in the proliferation or cell death or even 
metabolic activity of cells can affect the end products which could be used as a means 
to assess the toxicity of a certain agent, in this case the pharmacological inhibitor of 
Rac1, to the cells. No significant changes in cell viability were observed with 5 and 
15 μM of NSC23766 (Figure 7) that caused a decrease in the mitochondrial O2.- 
levels as shown earlier in Figure 6A & B. Similarly, no changes in protein levels of 
Rac1 and Bcl-2 were observed with NSC23766 exposure even at the highest dose of 
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3.4. Physical Interaction of Rac1 and Bcl-2 
3.4.1 mCherry-Rac1 Co-localized with GFP-Bcl-2 
Results discussed in the previous sections confirmed that Bcl-2-induced pro-
oxidant state in the mitochondria of cancer cells is mediated through Rac1 activation; 
therefore, investigation on the underlying mechanism(s) would be of great help in 
understanding the redox regulation in the mitochondria. Preliminary results from our 
laboratory indeed suggested co-localization and a physical interaction between these 
two proteins. In order to confirm this point, a fluorescent microscopic analysis on the 
subcellular localization of mCherry tagged Rac1 and GFP tagged Bcl-2 was carried 
out first. Both Rac1 and Bcl-2 are tagged with fluorescent proteins at the 5’ end to 
ensure: 1) expression of the fluorophores; 2) proper subcellular targeting of the 
proteins of interest due to the presence of transmembrane domain at the C-terminus of 
Bcl-2[127] and polybasic region at the C-terminus of Rac1 that contains the nuclear 
localization signal (NLS) and is also important for membrane association upon 
geranylgeranylation[244, 245, 248]. mCherry is better off as compared to the 
conventional red fluorescent protein (RFP) that was used in the preliminary 
experiments from our laboratory in terms of photostability (thus preventing premature 
photobleaching) and its monomeric nature (thus revealing more accurate subcellular 
localization details). The obligate tetramerization of RFP in vitro and in living cells 
has been reported where RFP fusion protein chimeras formed intracellular aggregates, 
which raises the question as to what extent will RFP tag affect the localizations and 
functions of Rac1[325, 326]. In this regard, the monomeric form mCherry fused Rac1 
is preferred and is co-transfected with GFP-Bcl-2 into HeLa cells and the fluorescent 
signals from both channels were measured under a fluorescent microscope. Control 
fluorescent proteins by themselves showed homogeneous overexpression all over the 
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cells without any specific subcellular localizations. Bcl-2, being associated primarily 
with membrane structures, was seen in the perinuclear regions while Rac1 is more 
predominantly all over the plasma membrane and cytosolic compartments. Overlay of 
the fluorescent signals from both the red and green channels showed yellow spots and 
patches mostly at the perinuclear regions suggesting co-localization of mCherry-Rac1 































































3.4.2 Rac1 and Bcl-2 Co-immunoprecipitated with Each Other in Cancer Cells with 
Higher Bcl-2 Expression Levels but not in PBMCs from Normal Healthy 
Volunteers 
To further validate the preliminary results obtained previously from our 
laboratory that suggested a physical interaction between Rac1 and Bcl-2 based on in 
vitro GST pull-down assay with recombinant proteins, co-immunoprecipitation assays 
were performed with pull down of either anti-Rac1 and anti-Bcl-2, respectively, 
across four cancer cell lines with differential Bcl-2 expression levels. Indeed, Bcl-2-
overexpressing HeLa (H/B) cells showed significantly enhanced association between 
Rac1 and Bcl-2 in both pull downs as compared to the control vector matched HeLa 
cells (H/N) (Figure 10A). Similarly, Jurkat cells that have higher endogenous Bcl-2 
expression levels as compared to Raji cells, also exhibited greater levels of association 
between the two proteins (Figure 10B). To make sure the existence of a interaction is 
a cancer-specific observation, co-immunoprecipitation assay was also carried out with 
anti-Bcl-2 pull down in peripheral blood mononuclear cells (PBMCs) obtained from 3 
healthy donors and no detectable associated Rac1 was observed since Bcl-2 is also 
non-detectable in these samples (Figure 11). The input panels here showed the 
relative expression of the two interacting partners in the whole cell lysates of various 
cancer cell lines or samples from healthy donors, which could serve to semi-quantitate 
the percentage of proteins that formed complex in their whole intracellular pools. 
Isotype matched control IgG antibodies were used as a negative control here, which 
non-specifically bind to any sorts of proteins but does not specifically recognize the 

















































































































































3.5. Geranylgeranylation of Rac1 is Required for Its Mitochondria 
Localization and Interaction with Bcl-2 
3.5.1 Mitochondrial Localization of Rac1 is Independent on Bcl-2 Expression 
Levels 
Results discussed in the previous section based on co-immunoprecipitation 
analysis on the whole cell lysates from cancer cells with higher Bcl-2 expression 
levels confirmed a physical interaction between Rac1 and Bcl-2 (Figure 10). Since 
Bcl-2-induced pro-oxidant state in the mitochondria is mediated through Rac1 
activation, this raises the question: is this interacting complex also localized in the 
mitochondria so that they can take part in redox regulation? Preliminary results from 
our laboratory suggested that this complex is localized to the outer mitochondria 
membrane where Bcl-2 resides. In addition, the fluorescent microscopic analysis on 
subcellular distributions of the two proteins also indicated that they co-localized at the 
perinuclear regions (Figure 9). In order to provide more evidences for the subcellular 
localization of this interacting complex, we checked for the mitochondrial presence of 
Rac1 following subcellular fractionation. Indeed, Rac1 was found to be present in the 
mitochondria-enriched heavy membrane (HM) fractions of both CEM/Neo and 
CEM/Bcl-2 cells. Although these two cell lines differ in Bcl-2 expression levels, Rac1 
expression levels at mitochondria-enriched HM fractions were comparable (Figure 
12A) indicating the localization of Rac1 to the mitochondria is probably independent 
on Bcl-2 expression. To further validate this point, two human fibroblast cell lines, 
MRC5 and IMR90, which have barely detectable Bcl-2 levels, were utilized for 
analyzing the mitochondria distribution of Rac1. Indeed, a significant proportion of 
Rac1 is still present in the HM fractions apart from light membrane (LM) and 
cytosolic fractions, confirming that the presence of Rac1 in the mitochondria is 
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independent on Bcl-2 (Figure 12B). This corroborates with studies from other groups 
that also demonstrated the mitochondrial presence of Rac1[276-278]. Flotillin (an 
integral plasma membrane protein), the voltage-dependent anion channel VDAC (that 
is present on the outer mitochondrial membranes), and the cytosolic isoform of 
superoxide dismutase Cu/Zn SOD served as LM, mitochondria-enriched HM and 
cytosolic markers, respectively, to demonstrate that there is no cross contamination 
among different fractions (Figure 12A & B). Although HM fractions are highly 
enriched in mitochondria, they do include other membrane structures such as 
lysosomes. Therefore, a confocal microscopic analysis was also carried out in RFP-
Rac1 transfected HeLa/Neo cells followed by incubation with MitoTracker green to 
visualize the mitochondria. The cell-permeant MitoTracker probes would passively 
diffuse across the plasma membrane and get accumulated in active mitochondria due 
to the mildly thiol-reactive chloromethyl moiety that the probes contain. Indeed, 
overlay panel showed yellow membranous patches resembling typical mitochondria 
morphology (Figure 12C) indicating the mitochondrial localization of Rac1. 
Moreover, immunoelectron microscopy was performed to localize both Rac1 and Bcl-
2 in HeLa/Neo and HeLa/Bcl-2 cells. The immunoreactivity with anti-Rac1 was 
detected prominently at the outer mitochondrial membranes of HeLa/Bcl-2 cells, 
which is also the case for Bcl-2. Negative control with just the secondary antibody 
was also included to rule out any non-specific binding and no immunoreactions with 
DAB were observed (Figure 12D). All these strongly supported the mitochondrial 
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3.5.3 Geranylgeranylation of Rac1 Is a Pre-requisite for Its Interaction with Bcl-2 
Since a predominant localization for Bcl-2 is at the outer mitochondria 
membranes and we have also shown in the previous section that geranylgeranylation 
is essentially required for the mitochondrial targeting of Rac1, in order to confirm 
what the preliminary results have suggested in our laboratory that Rac1 interacts with 
Bcl-2 at the mitochondrial membranes, their interaction levels were measured through 
co-immunoprecipitation assay upon blocking of the geranylgeranylation process of 
Rac1 with GGTI. Indeed, when the mitochondrial import of Rac1 got inhibited 
substantially at 5 μM of GGTI (Figure 13), there was also a significant reduction in 
the interaction levels between Rac1 and Bcl-2 and even to a non-detectable level with 
10 μM of GGTI treatment observed in Jurkat cells (Figure 14). The intracellular 
levels of Rac1 and Bcl-2 were not changed upon GGTI treatment as shown in the 
lower input panel (Figure 14) indicating that the change in the interaction levels was 
not due to the change in total protein levels of the two partners but rather the change 
of the subcellular distribution of Rac1. This confirms that it is the membrane 








































































3.6. Active Rac1 Has a Higher Affinity towards Bcl-2 
3.6.1 Crude Activation of GTPases by GTP-γS Loading Increased Rac1-Bcl-2 
Interaction Levels while Inactivation by GDP Loading Showed the Opposite 
Combining the preliminary results from our laboratory as well as the results 
discussed in the previous sections, Rac1 is critically involved in Bcl-2-induced pro-
oxidant state in the mitochondria and this regulatory property is highly likely to be 
mediated through a physical interaction between the two proteins at the mitochondrial 
membranes. As is known, Rac1, when it is in a GTP-bound active form, can lead to 
activation of NADPH oxidases for O2.- production[264-267, 272, 273]; thus it is 
interesting to know the nucleotide binding status for the pool of Rac1 that is 
associated with Bcl-2. In order to address this question, several approaches were used 
and the first experiment carried out utilized a crude in vitro manipulation of the 
activation levels of GTPases in general by loading excessive amount of either the non-
hydrolysable GTP analog GTP-γS to lock them in constitutively active states or GDP 
to inactivate them. Since the nucleotides are not cell permeable, the incubation was 
done with whole cell lysates for 15 mins at 37°C with agitation[327]. Interestingly, in 
Bcl-2-overexpressing HeLa cells, those that were loaded with GTP-γS showed 
significantly elevated interaction levels between Bcl-2 and Rac1 as compared to 
control cells without any loading while those loaded with GDP showed a remarkable 
reduction (Figure 15A) indicating a direct correlation between Rac1 activation status 
and its interaction levels with Bcl-2. GTP- γS loading also resulted in a significant 
increase in the O2.- levels of the isolated mitochondria from CEM/Bcl-2 cells (Figure 
15B) corroborating the findings presented in section 3.3 that Rac1 regulates 































































































3.6.2 Transient Overexpression of a Dominant Negative Rac1 Mutant N17 
Decreased Rac1-Bcl-2 Interaction Levels  
Although GTP-γS loading greatly enhanced the interaction levels between 
Rac1 and Bcl-2 and GDP loading resulted in the opposite, this is a crude manipulation 
where all GTPases got activated or inactivated. In order to specifically manipulate the 
activation levels of Rac1, two Rac1 mutants were utilized, the constitutively active 
Rac1V12 and the dominant negative Rac1N17. The mutants are tagged with a 
polypeptide (12 amino acids long) derived from c-myc so as to differentiate with the 
endogenous Rac1 in the western blot analysis by about 1KDa in molecular weight. 
Rac1V12, with a glycine to valine substitution, is deficient in the intrinsic GTPase 
activity, thus the bound GTP cannot be hydrolyzed and is constitutively locked in the 
active state[241]. On the contrary, N17, a threonine to asparagine substitution mutant, 
which has essentially no affinity for GTP and reduced affinity for GDP, is constantly 
either in a nucleotide free form or the inactive GDP-bound form. It binds to Rac GEFs 
in a very high affinity therefore blocking the activation of endogenous Rac1 by these 
GEFs[103]. In HeLa cells that were transiently transfected with myc-tagged Rac1N17, 
there was a significant decrease in the interaction levels between endogenous Rac1 
and Bcl-2 as compared to control vector transfected cells (Figure 16). The decrease in 
the endogenous interaction levels could probably result from the inactivation of 
endogenous Rac1 due to the sequestration of Rac GEFs by the dominant negative 
Rac1N17 since the amount of introduced exogenous myc-tagged Rac1N17 is 
comparable to the endogenous levels as shown in the lower input panel (Figure 16). 
This indicates that Rac1, when it is in the inactive GDP-bound state, loses its affinity 
for Bcl-2. However, due to the relatively lower transfection efficiency of the myc-
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3.6.3 Pharmacological Inhibition of Rac1 Activity Decreased Its Interaction Levels 
with Bcl-2  
To further confirm that Rac1 activation status is critical in determining its 
binding affinity towards Bcl-2, the pharmacological inhibitor of Rac1, NSC23766 was 
used to block Rac1 interaction with Rac GEFs. Indeed, a significant reduction in the 
interaction levels between Rac1 and Bcl-2 was observed even at the lowest dose of 10 
μM of NSC23766 used in HeLa cells (Figure 17). Since NSC23766 only blocks the 
interaction of Rac1 with a certain range of GEFs (including Tiam1 and TrioN) but not 
all (such as Vav1), a second generation pharmacological inhibitor of Rac1, EHT1864 
was also used. EHT1864 binds to Rac1 in high affinity (with KD of 40 nM) promoting 
dissociation of bound nucleotides therefore locking Rac1 in an inert and inactive state. 
EHT1864 is more potent as compared to the first generation inhibitor NSC23766 in 
the sense that it is expected to block all downstream effectors both in vitro and in vivo. 
Furthermore, EHT1864 has been shown to block a variety of downstream signaling 
activities even in the presence of the ectopic expression of Rac1V12 in vivo which 
couldn’t be achieved with NSC23766. The IC50 for EHT1864 is about 2.5 μM, 20-
fold more potent as compared with NSC23766 and its specificity for Rac is also 
demonstrated where it does not affect other members in the Rho GTPases family such 
as RhoA and Cdc42[243, 328]. Indeed, Bcl-2-overexpressing CEM cells, upon 
exposure to 5 or 10 μM EHT1864 for 2 hrs, showed dose-dependent reduction in Bcl-
2-Rac1 interaction levels after normalizing against the internal control β-actin based 
on densitometry analysis with ImageJ (Figure 18) confirming once again that active 
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3.6.4 Rac1-Bcl-2 Interaction Is Dependent on Nox Activity and Two Isoforms of 
Nox Family Proteins Nox2 and Nox4 Are Present in the Mitochondria of Bcl-
2-overexpressing Cancer Cells 
As discussed in the previous sections from 3.6.1 to 3.6.3, Rac1, when it is in a 
GTP-bound state, has a higher affinity towards Bcl-2 and since active Rac1 is able to 
activate NADPH oxidases for O2.- production, it is interesting to investigate whether 
Nox activity in turn could affect the interaction levels between Rac1 and Bcl-2. A 
general inhibitor for flavin-containing enzymes, diphenyleneiodonium (DPI), was 
used to block the activity of NADPH oxidases. CEM/Bcl-2 cells were subcellularly 
fractionated after DPI treatment for 2 hrs followed by co-immunoprecipitation 
analysis. There was a significant reduction in the interaction levels of Rac1 and Bcl-2 
in mitochondria-enriched HM fractions following inhibition of NADPH oxidases 
(Figure 19A) suggesting that the interaction could be redox regulated. Interestingly, 
the interaction was, for the first time, observed in LM fractions as well (Figure 19A) 
indicating that this interacting complex is possibly not restricted to mitochondrial 
membranes alone. Both the interaction levels and the protein expression levels of 
Rac1 in LM fractions went up after DPI treatment (Figure 19A), the mechanisms of 
which await further investigation. Whereas for cytosolic fractions, there were no 
detectable interaction levels (Figure 19A) since Bcl-2 is usually not a cytosolic 
protein.  
 
Intrigued by this finding that inhibition of Nox activity affected the interaction 
levels in the mitochondria of Bcl-2-overexpressing cancer cells, a screen for the 
presence of Nox isoforms and subunits in the mitochondria was carried out. 
Preliminary results from the initial screen in different subcellular fractions of 
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CEM/Bcl-2 cells revealed that an isoform of Nox family, Nox4 was present in both 
the mitochondria-enriched HM fractions and LM fractions. Another isoform Nox2 
(p91phox) was also detected in both fractions although to a lesser degree in HM 
fractions. However, the subunit common to both Nox1 and Nox2 complex, p47phox, 
was only detected in LM fractions but not in HM fractions (Figure 19B). VDAC, 
Flotillin and Cu/Zn SOD were used as fraction markers to show that there was no 








































































































3.7. Residue F37 of Rac1 Is Critical in Its Interaction with Bcl-2 
In order to further characterize the exact domain(s) or even residue(s) of Rac1 
involved in its interaction with Bcl-2, four point mutants currently available in our 
laboratory were checked for their binding ability towards Bcl-2 through co-
immunoprecipitation analysis. The four mutants used were L37 (with phenylalanine 
substituted by leucine), H40 (with tyrosine substituted by histidine), H103 (with 
alanine substituted by histidine) and K166 (with glutamic acid substituted by lysine), 
which are all in the constitutively active V12 background. In addition, they are 
functional mutants as well: L37 is defective in actin cytoskeleton reorganization, H40 
is defective in JNK activation, while H103 and K166 are both defective in NADPH 
oxidases activation[103, 329, 330]. V12 was also included serving as a positive 
control since active Rac1 has been shown to have a higher binding affinity towards 
Bcl-2 in previous sections. In order to minimize the interference coming from the fact 
that H40 is defective in JNK activation and Ser70 of Bcl-2 has been reported to be a 
phosphorylation site for JNK[171, 176, 183-185], a Bcl-2 S70E mutant was used 
where Ser70 is mutated to glutamic acid to mimic a phosphorylated status, instead of 
a wild type Bcl-2, to rule out any possible interference from phosphorylation. 
Furthermore, instead of Rac1 or Bcl-2 antibodies, a myc-tag specific antibody was 
used to pull down the transiently introduced myc-tagged Rac1 mutants to prevent any 
interference from the abundantly expressed endogenous Rac1. The portion of Bcl-2 
that had been pulled down together with the myc-tagged Rac1 mutants was the 
ectopically introduced Bcl-2 S70E since HeLa has very low intracellular Bcl-2 levels 
as shown in the input panel (Figure 20). After normalizing for the ectopic expressed 
Rac1 and Bc-2 levels due to variations in transfection efficiencies, preliminary 
screening results revealed that one of the four functional mutants, L37, had a 
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remarkable reduction in its interaction levels with the ectopically expressed Bcl-2 
S70E (Figure 20). Interestingly, residue 37 lies in the Switch 1 effector region 
(residues 29-40) that interacts with the magnesium ion Mg2+ which stabilizes the 
binding of guanine nucleotides and this region is also involved in Rac1’s interaction 
with GEFs[242], suggesting that Bcl-2 interaction with Rac1 could have great impact 
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3.8. The BH3 Domain but not BH4 Domain of Bcl-2 is Required for Its 
Interaction with Rac1 In Vivo 
3.8.1 Bcl-2 BH3 Peptides Disrupted Rac1 and Bcl-2 Interaction at the 
Mitochondria In Vivo 
Bcl-2, as discussed earlier in the introduction, possesses four Bcl-2 homology 
(BH) domains[127] and preliminary in vitro results from our laboratory showed a 
BH3 domain but not BH4 domain dependency of Bcl-2 in its interaction with Rac1. 
To confirm this point and extend it further to in vivo conditions, Bcl-2-overexpressing 
CEM cells were incubated with a short stretch of peptides with 15 amino acids long 
from Bcl-2 BH3 domain (Figure 21B)   followed by co-immunoprecipitation analysis 
on different subcellular fractions. To make the peptides cell permeable, an HIV TAT 
(Human Immunodeficiency Virus trans-activator of transcription) protein was tagged 
to the peptides for increasing their in vivo uptake[331]. Indeed, upon 2 hrs exposure of 
the TAT-Bcl-2 BH3 peptides which sit in and block the BH3 domain groove, there 
was a significant reduction in the Rac1-Bcl-2 interaction levels in the mitochondria-
enriched HM fractions (Figure 21A) confirming the BH3 domain dependency of this 
interaction in vivo. Interestingly, similar to what was observed in Figure 19A, the 
interaction was also observed at the LM fractions (Figure 21A); however, the exact 


















































































3.8.2 Bcl-2 and Rac1 Interaction Is BH4 Domain Independent In Vivo 
Similarly, the involvement of BH4 domain of Bcl-2 in the interacting complex 
was also tested by using a short stretch of peptides (24 amino acids long) from the 
Bcl-2 BH4 domain (Figure 22C). However, contrary to what was observed with Bcl-
2 BH3 domain peptides, exposure to the cell permeable TAT-Bcl-2 BH4 peptides for 
2 hrs did not affect the Rac1-Bcl-2 interaction levels in the whole cell lysates of 
CEM/Bcl-2 cells. There was also no change in the intracellular expression levels of 
Rac1 and Bcl-2 (Figure 22A). Since Bcl-2 is known to interact with another small 
GTPase Ras through its BH4 domain, this interaction was probed as a positive control 
where BH4 peptides significantly disrupted the interaction between Bcl-2 and pan-
Ras (including all three isoforms H-Ras, K-Ras and N-Ras) even with the lowest dose 
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3.9. The Phosphorylation Status at the Flexible Loop Region of Bcl-2 Is 
Critical for Its Interaction with Rac1 
3.9.1 A Non-phosphorylatable Bcl-2 Mutant T69A/S70A/S87A, When 
Overexpressed Transiently, Failed to Interact with Endogenous Rac1 in 
Cancer Cells 
As discussed in the previous sections, the Bcl-2-Rac1 interaction showed a 
Bcl-2 BH3 domain dependency but a BH4 domain independency in vivo. To further 
characterize the binding domains of Bcl-2 involved in its interaction with Rac1, the 
flexible loop region, which connects BH3 and BH4 domains, was also examined with 
a particular focus on the phosphorylation status due to its implications on the anti-
apoptotic activity of Bcl-2[131, 162, 163]. A phosphorylation deficient Bcl-2 mutant 
T69A/S70A/S87A (AAA) was utilized here since alanine lacks the –OH group for 
addition of a phosphate group thus it cannot be phosphorylated while structurally it 
still resembles serine/threonine (except that the –OH group is replaced with –CH3 in 
the case of threonine). The three residues (Thr69/Ser70/Ser87) are in close proximity 
to BH3 domain and thus addition of a negative charge from the phosphate group 
could likely affect the binding affinity between Bcl-2 and Rac1. Upon 48 hrs transient 
transfection of this Bcl-2 AAA mutant into HeLa/Neo cells with relatively low 
endogenous Bcl-2 levels, co-immunoprecipitation assay was performed to analyse the 
binding ability of the mutant towards endogenous Rac1. The absence of a phospho-
Bcl-2 band in the input panel of western blot indicated that this is a bona fide 
phosphorylation deficient mutant, as compared to the wild type (WT) Bcl-2 which 
showed certain levels of phosphorylation upon transient introduction into the cells 
(Figure 23A). Interestingly, the phosphorylation levels of Bcl-2 also translated into 
its binding affinity towards endogenous Rac1 where the Bcl-2 AAA mutant 
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completely lost the affinity as compared to WT Bcl-2 (Figure 23A) suggesting that 
the phosphorylation status in one or more than one of the three residues in the flexible 
loop region could be important in determining Bcl-2’s binding affinity towards Rac1. 
In addition, Bcl-2 AAA mutant was also tested for its binding affinity towards Bax, 
which is a well-known homologous interacting partner for Bcl-2 within the Bcl-2 
family. No change in the interaction levels between Bcl-2 and Bax was observed 
(Figure 23B) indicating that although both Bax-Bcl-2 interaction and Rac1-Bcl-2 
interaction show a BH3 domain dependency, their binding pocket is unlikely to be 



































































































































3.9.2 Bcl-2 Phosphorylation Status at Ser70 Is Critical for Its Interaction with Rac1 
In an attempt to nail down on the exact residue(s) among the three 
(Thr69/Ser70/Ser87) in the flexible loop region of Bcl-2 that could be critically 
involved in its interaction with Rac1, both a single phosphorylation deficient mutant 
S70A and a single phosphomimetic mutant S70E were examined for their binding 
affinity towards Rac1. Glutamic acid is an effective phosphomimetic in the sense that 
it is basic with one negative charge and also structurally similar to phosphorylated 
serine. Co-immunoprecipitation analysis performed 48 hrs post-transfection of these 
two mutants into HeLa/Neo cells with relatively low endogenous Bcl-2 expression 
levels revealed that the non-phosphorylatable mutant S70A had minimal binding 
affinity towards endogenous Rac1 while the phosphomimetic S70E showed slightly 
enhanced binding affinity as compared to WT Bcl-2. The phosphorylation status of 
WT Bcl-2 as well as S70A and S70E mutants was shown in the input panel of the 
western blot analysis indicating a direct correlation between the phosphorylation 




















































































3.10. Active Rac1 Induces Phosphorylation of Bcl-2 at Ser70 
3.10.1 Transient Overexpressed Bcl-2 Got Phosphorylated at Ser70 in Cancer Cells 
with a Constitutively Active Rac1 (V12) Background 
To better characterize the two interacting partners in this complex, two 
functional elements that are critical for the interaction: the activation status of Rac1 
and the phosphorylation status of Bcl-2, were checked to study if there is any cross 
talk between each other. Human melanoma M14 cells stably overexpressing either a 
constitutively active myc-tagged Rac1V12 or a dominant negative myc-tagged 
Rac1N17 and harbouring low endogenous Bcl-2 expression levels, were transiently 
transfected with Bcl-2. Interestingly, a significant proportion of the introduced Bcl-2 
got phosphorylated at Ser70 in cells with Rac1V12 background which was not 
observed in control vector matched cells or cells with Rac1N17 background (Figure 
25) suggesting a direct causal relationship between Rac1 activation and subsequent 
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3.11. Active Rac1-induced Bcl-2 Phosphorylation at Ser70 is Mediated 
through JNK 
3.11.1 JNK Is a Potential Upstream Kinase Responsible for Rac1V12-induced Bcl-2 
Phosphorylation at Ser70 
The phosphorylation status of a protein depends on the activities of both 
kinase(s) and phosphatase(s). In an attempt to look for the kinase(s) that is(are) 
responsible for active Rac1-induced Bcl-2 phosphorylation at Ser70, one group of 
kinases that have been pinpointed as promising candidates are the c-Jun N-terminal 
kinases (JNKs). JNKs belong to the mitogen-activated protein kinase (MAPK) family 
and as their name imply, were originally identified as kinases that phosphorylate the 
transcription factor c-Jun at Ser63 and Ser73 leading to downstream transcription of 
its target genes[332]. Rac1 activation has been shown to result in JNK activation[259, 
261] and in addition, Ser70 of Bcl-2 has been demonstrated in various reports to be a 
target site for JNK phosphorylation[171, 176, 183-185]. To investigate on the 
involvement of JNKs in Rac1V12-induced Bcl-2 phosphorylation at Ser70, a general 
pharmacological inhibitor of JNKs (including all three isoforms JNK1, JNK2 and 
JNK3), SP600125, was used as a reversible ATP-competitive inhibitor with more than 
20-fold selectivity towards JNKs versus other kinases and enzymes[333]. As shown in 
Figure 28A, Bcl-2, when transiently transfected into M14 cells with a constitutively 
active Rac1V12 background, got phosphorylated at Ser70 as compared to control 
vector matched cells and the phosphorylation levels went down in a dose-dependent 
manner upon 2 hrs exposure to SP600125 indicating that active Rac1-induced Bcl-2 
phosphorylation at Ser70 was potentially mediated through JNKs. This was further 
verified in another cancer model of CEM/Neo cells where the 10 and 20 μM of 
SP600125 used effectively led to a dose-dependent reduction in the phosphorylation 
130 
 
levels of Bcl-2 at Ser 70 as well as a decrease in the phosphorylation status and total 
protein levels of the well-known JNK target c-Jun (Figure 28B). No changes in the 
total intracellular protein levels of Bcl-2 and Rac1 were observed upon inhibition of 
JNK activity. β-actin and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) were 
included in the western blot analysis as internal loading controls (Figure 28). 
However, at the doses of SP600125 used, inhibition of other kinases that are reported 
to be involved in Bcl-2 phosphorylation at Ser70 such as PKC and MKKs (MAPK 
kinases) [172, 173, 180-182]couldn’t be ruled out, although the inhibitory effect on 
those kinases would be to a much lesser extent as compared to the inhibition of 
JNKs[333]. Further experiments using targeted siRNA-mediated silencing of JNKs 













































r 48 hrs fo
rs and the
 anti-β-act







































3.11.2 Pharmacological Inhibition of JNK Activity Decreased Rac1-Bcl-2 
Interaction Levels 
Bcl-2 phosphorylation status at Ser70 has been shown to be important in 
Rac1-Bcl-2 interaction in the previous section 3.9. Therefore, co-immunoprecipitation 
analysis in two cancer cell lines, HeLa and Jurkat, was carried out upon inhibition of 
JNK activity that has been demonstrated earlier to result in a decrease in p-Bcl-2 
(Ser70) levels (Figure 28). Indeed, upon increasing doses of JNK inhibitor SP600125, 
a dose-dependent decrease in both the Bcl-2 phosphorylation levels at Ser70 as well 
as the interaction levels between Rac1 and Bcl-2 were observed in both the cancer cell 
lines tested (Figure 29). This was further supported by evidence from confocal 
microscopic analysis on the localizations of the endogenous Rac1 and Bcl-2 in HeLa 
cells. Endogenous Rac1 was stained with FITC-conjugated secondary mouse IgG that 
recognizes anti-Rac1 while endogenous Bcl-2 was stained with rhodamine-conjugated 
secondary rabbit IgG that recognizes anti-Bcl-2. An overlay of the green and red 
fluorescent signals coming from FITC and rhodamine, respectively, revealed 
spots/patches of yellow at perinuclear regions indicating a co-localization of these two 
proteins there. However, upon exposure to increasing doses of SP600125, the overlay 
of yellow gradually changed to a more orangish and then to a more reddish color 
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3.12. Disruption of Rac1-Bcl-2 Interaction Leads to a Compromise of the 
Pro-oxidant Status of Bcl-2-overexpressing Cancer Cells 
The data presented thus far have concluded that Rac1 physically interacts with 
Bcl-2 and the activation status of Rac1 as well as the BH3 domain of Bcl-2 are critical 
for the interaction. In order to gain further insight into the functional relevance of this 
interacting complex, with a particular focus on redox regulation in the mitochondria 
since Rac1 has been demonstrated in earlier sections to be involved in Bcl-2-mediated 
pro-oxidant status in the mitochondria. This was tested by using two approaches that 
could disrupt the interaction between Rac1 and Bcl-2: 1) a pharmacological inhibitor 
of Rac1; 2) Bcl-2 BH3 domain peptides. As shown in Figure 6, Bcl-2-overexpressing 
CEM cells, when exposed to increasing doses of the pharmacological inhibitor of 
Rac1 NSC23766 that could disrupt the Rac1-Bcl-2 interaction (Figure 17), showed a 
dose-dependent decrease in the mitochondrial O2.- levels suggesting a probable redox 
regulatory property of this interacting complex.  This was further supported by the use 
of TAT-Bcl-2 BH3 peptides which disrupted the interaction in the mitochondria of 
CEM/Bcl-2 cells (Figure 21). Similarly, exposure to the cell permeable BH3 peptides 
for 2 hrs also led to a dose-dependent decrease in the mitochondrial O2.- levels as 
measured by MitoSox dye in Bcl-2-overexpressing CEM cells whereas not much 
change was observed in control vector matched CEM cells with relatively lower Bcl-2 
expression levels (Figure 31A). Control peptides with scrambled sequence that does 
not match any region in human proteins were used as a negative control where the 
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3.13. Disruption of Rac1-Bcl-2 Interaction Sensitizes Bcl-2-
overexpressing Cancer Cells to Chemotherapeutic Drug-induced 
Apoptosis 
3.13.1 Bcl-2 Overexpression Confers Resistance towards Chemotherapeutic Drug 
Treatment  
Data presented in the previous section showed that disruption of the Bcl-2-
Rac1 interaction using two approaches either through pharmacological inhibition of 
Rac1 activity or blocking of the Bcl-2 BH3 domain resulted in a compromise of the 
pro-oxidant status in the mitochondria of Bcl-2-overepxressing CEM cells. As 
discussed in the introduction section 1.3.2 that the pro-oxidant status induced by Bcl-2 
contributes towards its anti-apoptotic property, this was further investigated here to 
check whether the chemoresistance observed in cancer cells with Bcl-2 
overexpression could be overcome through disruption of its interaction with Rac1 that 
compromised the pro-oxidant status. Two conventional chemotherapeutic drugs that 
are in routine clinical use, etoposide and vincristine, were employed here as triggers. 
Etoposide is a topoisomerase II inhibitor where it forms a ternary complex with DNA, 
which blocks re-ligation of the DNA strands causing strand breaks while vincristine is 
a mitotic inhibitor where it binds to tubulin dimers inhibiting the assembly of 
microtubule structures leading to mitotic arrest in metaphase. Both of these eventually 
result in mitochondria-mediated apoptosis in rapidly dividing cells[334, 335]. To 
establish the Bcl-2 overexpression-induced chemoresistance model, the sensitivity of 
CEM/Neo and CEM/Bcl-2 cells was tested against these two drugs. Indeed, both 
etoposide and vincristine resulted in significantly reduced cell viability in a dose-
dependent manner with Bcl-2-overexpressing CEM cells showing more resistance 
towards these two treatments as compared to CEM/Neo cells (Figure 32). Since the 
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MTT assay used here for cell viability measurement is not a direct assessment for cell 
death, a pre-incubation with the cell permeable pan-caspase inhibitor Z-VAD-FMK 
was performed prior to drug treatment in order to confirm that the cells were dying via 
drug-induced apoptosis. Z-VAD-FMK blocks the activity of all caspases via the 
irreversible binding to the catalytic sites of caspase proteases. Indeed, inhibition of 
caspases through 1 hr pre-incubation of Z-VAD that prevents apoptotic execution, led 
to a 90% or more rescue of the cell death in both CEM/Neo and CEM/Bcl-2 cells 
(Figure 33) indicating that the reduced viability observed with etoposide and 
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3.13.2 Combination Treatment of Bcl-2 BH3 Peptides with Chemotherapeutic Drugs 
Greatly Jeopardized the Viability of Bcl-2-overexpressing Cancer Cells 
In order to test whether disruption of the Rac1-Bcl-2 interaction could 
compromise the chemoresistance of Bcl-2-overexpressing cancer cells, a combination 
treatment including the BH3 peptides and the conventional chemotherapeutic drugs 
was used. The effect of Bcl-2 BH3 peptides on cell viability was checked and no 
significant change was observed in both CEM/Neo and CEM/Bcl-2 cells up till the 
dose of 20 μM used (Figure 34), consistent with what others have reported that Bcl-2 
BH3 peptides did not induced cytochrome c release from isolated mitochondria unlike 
Bax BH3 or Bad BH3 peptides[302]. As such, the dose of 10 μM of Bcl-2 BH3 
peptides that not only disrupted Rac1-Bcl-2 interaction as shown earlier in Figure 21 
but also had minimal effect on cell viability (Figure 34), was used for subsequent 
experiments. Meanwhile sublethal doses of the two drugs, etoposide (1.25 and 2.5 μM) 
and vincristine (15 and 25 nM), which caused less than 30% of cell death in 
CEM/Bcl-2 cells (Figure 32) were also chosen in order to maximize the potential 
synergistic effects for the combination treatment, if there are any. Indeed, the 
combination treatment with 1 hr pre-incubation of the Bcl-2 BH3 peptides followed 
by 24 hrs exposure to the drugs resulted in a statistically significant reduction in cell 
viability in CEM/Bcl-2 cells: around 50% more reduction with BH3 peptides and 
etoposide combination as compared to etoposide alone and 30-40% more reduction 
with BH3 peptides and vincristine combination as compared to vincristine alone, with 
p-values less than 0.05 (Figure 35A & B). Moderate synergistic effects were also 
observed in CEM/Neo cells, although to a less remarkable extent as compared to 
CEM/Bcl-2 cells (Figure 35A & B) indicating a better targeting for the Bcl-2 BH3 
peptides to cancer cells with Bcl-2 overexpression.  Control peptides with scrambled 
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3.13.3 Combination Treatment of Bcl-2 BH3 Peptides with Chemotherapeutic 
Drugs Resulted in a Remarkably Elevated Sub-G1 Population in Bcl-2-
overexpressing Cancer Cells 
In order to assess whether the reduction in cell viability observed upon 
combination treatment was due to cell death, a cell cycle profile analysis based on 
propidium iodide (PI) staining was performed. PI intercalates with DNA with a 
stoichiometry of one dye per 4.5 base pairs (bp); therefore, its fluorescence is a direct 
representation of the DNA content in a cell. In rapidly proliferating cells such as 
cancer cells, majority of the cells would be at G1 phase of the cell cycle, or growth 
phase (since this phase takes up approximately half of the time of the whole cell 
cycle), where they gear up biosynthetic activities to prepare for DNA synthesis during 
S phase. Once entering S phase, DNA synthesis commences and at the end of S phase, 
all the chromosomes have been replicated resulting in double the content of DNA (4N) 
and the increase in the DNA content can be picked up by PI staining shown as a right 
shift in the histogram of flow cytometry analysis. After the completion of DNA 
replication, the cell then enters G2 phase with significant biosynthesis mainly on 
microtubule production required for subsequent mitosis or M phase. It is not until the 
end of cytokinesis when the multiplied cell have divided into two daughter cells that 
the DNA content go back to 2N for a normal diploid cell[336]. However, for cells that 
are undergoing apoptosis, endonucleases will break the linkers between the 
nucleosomes, resulting in small fragments of DNA oligomers with about 180 bp. 
During the fixation and rehydration processes for PI staining, some of the lower 
molecular weight DNA got leached out and this will lead to a “hypodiploid” state 
observed with a sub-G1 peak that is shown as a left shift to G1 peak in the histogram 
of the flow cytometry analysis. For Bcl-2-overexpressing CEM cells, at resting state, 
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relatively low basal levels of sub-G1 population were detected (0.64% of whole cell 
population as indicated on the sub-G1 scale in the histograms) which went up to 2.45% 
and 5.43% with 1.25 and 2.5 μM of etoposide indicating that most probably there was 
a small population of cells undergoing apoptosis. Treatment with Bcl-2 BH3 peptides 
also did not result in much change in the sub-G1 population. However, the sub-G1 
population went remarkably higher to 28.49% and 50.28% with combination 
treatment of 10 μM Bcl-2 BH3 peptides and 1.25 and 2.5 μM of etoposide, 
respectively. Elevated sub-G1 population was also observed in CEM/Neo cells upon 
combination treatment although to a lesser extent as compared to CEM/Bcl-2 cells 
(Figure 36A). Cell cycle profile analysis was also performed for combination 
treatment of Bcl-2 BH3 peptides and vincristine where similar results were observed 
with 15- to 30-fold increase in the sub-G1 population following combination treatment 
as compared to vincristine treatment alone in CEM/Bcl-2 cells (Figure 36B). These 
findings, together with the cell viability analysis through MTT assay discussed in the 
previous section (Figure 35A & B), suggested that Bcl-2 BH3 peptides significantly 
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3.13.4 Combination Treatment of Functional Inhibition or siRNA mediated 
Silencing of Rac1 with Chemotherapeutic Drugs Greatly Jeopardized the 
Viability of Bcl-2-overexpressing Cancer Cells 
Data presented in the previous sections showed that Bcl-2 BH3 peptides, 
which disrupted the interaction between Rac1 and Bcl-2, could also sensitize Bcl-2-
overexpressing cancer cells to drug-induced apoptosis. To further investigate whether 
the chemoresistance resulted from Bcl-2 overexpression could be overcome through 
disruption of the interaction between Rac1 and Bcl-2, another two approaches were 
taken to disrupt the interaction either through pharmacological inhibition of Rac1 
activity or siRNA-mediated silencing of Rac1 expression levels and the subsequent 
sensitization effect towards drugs would be analyzed through MTT assay and cell 
cycle profile analysis. Apart from the two chemotherapeutic drugs used previously, an 
additional drug daunorubicin was also employed here, which intercalates with DNA 
leading to apoptotic cell death[337]. Pre-incubation with the pharmacological 
inhibitor of Rac1 NSC23766 at doses (5 and 10 μM) that had minimal effect on cell 
viability when used alone (Figure 7), resulted in a remarkable reduction in the cell 
viability following conventional drug treatment with etoposide, vincristine or 
daunorubicin. The greatest sensitization effect was observed in the combination 
treatment of 2.5 μM, 5 μM of etoposide or 100 ng/ml of daunorubicin with 10 μM of 
NSC23766 in HeLa/Bcl-2 cells and 1.25 μM, 2.5 μM of etoposide or 25 nM of 
vincristine with 5 μM of NSC23766 in CEM/Bcl-2 cells with p-values less than 0.05 
as compared to drug treatment alone (Figure 37). 
 
Apart from blocking the activity of Rac1 through a pharmacological inhibitor, 
a smart pool of exogenous siRNAs, the small interfering RNAs, which are targeted 
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specifically to Rac1, were transiently introduced into HeLa/Bcl-2 cells to knock down 
the expression levels of Rac1. The double-stranded siRNA pool, with short stretches 
of sequences (20 – 25 bp) matching to different regions of Rac1, base-pair to the 
target sites in a single strand RNA-enzyme complex called RISC (RNA-Induced 
Silencing Complex) and induce cleavage of the mRNA therefore preventing the 
mRNA from being translated into a protein product[338]. The siRNA-mediated 
silencing effect was confirmed through western blot analysis where the target protein 
expression, Rac1, was reduced to less than 20% of that in the negative control siRNA 
(with scrambled sequence) transfected cells (Figure 38A). The sensitivity of 
HeLa/Bcl-2 cells towards etoposide and vincristine following siRNA-mediated 
silencing was assessed via MTT assay where a statistically significant reduction in 
cell viability was observed in this combination regime as compared to the treatment of 
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3.13.5 Combination Treatment of Rac1 Inhibitor with Chemotherapeutic Drugs 
Resulted in a Remarkably Elevated Sub-G1 Population in Bcl-2-
overexpressing Cancer Cells 
To further understand whether the reduced cell viability observed with the 
combination treatment of Rac1 inhibitor and chemotherapeutic drugs was due to 
either a reduction in cell proliferation or an increase in cell death, cell cycle profile 
analysis based on PI staining was performed. Similar to the combination treatment of 
Bcl-2 BH3 peptides and drugs, this combination involving Rac1 inhibitor also 
resulted in a significant elevation in the sub-G1 population of CEM/Bcl-2 cells: about 
10-fold increase with the combination treatment of 5 μM NSC23766 and either 
etoposide or vincristine as compared to drug treatment alone (Figure 39). Elevation in 
the sub-G1 population was also observed upon combination treatment in CEM/Neo 
cells but to a much lesser extent (Figure 39) indicating that inactivation of Rac1 
activity could have more profound sensitization effect in cancer cells with higher Bcl-
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3.14. ™CELLWORKS In Silico Modelling Identified STAT3 as a 
Potential Downstream Functional Target of the Tumorigenic Rac1-
Bcl-2 Pathway 
3.14.1 Rac1 and/or Bcl-2 Overexpression Greatly Enhanced Phenotypic Indices on 
Tumourigenesis as Predicted by ™CELLWORKS In Silico Modelling while 
Knocking Down of Rac1 or Bcl-2 Expression Resulted in the Opposite 
To gain further insight into the functional relevance of the interaction between 
Rac1 and Bcl-2, computer simulation driven virtual predictive experiments based on 
the protein pathway dynamic network created by ™CELLWORKS Group Inc. were 
carried out. This is achieved by combining functional proteomics data based on 
various publications known to date together with engineering technologies and 
methodologies (such as interconnecting ordinary differential equations that describe 
enzyme kinetics, pathway flux distribution, etc.). It is a platform that mimics the 
human physiology system and allows the visibility into how pathways/phenotypes 
respond/change in a dynamic fashion upon certain stimuli/manipulation. The 
predictive results can be subsequently validated through wet lab experiments which 
greatly reduce the time and cost needed for the initial large-scale screening required 
otherwise[339]. With this virtual platform, it could serve as a visualization tool, in this 
case here, to predict the impact on tumorigenic phenotypes and pathway dynamics 
upon the presence or disruption of Rac1-Bcl-2 interaction in a cancer context. As such, 
an HCT116 human colorectal cancer cell line with K-Ras over-activation, PI3K 
(phosphoinositide 3-kinase) overexpression, CDKN2A (cyclin-dependent kinase 
inhibitor 2A) deletion and β-catenin overexpression was modeled in silico to 
recapitulate the major pathological system in colorectal cancer. An additional Bcl-2 
overexpression was created in virtual serving as a base line and based on this a variant 
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cell line with Rac1 overexpression was also set up (Figure 40A). As shown in Figure 
40B & C, phenotypic indices of angiogenesis, proliferation, viability, metastasis as 
well as tumor volume were all found to be amplified in the base and variant cell lines 
with Bcl-2 and/or Rac1 overexpression, as compared to the control HCT116 cells in 
the absence of Bcl-2 overexpression; on the contrary, upon knocking down of Rac1 or 
Bcl-2, these indices all went down in both the base and variant cell lines, confirming 
the tumorigenic effects of both proteins, in accordance with a plethora of published 
reports previously[126, 259-263, 279-281].  
 
Apart from these general tumorigenic phenotypes, change in redox status, in 
particular the O2.- levels, which have been well known to contribute to 
tumourigenesis[24, 47, 83, 84, 97, 103-110, 115], were also checked in the virtual 
HCT116 platform upon manipulation of Rac1 and/or Bcl-2 expression levels in silico. 
Indeed, overexpression of Bcl-2 in the base cell line resulted in a predicted significant 
elevated levels of O2.- as compared to the control (Figure 41), which is consistent 
with what has been described by our group as well as other groups that Bcl-2 acts as a 
pro-oxidant intrinsically[114, 203, 218, 225-227]. Additional overexpression of Rac1 
in the variant cell line resulted in double the amount of O2.- produced as compared to 
the base cell line while knocking down of either Rac1 or Bcl-2 in both the base and 
variant cell lines led to a decrease in the O2.- production (Figure 41). These predictive 
results are in accordance with our wet lab experimental data presented in earlier 
sections 3.1.1 (Figure 1) and 3.3 (Figure 6) confirming the definite involvement of 




Furthermore, a detailed look into the different apoptotic markers upon 
knocking down of Rac1 or Bcl-2 expression revealed that Bax, caspase 3 as well as 
cleaved PARP-1 (PARP-1, poly ADP ribose polymerase 1, which is involved in DNA 
damage repair and a substrate for activated caspase 3 protease during apoptosis[340, 
341]) all went up significantly (Figure 42) confirming once again the pro-survival 
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3.14.2 Rac1 and/or Bcl-2 Overexpression Greatly Amplified STAT3 Protein 
Levels as Predicted by ™CELLWORKS In Silico Modelling while 
Knocking Down of Rac1 or Bcl-2 Expression Resulted in the Opposite 
In an attempt to identify the potential downstream targets that could mediate 
the pro-survival effects of Rac1 and Bcl-2, a large-scale in silico screening was 
performed on all the proteins that have been documented so far to be involved in 
tumorigenic signaling. Bcl-2 overexpression in the base HCT116 cell line resulted in 
a significant amplification in the protein levels of STAT3 and β-catenin and an 
additional Rac1 overexpression in the variant cell line led to a further enhancement in 
the expression levels of these two proteins (Figure 43A). On the contrary, knocking 
down on the expression levels of Rac1 or Bcl-2 in both the base and variant cell lines 
affected the expression levels of four proteins including STAT3 and β-catenin which 
are also the targets in the overexpression models as mentioned above as well as 
AGER and NF-κB1(Figure 43B). AGER, the Receptor for Advanced Glycation End-
products, is involved in innate immunity[342] while NF- κB1, nuclear factor κ-light-
chain-enhancer of activated B cells p105 subunit, is a Rel (the Class II NF-κB 
transcription factors) protein-specific transcription inhibitor involved in a wide variety 
of cellular functions including proliferation and survival[343]. Apparently, the two 
proteins that are consistently in direct correlation with the changes in the expression 
levels of both Rac1 and Bcl-2 are STAT3 and β-catenin (Figure 43). Subsequent 
follow-up studies to validate these in silico predictive results were carried out through 
web lab experiments, with a specific focus on STAT3 in this thesis due to its 
documented involvement in mitochondrial respiration, ROS signaling and Rac1 
pathways[87, 89, 344, 345]. However validation for β-catenin, a subunit of the 
cadherin protein complex involved in Wnt signaling pathway that has been implicated 
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in oncogenesis[346], is beyond the scope of this thesis and will be carried out by other 
members in our laboratory. 
 
STAT3 belongs to the family of proteins named as signal transducers and 
activators of transcription. Upon receiving signals from upstream activated cytokine 
and growth factor receptors, STAT3 gets phosphorylated at Tyr705, homodimerizes 
and translocates to the nucleus modulating the transcription of downstream responsive 
genes[347-352]. It has been demonstrated by various groups that STAT3 is critically 
involved in the initiation, progression and maintenance of different types of 
cancers[348, 350-353]. Elevated levels of active STAT3 have been found in most of 
the major human malignancies, including leukaemia, lymphoma, multiple myeloma, 
melanoma, cervical squamous-cell carcinoma, osteosarcoma, head and neck 
squamous cell carcinoma, breast cancer, non-small-cell lung cancer, gastric carcinoma, 
hepatocellular carcinoma, pancreatic adenocarcinoma, cholangiocarcinoma, colorectal 
cancer, renal cell carcinoma, ovarian carcinoma and prostate carcinoma[348, 350, 
352-354]. STAT3-activated genes not only promote cell proliferation and survival, 
angiogenesis and metastasis but also inhibit apoptosis, differentiation and anti-tumor 
immune responses[348, 350-353, 355], therefore elevated levels of active STAT3 are 
usually associated with poor prognosis in many cancers[348, 350, 351, 353, 354, 356]. 
In addition, a constitutively active form of STAT3 has been shown to be sufficient in 
transforming normal epithelial and immortalized fibroblasts derived from prostate and 
breast tissues[357]. Active STAT3 is also required in the viral oncogene v-src-
induced cellular transformation[348, 353, 354, 357-359]. The oncogene addiction 
phenotype of these cancer cells that require continued STAT3 activation render it as a 
good candidate for anti-cancer therapy. Indeed, various studies have shown that 
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disruption in STAT3 signalling results in growth inhibition and apoptosis in cancer 
cell lines as well as tumor growth inhibition in mouse xenograft cancer models 
including myeloproliferative neoplasms, acute lymphoblastic leukaemia, glioblastoma, 
head and neck squamous cell carcinoma, breast cancer, lung adenocarcinoma and 
renal cell carcinoma[348, 351-353, 358, 360-366]. 
 
Apart from being a transcription factor for many genes that are of tumorigenic 
nature such as Bcl-2[357], what makes STAT3 an appealing candidate to follow up 
based on the predictive screening results is its involvement in mitochondrial 
respiration, ROS signaling and most importantly its physical interaction with Rac1 
and implications in Rac1 pathways[87, 89, 344, 345]. STAT3 has been found in the 
mitochondria, where it regulates cellular respiration. A loss of mitochondrial STAT3 
results in a decrease in the activity of both Complex I and II in the ETC leading to a 
decrease in the oxygen consumption rate. This function of STAT3 has been 
demonstrated to be independent on its transcriptional activity but rather dependent on 
the phosphorylation status of Ser727. However, the precise mechanism on how 
STAT3 regulates the activity of Complex I and II remains elusive[344]. It has also 
been shown that Rac1, when in an active form, can directly bind, through its effector 
domain, to STAT3. Moreover, STAT3 phosphorylation on both Tyr705 and Ser727 
can be stimulated with active Rac1, whereas dominant negative Rac1 inhibits STAT3 
activation induced by growth factors[345]. Furthermore, it is well known that Rac1 is 
involved in ROS production[264, 272, 273] and ROS have been demonstrated to 
activate Jak2 (Janus kinase 2) and TYK2 (tyrosine kinase 2) [87] that phosphorylate 
STAT3 while inhibiting low molecular weight-protein tyrosine phosphatase (LMW-
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3.14.3 Bcl-2-overexpressing Cancer Cells Harbour Higher Activation Levels of 
Mitochondrial STAT3 
Being intrigued by the in silico predictive results and the documented 
involvement of STAT3 in ROS signaling and Rac1 pathways[87, 89, 344, 345], a set 
of wet lab experiments were carried out in a sequential order to validate whether 
STAT3 is functionally relevant in the Rac1-Bcl-2 pathways.  First of all, the 
localization of STAT3 was examined through western blot analysis following 
subcellular fractionation and indeed, STAT3 was found both in the cytosolic as well 
as mitochondria-enriched HM fractions, where the latter is the resident place for the 
Rac1-Bcl-2 interacting complex. The mitochondrial distribution of STAT3 is also in 
consistence with reports from other groups[344]. Interestingly, although the protein 
levels of STAT3 in the HM fractions were comparable in both CEM/Neo and 
CEM/Bcl-2 cells, its phosphorylation status at Tyr705, which marked the activation 
levels, differed remarkably with Bcl-2-overrexpressing cells harbouring a higher 
phosphorylated levels of STAT3 (Figure 44). The phosphorylation levels of Bcl-2 at 
Ser70 were also higher in CEM/Bcl-2 cells apparently due to the higher total protein 
levels of Bcl-2. VDAC and Cu/Zn SOD were used as markers for HM and cytosolic 
fractions, respectively, to show that there was no cross contamination between 































































3.14.4 Bcl-2-induced STAT3 Activation is Mediated through Rac1 Activation and 
ROS Production 
In order to gain further insight into the relationship between STAT3 activation 
and Bcl-2 expression levels, Bcl-2 was transiently overexpressed in HeLa cells and 
the activation levels of STAT3 as marked by its phosphorylation levels at Tyr705 
were monitored through western blot analysis. Indeed, a clear causal relationship was 
observed where transient overexpression of Bcl-2 induced a significant increase in 
STAT3 phosphorylation levels at Tyr705 as compared to the empty vector transfected 
control cells (Figure 45).  
 
Since data presented in the section  3.2 showed that Bcl-2 overexpression 
induced Rac1 activation in cancer cells (Figure 3-4)  and it has also been reported that 
STAT3 phosphorylation on both Tyr705 and Ser727 can be stimulated with active 
Rac1 whereas dominant negative Rac1 inhibits STAT3 activation induced by growth 
factors[345], the pharmacological inhibitor of Rac1 EHT1864 was utilized to 
investigate whether Bcl-2-induced STAT3 activation could be mediated through Rac1 
activation. HeLa cells that stably overexpress Bcl-2 showed constitutively higher 
activation levels of STAT3 as marked by phospho-Tyr705 as compared to empty 
vector matched control HeLa/Neo cells. Interestingly indeed, a dose-dependent 
decrease in the phospho-STAT3 levels at Tyr705 was observed with increasing doses 
of EHT1864 (Figure 46) that locked Rac1 in an inactive state indicating that Rac1 
activation was required for Bcl-2-induced activation of STAT3. A dose-dependent 
decrease in the phosphorylation levels of Bcl-2 at Ser70 was also observed with 
EHT1864 corroborating with previous discussed data in the section  3.10 that active 
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3.14.5 Rac1, Bcl-2 and STAT3 Co-immunoprecipitated with Each Other in Cancer 
Cells with Higher Bcl-2 Expression Levels 
Data presented thus far revealed that Bcl-2-induced STAT3 activation was 
mediated through Rac1 activation and ROS production. Interestingly, these three 
proteins are functionally linked through physical interactions between Rac1 and Bcl-2 
as presented in the previous sections of this thesis (Figure 10) as well as between 
Rac1 and STAT3 as described by other groups[345]. Intrigued by these findings, co-
immunoprecipitation analysis was performed in different cancer cell lines with 
varying amount of Bcl-2 expression by pulling down each of these three proteins and 
probing for the rest two. Apart from the physical interactions known between Rac1 
and Bcl-2 as well as between Rac1 and STAT3, a novel physical interaction was 
observed between Bcl-2 and STAT3. All the three interactions (Rac1-Bcl-2, Rac1-
STAT3 as well as Bcl-2-STAT3) showed a Bcl-2 expression dependency where 
higher interaction levels were observed in cell lines with higher Bcl-2 expression 
levels such as Jurkat and HeLa/Bcl-2 (Figure 48). However, whether the activation of 
STAT3 could be a direct functional readout for its interaction with Rac1 or Bcl-2 
awaits further exploration. Of a particular note are the expression levels of STAT3, 
which seem to correlate with Bcl-2 expression levels as well in this case where Jurkat 
and HeLa/Bcl-2  had higher STAT3 protein levels as compared to Raji and HeLa/Neo, 
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CHAPTER 4: DISCUSSION 
 
4.1. Pro-oxidant vs. Reductive Intracellular Milieu in Cancers 
One common denominator for all cancers is the dysregulated or defective ratio 
between cell proliferation and cell death. Our group as well as others have 
hypothesized that reactive oxygen species (ROS) are one of the major underlying 
culprit signals, which has been supported by abundant evidences over the past couple 
of years[2, 24-32, 47, 82-110, 112-117, 120-122]. Unlike their universal detrimental 
effects at high concentrations among all reactive members of ROS, the exact 
proliferative and/or pro-survival roles ROS play at low doses depend very much on 
the ratio of respective species involved, to be specific, the ratio between O2.- and H2O2. 
It is now well established that, as compared to their normal counterparts, a number of 
cancers exhibit a constitutively elevated levels of O2.- which creates a pro-oxidant 
intracellular milieu favouring proliferation as well as survival (indirectly through 
inhibition of apoptosis). On the contrary, a reductive milieu is created when the ratio 
tilts in favour of H2O2, which is permissive for apoptotic execution[24, 47, 103-110]. 
In this regard, identifying potential intracellular targets responsible for maintaining 
the redox-mediated proliferative and/or pro-survival signals could have invaluable 
impact for cancer therapeutics and this has always been the interest of many 
researchers including our group. One of the targets that has surfaced and will remain 






4.2. Bcl-2-induced Chemoresistance Could be Mediated through Redox 
Regulation: A Non-canonical Perspective 
4.2.1 Bcl-2 as a Culprit for Inducing the Pro-oxidant Intracellular Milieu in Cancer 
Cells 
During the course in search for potential druggable targets that could be 
utilized to manipulate cellular redox status for therapeutic purpose, the anti-apoptotic 
protein Bcl-2 has come to our notice for its non-canonical role as a redox regulator[70, 
123, 203, 204]. It has been well established that Bcl-2 acts as an oncogene by virtue 
of its ability to guard the integrity of the mitochondrial membranes, for example 
through sequestration of the pro-apoptotic and/or BH3 only proteins of the Bcl-2 
family members[124, 126, 137, 152, 155, 156]. This has been linked to the lack of 
efficacy of chemotherapy regimens in hematopoietic and other malignancies where 
Bcl-2 overexpression is observed, be it intrinsic or acquired[123, 282-289].  However, 
it has not been clearly studied on other alternative paradigms that Bcl-2 relies on for 
apoptotic evasion. Being intrigued by the facts that ROS being the underlying signals 
for numerous tumorigenic events and Bcl-2 being localized at the sites of ROS 
generation, i.e. mitochondria, endoplasmic reticulum (ER) and nucleus, we began to 
explore the possibility of Bcl-2 being a redox regulator. Interestingly, the initial 
reports that linked Bcl-2 and ROS dated back as early as 1993 where Bcl-2 was 
described to protect against ROS-induced apoptosis decreasing ROS production and 
preventing oxidants-induced lipid peroxidation[112, 206]. Although subsequent 
studies suggested Bcl-2’s protective capacity against ROS triggers could be due to its 
function as an antioxidant, this was soon challenged by the findings that Bcl-2 itself 
possesses no intrinsic antioxidant property[215]. In 1995, a study done by 
Steinmann’s group revealed that on the contrary, Bcl-2 is inducing a basal oxidative 
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stress which led to the subsequent enhancement in the antioxidant capacity observed 
providing the first evidence that Bcl-2 is functioning as a pro-oxidant[225]. In that 
light, our laboratory observed in 2003 that in chronic myeloid leukaemia (CEM) cells, 
overexpression of Bcl-2 resulted in a mild but constitutive elevation in the 
intracellular O2.- levels creating a pro-oxidant milieu and this is demonstrated, for the 
first time, to contribute towards Bcl-2-mediated chemoresistance of those cells[114]. 
Similarly, we showed in this thesis as well that CEM cells stably overexpressing Bcl-
2 exhibited enhanced O2.- levels in the mitochondria (Figure 1) which confirms a 
definite pro-oxidant nature of Bcl-2 corroborating earlier findings from our group and 
others[114, 203, 218, 226, 227]. However, despite sharing homologous sequence and 
structure, another pro-survival member of the Bcl-2 family, Bcl-xL, could not 
function as a pro-oxidant by inducing an increase in the O2.- levels per se (Figure 2) 
indicating that the redox regulatory property, specific for Bcl-2, is very likely not 
related to its conventional role in preventing MOMP (mitochondrial outer membrane 
permeabilization). Being intrigued by this notion, we set off to explore the underlying 
mechanism(s) for this new facet of Bcl-2 biology in redox regulation. 
 
4.2.2 Mechanisms Employed by Bcl-2 in Inducing the Pro-oxidant State: 
Involvement of COX, Nox and Rac1 
4.2.2.1 Engaging the mitochondrial respiration through COX 
Bcl-2, being largely localized to the mitochondria[127], its connection with 
the mitochondrial respiration, a major source of intracellular ROS production[34], 
was first studied. A greater basal oxygen consumption rate and COX activity 
(cytochrome c oxidase or Complex IV, which is the rate-limiting step of the electron 
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transport chain (ETC)) was observed in Bcl-2-overexpressing cancer cells, which 
could explain, at least in part, to the elevated mitochondrial O2.- produced. More 
importantly, the impact of Bcl-2 on mitochondrial respiration is bidirectional where 
Bcl-2 can modulate the activity of COX and thus oxygen consumption upon “sensing” 
overt oxidative stress maintaining the ROS levels at an optimal threshold promoting 
survival of cancer cells. This is achieved through a physical interaction with the Va 
subunit of COX[203, 204]. 
 
4.2.2.2 Involvement of Nox  
Other than the mitochondrial respiration, the connection between Bcl-2 and 
another major intracellular source for ROS production, the Nox family proteins[43, 72, 
73], is also being studied in our laboratory. The first piece of evidence came from the 
observation that introduction of a general pharmacological inhibitor of Nox, DPI, led 
to a decrease in the intracellular O2.- levels in Bcl-2-overexpressing cancer cells[114]. 
Interestingly, here we showed that a preliminary screening of different Nox complex 
subunits in these cancer cells revealed the presence of 2 isoforms of Nox at the 
mitochondrial membranes, predominantly Nox4 and to a lesser extent Nox2 (Figure 
19B). Although the mitochondrial localization of Nox4 and its regulation on 
mitochondrial O2.- levels have been reported earlier in cultured mesangial cells, 
kidney cortex and cardiac myocytes[67-69], its particular involvement in the Bcl-2-





4.2.2.3 Preliminary findings: Activity of Rac1 is critical in Bcl-2-mediated pro-
oxidant state in cancer cells 
Another piece of evidence suggesting the involvement of Nox complex in Bcl-
2-mediated pro-oxidant status is from the report where our group showed that 
transient introduction of a dominant negative mutant of the small GTPase Rac1, a 
subunit of Nox complex which is required in a GTP-bound active form for the 
assembly and activation of Nox1, Nox2 and Nox3 complexes[59, 60, 273], led to a 
decrease in the intracellular O2.- levels of Bcl-2-overexpressing cells[114] indicating a 
functional involvement of Rac1 in Bcl-2-mediated pro-oxidant milieu. However, the 
use of dominant negative mutant Rac1N17 is confounding since it sequesters 
endogenous GEFs (guanine nucleotide exchange factors) shared by GTPases other 
than Rac1 as well[367], for example, its expression has been shown to interfere with 
the activation of RhoA by the Dbl GEF[368]. The problem on lack of specificity was 
later solved by using siRNA-mediated silencing targeted specifically at Rac1 and 
indeed knocking down the expression of Rac1 reduced the O2.- levels both 
intracellularly and intra-mitochondrially[70]. This is confirmed again in this thesis 
using a pharmacological inhibitor of Rac1, NSC23766, which disrupts the interaction 
between Rac1 and Rac specific GEFs such as TrioN and Tiam1[243]. Here we report 
that upon blocking of Rac1 activation (Figure 5), there was a significant drop in the 
O2.- levels in the mitochondria of Bcl-2-overexpressing cancer cells (Figure 6). Of 
particular note is the different extent in the decrease of Rac1 activation levels upon 
NSC23766 treatment in CEM cells with varying Bcl-2 expression levels where the 
inhibition of Rac1 activity was more prominent in Bcl-2-overexpressing CEM cells 
(CEM/Bcl-2) with higher basal activation levels to begin with as compared to the 
control vector matched CEM/Neo cells (Figure 5). The extent in the decrease of Rac1 
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activity is reflected in the degree of reduction in mitochondrial O2.- levels (Figure 6) 
indicating a direct correlation between these two. The functional involvement of Rac1 
in Bcl-2-mediated pro-oxidant state was further supported by the observations that 
Bcl-2 expression levels are directly correlated with GTP loading of Rac1 (Figure 3) 
and moreover activation of Rac1 can be induced upon Bcl-2 overexpression (Figure 
4). However, the exact mechanism for Bcl-2-induced Rac1 activation is currently still 
under investigation. Interestingly, it has been reported that similar to small GTPases, 
Bcl-2 has GTP binding property although the GTP loading mechanism has not been 
studied in details[369]. Intriguingly, the viral homologue of Bcl-2, BNIP-2, has been 
shown to bind to one of the Rho GTPases, Cdc42 and the corresponding Cdc42GAP 
(GTPase activating protein) as well stimulating the intrinsic GTPase activity of Cdc42. 
The association between BNIP-2 and Cdc42GAP is mediated through the homology 
between the catalytic domain of BNIP-2 with the noncatalytic domain of 
Cdc42GAP[370, 371]. These findings raise the possibility of Bcl-2 interacting with 
Rac1 or its corresponding GAP(s) or GEF(s) either directly or indirectly and 
modulating their activities leading to an induced Rac1 activation.  
 
4.2.2.3.1 Studies from other groups on the role of Rac1 in mitochondrial redox 
regulation 
The role of Rac1 in regulating O2.- production has been well established in 
phagocytes through activation of Nox2 complex as well as in non-phagocytic cells 
through activation of other isoforms such as Nox1 and Nox3[59, 60, 273]. However, 
most of the studies centre on Rac1 at the plasma membrane where Nox complexes are 
commonly known to be assembled and activated. Less is known about the role of 
Rac1 in the mitochondrial redox homeostasis except only a handful of reports. It has 
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been reported that Rac1 was enriched in the mitochondrial fractions as early as 
1995[276] and this is supported by another two reports in 2003 and 2012 [277, 278]. 
Indeed, the presence of Rac1 in mitochondria was also demonstrated by our group in 
2011[70] and it is further confirmed here in this thesis in a number of cell lines 
including not only cancerous but also normal immortalized human fibroblasts (Figure 
12). Up to date, there are only four reports that described a link between Rac1 and 
mitochondrial ROS production. Werner and group showed in 2002 that Rac1 
activation was induced upon integrin engagement in fibroblasts changing the 
mitochondrial membrane potential and leading to production of mitochondrial ROS, 
which was insensitive to Nox inhibition by DPI. Interestingly, the ROS production 
could be inhibited by Bcl-2 suggesting an indirect association of Bcl-2 in Rac1’s 
ability to modulate mitochondrial redox status[372]. Another report by Irani and 
group in 2003 also described that introduction of a constitutively active mutant 
Rac1V12 resulted in mitochondrial oxidative stress in human vascular endothelial 
cells leading to senescence of those cells. The production of mitochondrial ROS could 
be inhibited with the Complex I inhibitor rotenone but not with the Nox inhibitor 
apocynin and this was attributed to Rac1’s ability in generating intracellular ceramide 
which is known to disrupt mitochondrial ETC[373]. In addition, Nieto and group 
reported in 2005 that Rac1b, the splice variant of Rac1, through disruption of the 
mitochondrial transmembrane potential, was able to induce mitochondrial oxidative 
stress as well and this led to oxidative damage and genomic instability enhancing the 
invasiveness of the breast cancer cells[374]. More recently Carter and group showed 
that Rac1 localizes in mitochondria and can increase mitochondrial H2O2 production 
in alveolar macrophages of asbestosis patients, through direct electron transfer from 
cytochrome c[278]. These four reports indicated the involvement of Rac1 in 
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modulating mitochondrial redox status which is critical in oncogenesis or aging or 
other pathological states such as pulmonary fibrosis. Intrigued by these findings and 
our own observations that Rac1 is involved in Bcl-2-mediated pro-oxidant state both 
intracellularly[70] and intra-mitochondrially (Figure 6), we went ahead to investigate 
the underlying mechanism(s) and hypothesize a direct association between Bcl-2 and 
Rac1 since Bcl-2 is known to interact with other small GTPases including Ras[194], 
RalA and Cdc42[70] as well. Indeed we identified for the first time, a physical 
interaction between Rac1 and Bcl-2 at the mitochondrial level[70]. 
 
4.3. Identification of the Small GTPase Rac1 as a Novel Binding Partner 
for Bcl-2 and Characterization of the Binding Domains/Residues 
4.3.1 Existence of a Physical Interaction between Bcl-2 and Rac1 in Cancers with 
Bcl-2 Overexpression  
Previous results from our laboratory identified a direct association between 
Rac1 and Bcl-2 at the mitochondria both in vitro with cell free system and in vivo 
with cancer cell lines and lymphoma patient samples.  Here we confirmed once again 
on the existence of this physical interaction through co-immunoprecipitation assays 
(Figure 10) as well as co-localization between these two proteins through fluorescent 
microscopic analysis (Figure 9). The interaction is specific for cancerous cells, higher 
the Bcl-2 expression levels, higher the interaction levels (Figure 10) while no 
interaction was observed in peripheral blood mononuclear cells (PBMCs) obtained 




Interestingly, despite sharing sequence and structural homology, the 
interaction with Rac1 is specific to Bcl-2 but not other Bcl-2 family members such as 
Bcl-xL and Bax[70] raising the possibility that the interaction could potentially 
involve regions that are less conserved (e.g. the flexible loop region that links BH3 
and BH4 domains of the pro-survival members) or structurally dissimilar (e.g. a wider 
hydrophobic BH3 domain groove in Bcl-2 as compared to Bcl-xL)[129-134, 375]. 
These differences would affect the topology and electrostatic status of Bcl-2, which 
could probably explain its unique interacting property with Rac1. This intrigued us to 
go on to characterize the binding domains/residues involved which could have great 
impact not only on understanding the structural biology of Bcl-2 family members but 
also on future therapeutic design targeting specifically at malignancies with Bcl-2 
overexpression. 
 
4.3.2 Characterization of the Essential Binding Domains/Residues Required for the 
Rac1-Bcl-2 Interaction 
4.3.2.1 Geranylgeranylation at the C-terminus of Rac1 is required for its membrane 
localization and interaction with Bcl-2 
The trafficking of Rac1 to different membrane compartments is dependent on 
a post-translational modification named as geranylgeranylation, i.e. covalent 
attachment of a geranylgeranyl pyrophosphate (GGPP) group, to the C-terminal 
cysteine residue (CAAX motif) of Rac1. The GGPP moiety is then recognized by Rho 
GDI (guanine nucleotide dissociation inhibitor) to keep Rac1 in a soluble state in 
cytosol for subsequent shuttling to various membrane compartments[248]. Here we 
report that this post-translational modification is indeed essential in the mitochondrial 
190 
 
targeting of Rac1 where pharmacological inhibition of the geranylgeranyltransferase I 
resulted in a dose-dependent decrease in the protein levels of Rac1 at mitochondria 
(Figure 13). Similarly, another group also described recently that Rac1 localizes to 
the mitochondria in the alveolar macrophages of asbestosis patients, which is 
dependent on the geranylgeranylation of Cys189 at the C-terminus[278]. More 
importantly, we observed that upon inhibition of the enzyme that resulted in the 
failure of Rac1 to be targeted to mitochondria, there was a corresponding significant 
decrease in the interaction levels between Rac1 and Bcl-2 in the whole cell lysates 
(Figure 14) indicating that the mitochondrial localization, or at least the membrane 
localization of Rac1, is essential for its interaction with Bcl-2. Indeed, previous results 
from our laboratory confirmed that Rac1 interacts with Bcl-2 at the outer 
mitochondrial membranes based on electron microscopic and confocal microscopic 
analysis, co-immunoprecipitation and GST pull-down assays on different subcellular 
fractions[70].  
 
Interestingly, Bcl-2 has been shown to interact with another small GTPase Ras 
and a similar post-translational modification, i.e. farnesylation at the C-terminal 
CAAX motif (which differs from geranylgeranylation in the non-sterol isoprenoid that 
is added)[376], is essential for the association in the mitochondria[194]. Raf-1, the 
serine/threonine kinase downstream of the Ras subfamily of membrane associated 
small GTPases, has also been reported to associate with Bcl-2 and this helps in the 
targeting of Raf-1 to the mitochondrial membranes allowing phosphorylation of its 
targets there, e.g. the BH3 only protein Bad[195]. In addition, another report 
suggested that Bcl-2 is able to target the serine/threonine phosphatase PP1α to its 
substrate Bad via a tripartite interaction as well[377]. These findings lead us to 
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speculate whether the Rac1-Bcl-2 interaction that we reported could aid in the 
mitochondrial targeting of Rac1 in a similar fashion. However, although the 
expression levels of Rac1 in the total mitochondrial membranes seem to be 
independent on Bcl-2 expression (Figure 12), the presence of Nox isoforms in the 
mitochondria (Figure 19B), in particular Nox2 since Rac1 is known to be a subunit of 
the Nox2 complex, still raises the possibility that the microdomain(s) within the 
mitochondrial membranes where Rac1 resides could be affected via interaction with 
Bcl-2 thus allowing micro-targeting of Rac1 to site(s) of biological importance so that 
it could potentially mediate the assembly and activation of Nox complex(es) for O2.- 
production. Indeed, previous results from our laboratory (results not published) 
showed that proteinase K treatment that proteolytically depleted Bcl-2 from the outer 
mitochondrial membranes also decreased the mitochondrial levels of Rac1 although 
not completely suggesting that Bcl-2 could have a function in the sequestration of 
Rac1 in the outer mitochondrial membranes thus changing its localization within the 
mitochondria. 
 
4.3.2.2 The GTP-bound active form of Rac1 has a greater affinity for Bcl-2 
The nucleotide bound status of Rac1 is the second parameter that we have 
examined when investigating the requirements for its interaction with Bcl-2. Being a 
small GTPase that acts as a molecular switch, the GTP/GDP cycling of Rac1 is 
essential in carrying the upstream signals downwards. Based on a variety of methods 
to manipulate the activation levels of endogenous Rac1 including crude in vitro GTP-
γS/GDP loading (Figure 15A), transient introduction of the dominant negative 
Rac1N17 mutant (Figure 16) as well as the pharmacological inhibition of Rac1 
activity with either the 1st generation inhibitor NSC23766 (Figure 17) or the 2nd 
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generation inhibitor EHT1864 (Figure 18), we identified that the GTP-bound form of 
Rac1 that is active, has a significantly higher affinity towards Bcl-2 while the GDP 
bound inactive form of Rac1 has a minimal affinity. Interestingly, the interaction of 
Bcl-2 with Ras at the mitochondria, as mentioned in the previous section, also 
requires an activated GTPase[194]. 
 
This finding that active Rac1 has a higher affinity towards Bcl-2 is intriguing 
since first of all, Rac1, when it is activated, is known to aid in the assembly and 
activation of the Nox complexes for O2.- production[59, 60, 273] and this sheds light 
on the possibility that the Bcl-2-induced pro-oxidant state in the mitochondria could 
be mediated through its interaction with an activated Rac1. The further observation 
that the interaction between Rac1 and Bcl-2 is dependent on Nox activity (Figure 
19A) lends more weight to this hypothesis. Secondly, the essential requirement in the 
GTP loading for the interaction highlights that the nucleotide binding pocket of Rac1 
could be a potential contact site between the two interacting partners, which consists 
of 1) the two guanine recognition loops (residues 116-119 and residues 158-160); 2) 
the two phosphate-binding loops (residues 10-17 named as the P-loop, and residues 
57-61 including part of the Switch 2); 3) the Switch 1 effector loop region (residues 
29-40) that interacts with the ribose and the magnesium ion Mg2+. Moreover, the 
remarkable reduction in the Rac1-Bcl-2 interaction levels observed in cancer cells 
exposed to the 1st generation Rac1 inhibitor (that disrupts its interaction with Rac 
GEFs) also stresses the importance of the groove formed by Switch 1, Switch 2 and 




4.3.2.3 The effector loop region of Rac1, in particular residue 37, is implicated as a 
potential binding site with Bcl-2 
In an attempt to nail down on the domains/residues of Rac1 involved in its 
interaction with Bcl-2, we performed a preliminary screening on four point mutants of 
Rac1, L37F, H40Y, H103A and K166E and all these four mutants are in a 
constitutively active V12 background. In addition, they are functional mutants as well 
where L37 is defective in actin cytoskeleton reorganization, H40 is defective in JNK 
activation, H103 and K166 are both defective in NADPH oxidase activation[103, 329, 
330]. Co-immunoprecipitation analysis revealed that L37 mutant had a significantly 
reduced affinity towards ectopically introduced Bcl-2 in human cervical cancer HeLa 
cells while the rest three mutants had more or less comparable affinity as compared to 
Rac1V12 mutant after normalizing for different transfection efficiency (Figure 20). 
This indicates that the benzene ring present in the phenylalanine residue in the wild 
type Rac1 but lost when mutated to leucine could be somehow essential for the 
interaction. Interestingly, residue 37 lies in the Switch 1 effector loop region (residues 
29-40) that interacts with the magnesium ion Mg2+ which stabilizes the binding of 
guanine nucleotides corroborating our observation discussed in the previous section 
that GTP-loaded Rac1 had a greater affinity towards Bcl-2 (Figure 15A-18). In 
addition, the groove where Rac1 interacts with Rac GEFs also involves this 
region[242] and thus it is tempting to speculate that Bcl-2-induced Rac1 activation as 
we observed (Figure 3-5) could be mediated through a more efficient GEF(s) 
recruitment as a result of the Rac1-Bcl-2 interaction. Furthermore, the docking sites 
where the pharmacological inhibitor NSC23766 binds on Rac1 that could disrupt its 
interaction with Bcl-2 (Figure 17) include Asp38 and Asn39[243] which are right 
beside residue 37. All these suggest that the Switch 1 effector region of Rac1 could be 
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a potential contact site in its interaction with Bcl-2, which awaits further deletional 
mutation analysis for confirmation. The flexibility of the Switch 1 effector loop is 
probably important for specificity towards different GEFs to signal distinct 
downstream functions; therefore, interaction with other proteins at this region[242, 
243], in our case with Bcl-2, could potentially in turn alters the conformation of Rac1 
and modulates its activity, opening doors to further exploration. 
 
4.3.2.4 The Rac1-Bcl-2 interaction shows a Bcl-2 BH3 domain dependency 
After identification of the three critical parameters in Rac1 that are essentially 
required for its interaction with Bcl-2, namely the geranylgeranylation modification, 
activation status as well as the Switch 1 effector loop region of Rac1 (Figure 14-18 & 
20), we went on to characterize the domains/residues in Bcl-2 that are critical for the 
interaction. Structurally, Bcl-2 possesses four Bcl-2 homology (BH) domains, namely 
BH1, BH2, BH3 and BH4 domains as well as a carboxyl terminal hydrophobic 
transmembrane domain (TM) responsible for its membrane localization. The 
hydrophobic groove present on the surface of the protein that is formed by BH1, BH2 
and BH3 domains has been reported to be mostly essential in heterodimerization of 
Bcl-2 with BH3 domain containing pro-apoptotic family members[128]. However, 
there are also interesting reports showing that the BH3 domain binding groove of Bcl-
2 can interact with non-familial proteins such as Beclin-1 for initiation of autophagy 
as well as GSH for redox regulation at the mitochondria[223, 378]. On the other hand, 
the BH4 domain is mostly involved in the interaction of Bcl-2 with other non-
homologous proteins including Ras[194], Raf-1[196] and PP2A[186], etc. As such, 
we started off by examining the involvement of BH3 and BH4 domains of Bcl-2 in its 
interaction with Rac1 using a peptide walking approach. Peptide walking was first 
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utilized to map the functional binding domains between Rac1 and NADPH oxidase, 
which is a useful tool to study the activity of an interacting complex[271]. Synthetic 
BH3 domain peptides that are able to sit in the hydrophobic groove of Bcl-2 pro-
survival family members and dislodge their pro-apoptotic binding partners, have been 
widely used to study the homodimerization and heterodimerization within the family 
and their subsequent effects on apoptosis[155, 158, 304].  
 
Exposure to short stretches of amino acids corresponding to the BH3 domain 
of Bcl-2 with cell permeable tags resulted in a remarkable disruption in the interaction 
levels at mitochondrial membranes in vivo (Figure 21) indicating a BH3 domain 
dependency for Rac1-Bcl-2 interaction corroborating our previous results using BH3 
peptides in vitro as well as small-molecule BH3 mimetics in vivo[70]. Although the 
cell permeable Bcl-2 BH4 peptides successfully disrupted the interaction between 
Bcl-2 and Ras as described by others that Ras-Bcl-2 interaction is BH4 domain 
dependent[194], there was no change in the Rac1-Bcl-2 interaction observed in 
vivo(Figure 22) which is in consistency with our previous results in vitro[70] 
indicating that Bcl-2 BH4 domain is most likely not involved in its interaction with 
Rac1. Despite the homology between Rac1 and Ras which both fall under the Ras 
superfamily of small GTPases, the presence of an additional insert region in Rac1 
(residues 124-135) distinct from Ras[379] could be a highly probable contributing 




4.3.2.5 Phosphorylation status at the flexible loop region of Bcl-2, in particular the 
residue Ser70, is critical for its interaction with Rac1 
The finding discussed in the previous section that Rac1-Bcl-2 interaction 
showed a BH3 domain dependency raises the question whether Rac1 would compete 
with the pro-apoptotic Bcl-2 family proteins, which also bind to the BH3 domain 
groove of Bcl-2[128]. In our quest to figure out whether or not there is an existence of 
a competitive binding which could have profound effects for apoptotic signalling, we 
examined the adjacent region that lies in between BH3 and BH4 domains of Bcl-2, 
namely the flexible loop region[129]. Based on X-ray crystallographic and nuclear 
magnetic resonance (NMR) spectroscopic studies on Bcl-xL[129], a putative 
unstructured loop is also present in Bcl-2 between the first and second helix[128].  In 
addition, specific residues within that flexible loop, to be specific Thr56, Thr69, 
Thr74, Ser70 as well as Ser87, are subjective to phosphorylation in response to a 
variety of stimuli[130-134]. Although the significance of Bcl-2 phosphorylation in the 
flexible loop region on its anti-apoptotic activity has been controversial, a closer 
examination on the specific residues being phosphorylated reveals that generally 
speaking, single site phosphorylation on Ser70 enhances Bcl-2’s anti-apoptotic 
function while multi-site phosphorylation on Thr69, Ser70 and Ser87 leads to both 
activation/inactivation of Bcl-2 depending on the cellular context[171-174].  
 
As such, we first made use of a triple Bcl-2 mutant T69A/S70A/S87A (AAA) 
where the respective serines or threonine are replaced by alanines thus it cannot be 
phosphorylated. Interestingly, the transiently introduced non-phosphorylatable Bcl-2 
mutant AAA completely lost its ability to interact with endogenous Rac1 while it still 
retained the ability to bind endogenous Bax (Figure 23). This suggests that although 
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both Rac1 and Bax associate with the BH3 domain groove of Bcl-2, Rac1 is probably 
associating with the region of BH3 groove that is closer to the flexible loop region 
(since phosphorylation status of Thr69, Ser70 and Ser87 are critically required for the 
interaction) thus it is highly likely that the region where Bax associates with Bcl-2 
remain largely unaffected when Rac1 binds Bcl-2. Subsequent experiments 
attempting to nail down on the exact residue(s) involved revealed that the 
phosphorylation deficient mutant of Ser70, S70A had a similarly minimal binding 
affinity towards Bcl-2 while the phosphomimetic mutant S70E had the opposite effect 
(Figure 24) indicating that the phosphorylation status at Ser70 alone is positively 
correlating with the interaction levels between Bcl-2 and Rac1. These findings are 
intriguing since single site phosphorylation on Ser70 has been reported to enhance the 
anti-apoptotic activity of Bcl-2[172, 174] and this leads us to speculate that it could be 
mediated through its interaction with Rac1, at least partially. Interestingly, studies 
from other groups have also shown the importance of the phosphorylation status in 
the loop region of Bcl-2 on its interaction with other proteins such as p53[201] and 
FKBP38[197-199] leading to modulation of the anti-apoptotic activity of Bcl-2. 
 
4.3.2.6 Crosstalk between Rac1 activation and Bcl-2 phosphorylation at Ser70: 
Involvement of the kinase JNK and ROS production 
So far we have identified five critical parameters that are required in Rac1-
Bcl-2 interaction, namely the geranylgeranylation of Rac1 (Figure 14), the activation 
of Rac1 (Figure 15A-18), the Switch 1 effector loop region (in particular residue 37) 
of Rac1 (Figure 20) as well as the BH3 domain groove of Bcl-2 (Figure 21) and the 
phosphorylation of the flexible loop region (in particular Ser70) of Bcl-2 (Figure 23 
& 24). In order to investigate if there is any cross talk between these parameters, we 
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started off by checking the link between Rac1 activation and Bcl-2 phosphorylation 
since one group of the kinases responsible for phosphorylating Bcl-2 at Ser70, 
JNKs[171, 176, 183-185], are also known to function downstream of Rac1 
activation[259, 261]. Indeed, the existence of cross talk between Rac1 and Bcl-2 was 
identified where active Rac1 can induce the phosphorylation of Bcl-2 at Ser70 and 
this was confirmed via manipulation of Rac1 activity either through introduction of 
Rac1V12 or Rac1N17 mutants both transiently (Figure 26) and stably (Figure 25) or 
through the pharmacological inhibition of Rac1 (Figure 27). A preliminary screening 
on the kinase involved revealed that pharmacological inhibition of JNK activity 
resulted in a dose-dependent decrease in the constitutively active Rac1V12-induced 
Bcl-2 phosphorylation at Ser70 (Figure 28), which led to the subsequent disruption of 
Rac1-Bcl-2 interaction (Figure 29-30) emphasizing again on the importance of the 
phosphorylation status at Ser70 of Bcl-2 for its interaction with Rac1. Together with 
the results discussed in earlier sections that Bcl-2 overexpression led to Rac1 
activation, the identification of the crosstalks between these three parameters, Bcl-2 
overexpression, Rac1 activation and Bcl-2 phosphorylation at Ser70, suggest the 
possibility of the existence of a positive feedback loop in cancer cells with Bcl-2 
overexpression which establishes an enhanced interaction between Rac1 and Bcl-2. 
 
Interestingly, phosphorylation levels of Bcl-2 at Ser70 were also decreased 
with DPI treatment (Figure 47) indicating that it could also be redox regulated. The 
ROS could be coming from Rac1 activation-induced Nox complex activation, which 
either affect the corresponding kinase(s) or the phosphatase(s). It is well established 
that JNKs, being among the oxidation-reduction-sensitive mitogen-activated protein 
kinase (MAPK) members, can be activated through redox changes such as elevated 
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levels of O2.- as well as H2O2[380-385]. On the other hand, the activity of the 
serine/threonine protein phosphatase, PP2A (where Ser70 of Bcl-2 is one of its 
substrates[186-189]), has also been shown to be susceptible to redox changes[386-
392]. Indeed, unpublished results from our laboratory provide evidence that PP2A is 
inactivated through S-nitrosylation mediated by the production of peroxynitrite from 
O2.- and No.. Taken together, the activation of JNKs and inactivation of PP2A under 
the pro-oxidant state induced by Bcl-2 could explain the constitutively elevated 
phosphorylation levels at Ser70 of Bcl-2 itself enhancing its affinity towards Rac1. 
This also corroborates with the observation that inhibition of Nox activity by DPI 
resulted in a decrease in the Rac1-Bcl-2 interaction at mitochondrial membranes 
(Figure 19A). 
 
4.4. Functional Implications of the Rac1-Bcl-2 Interaction in Redox 
Regulation: Clinical Relevance for Targeted Cancer Therapy 
4.4.1 Disruption of the Rac1-Bcl-2 Interaction Compromises Bcl-2-induced Pro-
oxidant Milieu in Cancer Cells 
As discussed earlier, it is well established that Bcl-2 functions as a pro-
oxidant[70, 123, 203, 204] and we demonstrated here once again that overexpression 
of this protein could indeed induce a mild but constitutive elevation in the 
mitochondrial O2.- levels in cancer cells (Figure 1). On the other hand, the small 
GTPase Rac1 is also known to be involved in O2.- production through activating Nox 
complexes[59, 60, 273]. The fact that there is a physical interaction between these two 
proteins at the mitochondrial membranes[70] which is confirmed in this thesis as well 
(Figure 10 & 14) makes it tempting to hypothesize that Bcl-2-induced pro-oxidant 
200 
 
state, particularly at the mitochondria, could be mediated through its interaction with 
Rac1. Indeed, GTP-γS loading that resulted in a dramatic increase in Rac1-Bcl-2 
interaction levels (Figure 15A) led to a prominent increase in O2.- levels in the 
mitochondria of CEM/Bcl-2 cells (Figure 15B). Moreover, two approaches that 
disrupted the interaction between Rac1 and Bcl-2, either through the use of the 
pharmacological inhibitor of Rac1 NSC23766 (Figure 17) or the Bcl-2 BH3 domain 
peptides (Figure 21), both resulted in a significant drop in the mitochondrial O2.- 
levels in Bcl-2-overexpressing CEM cells (Figure 6 & 31) suggesting that disruption 
of the interaction led to a compromise in the pro-oxidant state of those cancer cells. 
Similarly, we have previously reported that transient introduction of the dominant 
negative Rac1N17, which not only had minimal affinity towards Bcl-2 itself but also 
remarkably abolished the interaction between endogenous Rac1 and Bcl-2 as shown 
in Figure 16, led to the same compromising effect on the pro-oxidant milieu as 
well[114]. Whether inhibition of the post-translational geranylgeranylation process by 
GGTI, that resulted in a significant reduction in Rac1-Bcl-2 interaction (Figure 14), 
also would lead to a compromise in Bcl-2-induced pro-oxidant state remains to be 
explored. Nonetheless, the suppressing effect of GGTI on O2.- production by NADPH 
oxidase was reported. It has also been demonstrated by another group that a reduction 
in  O2.- production stimulated by constitutively active mutant H-Ras or PDGF or IL-
1β was observed following GGTI exposure in pulmonary vascular smooth 
muscle[393]. In addition, inhibitory effect of GGTI on O2.- production in LPS-
stimulated microglial cells was reported as well[394]. All these findings make it 
tempting to speculate a similar effect of GGTI on the pro-oxidant state in Bcl-2-
overexpressing cancer cells. However, further evidences based on point mutants of 
either Rac1 (such as L37) or Bcl-2 (such as S70A) with minimal interacting affinity 
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are still needed to confirm the redox regulatory property of Rac1-Bcl-2 interaction. 
Nonetheless, the importance of Bcl-2 BH3 domain and the activation status of Rac1 in 
Bcl-2-mediated pro-oxidant state in cancer cells cannot be overestimated. 
Interestingly, transient introduction of another pro-survival Bcl-2 family member Bcl-
xL (Figure 2), which does not interact with Rac1[70], did not alter the intracellular 
O2.- levels providing further evidence in favour of our hypothesis. 
 
4.4.2 Overcoming Bcl-2-mediated Chemoresistance in Cancers: Cellular Redox 
Status as a Novel Target 
Overexpression of Bcl-2 has been well known as one of the mechanisms for 
chemoresistance in cancers, be it intrinsic or acquired, which has been associated with 
poor disease prognosis[123]. This is mainly observed in hematologic 
malignancies[282]; however recently the list of examples in solid tumours is on the 
increase as well[283-289]. The failure of conventional chemotherapeutic drugs to 
induce apoptosis in Bcl-2-overexpressing cancers has urged the need to develop 
targeted therapy for Bcl-2 specifically in the clinical settings. With regards to this, the 
emerging role of Bcl-2 as a redox regulator[70, 123, 203, 204] as well as the 
significance of ROS in cell fate decision[2, 24-32, 47, 82-110, 112-117, 120-122] 
discussed in previous sections of this thesis, have highlighted the potential of a novel 
approach that combines the targeting of pro-oxidant Bcl-2 with conventional 
therapies[123, 290]. To that end, we have utilized treatment regimes that combine 
sublethal doses of chemotherapeutic drugs currently available in the clinics with the 
different agents that have all been demonstrated to compromise the pro-oxidant state 
in Bcl-2-overexpressing cancer cells including the Bcl-2 BH3 domain peptides 
(Figure 31), the pharmacological inhibitor of Rac1 (Figure 6) as well as siRNA 
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targeted specifically at Rac1 to knock down its expression levels[70]. Since both the 
anti-apoptotic activity of Bcl-2 as well as Rac1 activation are essentially required for 
survival, in order to observe the synergistic effects, if there are any, we picked up 
doses of the Bcl-2 BH3 peptides and Rac1 inhibitor to be on the lower end which 
manifested the blocking effect on mitochondrial O2.- levels (Figure 6 & 31A) but yet 
had minimal killing effect for the cancer cells (Figure 7 & 34). Altogether there were 
three main combination regimes tested in Bcl-2-overexpressing cells (both in CEM 
and HeLa): 1) Bcl-2 BH3 peptides with either etoposide or vincristine; 2) Rac1 
inhibitor with either etoposide or vincristine or daunorubicin; 3) siRNA targeted at 
Rac1 with either etoposide or vincristine. Most of these combination therapies 
resulted in statistically significant reduction in the cell viability (p-values less than 
0.05) as compared to drug treatment alone (Figure 35, 37 & 38). Peptides with 
sequence not matching any existing human proteins were also included as a negative 
control and no change in the cellular response to drugs was observed (Figure 35C & 
D). These findings indicate the existence of synergism when combining conventional 
DNA damaging (etoposide and daunorubicin)[335, 337] or mitotic inhibiting 
(vincristine)[334] chemotherapeutic drugs with agents that targeted to compromise 
Bcl-2’s pro-oxidant property. In addition, significant elevation in the sub-G1 
population was observed in the BH3 peptides and Rac1 inhibitor combination 
regimens (Figure 36 & 39) indicating that the cancer cells were probably dying 
through apoptosis as a result of destabilization of the anti-apoptotic activity of Bcl-2 
via blocking its pro-oxidant property.  
 
These novel findings shed light on the potential development of combination 
treatment for cancers that include both the conventional drugs and the targeted 
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therapies that could manipulate the cellular redox status and in our case here, through 
blocking the pro-oxidant property of the anti-apoptotic protein Bcl-2. Furthermore, 
the identification of Rac1-Bcl-2 interaction in patients diagnosed with diffuse B-cell 
lymphoma, follicular lymphoma and chronic lymphocytic leukaemia[70] but not in 
noncancerous PBMCs (peripheral blood mononuclear cells) (Figure 11) demonstrated 
the translational relevance of targeting this redox regulating complex for future cancer 
therapeutics design without incurring much toxicity to normal tissues. Among the five 
parameters that we have identified to be essential for the Rac1-Bcl-2 interaction as 
reported in this thesis, the geranylgeranylation of Rac1, the activation status of Rac1 
and the BH3 domain of Bcl-2 are all promising targets that could be exploited as 
means to disrupt the interaction to achieve potential therapeutic outcome. Indeed, one 
of the BH3 mimetics, ABT-737, which binds to the BH3 domain groove of Bcl-2, is 
currently in phase II clinical trial[311] and its modified version, ABT-263, with 
higher oral availability, is now in phase I/II clinical trials as well for the management 
of various human malignancies including chronic lymphocytic leukaemia (CLL), non-
Hodgkin’s lymphoma (NHL) and small cell lung cancer[311, 317-319]. The inhibitor 
for the geranylgeranylation process, GGTI-2418, has also demonstrated promising 
results both in vitro and in animal models and is currently in phase I clinical trial for 
patients with refractory solid tumours[395]. Although GGTI-2418 is originally 
developed mainly to treat cancers that are addicted to mutant Ras (where K-Ras and 
N-Ras undergo alternative geranylgeranylation when farnesylation is inhibited) and 
the downstream small GTPases in the Ras pathway[395], it would be interesting to 
investigate its potential usage in Bcl-2-overexpressing cancers vis-a`-vis the effect 




4.5. A Computational Approach Based on the Virtual Cancer Platform 
from ™CELLWORKS Identified Potential Therapeutic Targets for 
Further Exploration in Human Malignancies with Bcl-2 
Overexpression 
4.5.1 ™CELLWORKS In Silico Modelling Confirmed the Tumorigenic Nature of 
Rac1-Bcl-2 Pathway 
We have discussed thus far that Bcl-2-induced pro-oxidant state, which 
contributes towards chemoresistance, could be mediated through its interaction with 
Rac1. To further assess the functional relevance of this interaction in the cancer 
context, we carried out computer simulation driven predictive experiments in 
collaboration with ™CELLWORKS Group Inc.. This is achieved through a virtual 
platform that mimics the human physiology system which serves as a visualization 
tool to predict the impact on phenotypes and pathway dynamics upon certain 
stimuli[339], which in this case here would be the presence or blockage of Rac1-Bcl-2 
interaction through manipulating their expression levels. The cell line used is a 
modelled HCT116 which recapitulates the relevant genetic abnormalities in human 
colorectal carcinoma. An additional Bcl-2 amplification was created to mimic 
malignancies with Bcl-2 overexpression and this is treated as a base line and a variant 
cell line with Rac1 overexpression based on the base line was also created (Figure 
40A). In consistency with the literature findings on the tumorigenic nature of both 
Rac1 and Bcl-2[126, 259-263, 279-281], it was reflected in the predictive results that 
the phenotypic indices of angiogenesis, proliferation, viability, metastasis as well as 
tumor volume are all positively correlated with Bcl-2 and/or Rac1 expression levels 
(Figure 40B & C). Moreover, the pro-oxidant nature of Bcl-2 in inducing an elevated 
O2.- levels and the functional involvement of Rac1 in the pro-oxidant intracellular 
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milieu of Bcl-2-overexpressing cancer cells were also confirmed in the simulated 
model (Figure 41) corroborating our wet lab findings (Figure 1 & 6)[70]. Knowing 
that slightly elevated O2.- levels have been well demonstrated to contribute to 
tumourigenesis[24, 47, 83, 84, 97, 103-110, 115], these computer simulated 
predictions lend further weight to our hypothesis that the pro-oxidant state observed in 
malignancies with Bcl-2 overexpression could be attributed to its interaction with 
Rac1 leading to chemoresistance and tumour progression.  
 
4.5.2 STAT3: A Potential Functional Readout for Rac1-Bcl-2 Interaction?  
Being inspired by the findings shown earlier that disruption of the Rac1-Bcl-2 
interaction, through the pharmacological inhibitor of Rac1, siRNA-mediated silencing 
of Rac1 or the Bcl-2 BH3 domain peptides, led to sensitization of Bcl-2-
overexpressing cancer cells to conventional chemotherapeutic drugs (Figure 35-39), 
we continue to search for potential druggable targets that lie downstream of Rac1-Bcl-
2 interaction. A large scale of in silico screening was performed and two potential 
targets with high hit score for positive correlation to Rac1 and/or Bcl-2 expression 
levels were identified, which are STAT3, signal transducers and activators of 
transcription 3, and β-catenin, a subunit of the cadherin protein complex involved in 
Wnt signaling pathway (Figure 43). STAT3 is chosen for the follow-up validation 
wet lab experiments here not only because STAT3-activated genes are known to 
promote cell proliferation, survival, angiogenesis and metastasis[348, 350-353, 355] 
but more importantly due to its documented involvement in mitochondrial respiration, 
ROS signaling and Rac1 pathways as discussed earlier[87, 89, 344, 345]. Indeed, 
consistent with what other groups have reported[344], STAT3 was found in the 
mitochondria (Figure 44), where the Rac1-Bcl-2 interacting complex resides. More 
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intriguingly, the activation levels of mitochondrial STAT3, as marked by the 
phosphorylation status of Tyr705, were significantly higher in Bcl-2-overrexpressing 
cancer cells (Figure 44) and this Bcl-2-induced STAT3 activation (Figure 45) was 
shown to be mediated through both Rac1 and Nox activities (Figure 46 & 47). 
Knowing that 1) Bcl-2 overexpression could induce Rac1 activation in cancer cells 
(Figure 3-4); 2) STAT3 phosphorylation on Tyr705 can be stimulated with active 
Rac1 whereas dominant negative Rac1 inhibits STAT3 activation induced by growth 
factors[345]; 3) ROS have been demonstrated to activate STAT3 through either 
activating the corresponding kinases[87] and/or inhibiting the phosphatase[89]; it is 
therefore tempting to hypothesize that in human malignancies with Bcl-2 
overexpression, there is a stimulated Rac1 activation and interaction between the two 
at the mitochondria leading to elevated production of O2.- that results in STAT3 
activation which initiates the downstream transcription of target genes involved in 
proliferation and survival. Subsequent identification of the existence of physical 
interactions between each of these three proteins, Rac1, Bcl-2 and STAT3 in Bcl-2-
overexpressing cancer cells (Figure 48) raised the possibility of a potential tripartite 
interacting complex involved in translating the signals from intra-mitochondrial redox 
changes to the transcription of target genes involved in tumourigenesis. However, 
Rac1, when it is in an active form, has been described to associate with STAT3 via 
the residue 37 in the Switch 1 effector loop[345], which is also implicated in the 
Rac1-Bcl-2 interaction (Figure 20A). It is unlikely that the two proteins Bcl-2 and 
STAT3 will bind to the same spot of Rac1 at the same time; thus alternatively, it 
could be possible that in cancers with Bcl-2 overexpression, the induced GTP loading 
onto Rac1 causes it to interact with STAT3 and leads to the activation of the latter 
probably as a result of redox changes or induced conformational change. With regard 
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to the Bcl-2-STAT3 interaction, whether it has any functional relevance in the whole 
Rac1-Bcl-2 pathway on redox regulation and chemoresistance requires further 
exploration. 
 
However, discrepancy between ™CELLWORKS in silico prediction results 
and wet lab experimental data does exist where the latter demonstrate a correlation 
between expression levels of Bcl-2 and phosphorylation levels of STAT3 (Tyr705) 
instead of the total protein levels as predicted through modeling. This could probably 
be explained by the different cell line models utilized by the virtual prediction and wet 
lab experiments with the former being HCT116 human colorectal carcinoma cells and 
the latter being CEM human chronic myeloid leukemia and HeLa human cervical 
cancer cells. The limitations of modeling on signaling pathways are conceivable by 
virtual of the heterogenous nature of cancer as a disease and the complexities of 
biological signaling system. Indeed, based on the feedback from the wet lab 
experimental data presented in this thesis, optimization of the ™CELLWORKS 
virtual cancer platform is currently being carried out to incorporate 
phosphorylation/dephosphorylation pathways for a better representation of the 
physiological signaling system. Nonethelss, the identification of STAT3 as a potential 
downstream functional player in Rac1-Bcl-2 pathway through in silico modeling by 
™CELLWORKS highlighted a way to screen for targets that have been addicted to in 
cancers with Bcl-2 overexpression, in a faster and more economical manner. Potential 
targets that have positive correlation with Bcl-2 are found through in silico simulation 
and subsequently the effects on cell viability upon inhibition of the identified targets 
in Bcl-2-overexpressing modelled cell line can be checked in the virtual platform via 
apoptotic indicators including cleaved active caspases and cleaved PARP (where 
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PARP is a substrate for active caspase 3)[118, 340, 341]. This is conceptually similar 
to “synthetic lethality screen”. For a given mutation A, if there is an existence of 
another mutation B which is lethal to the organism when mutation A is present, 
mutation B is considered as synthetic lethal with mutation A[396]. In our case here, 
mutation A would be the overexpression of Bcl-2 resulting from the chromosomal 
translocation and gene fusion[125] and B is the target that we are trying to identify 
which cancer cells with Bcl-2 mutation are addicted to for survival. The mutation B 
does not necessary have to be a genetic mutation but instead it could be an inhibition 
of the protein function with a drug-like small molecule[397]. This approach has been 
adopted by various studies where they identified small molecules that are selectively 
synthetic lethal for cancers harbouring a specific oncogenic aberration[398-405].  
 
Furthermore, the identification of STAT3 as a downstream target in Rac1-Bcl-
2 interaction in silico followed by the wet lab experimental validation of the 
association between STAT3 activation and Bcl-2 overexpression (mediated through 
the activity of Rac1 and Nox) opens up another possible avenue to overcome Bcl-2-
induced chemoresistance by targeting STAT3, in addition to the previously suggested 
BH3 mimetics and geranylgeranyl transferase I inhibitor that are out in clinical trials. 
Indeed, a dual inhibitor of NF-κB and STAT3, RTA 402, is currently undergoing 
phase II clinical trial in patients with solid tumours and lymphoid malignancies and 
another STAT3 inhibitor, OPB-31121, has just entered phase I clinical trial for 
advanced solid tumours. It would be then interesting to look at their efficacy vis-a`-vis 
cancers with Bcl-2 overexpression. Further investigation on the potential network 
among the following three parameters: Bcl-2 overexpression, Rac1 activation and 
STAT3 activation, in relation to the disease severity and chemoresistance of cancers 
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would be beneficial in stratifying malignancies where Bcl-2 overexpression presents a 

























CHAPTER 5: CONCLUSION AND FUTURE PERSPECTIVES 
 
 Overexpression of the anti-apoptotic protein Bcl-2, is a major hindrance in the 
therapeutic management of a number of hematopoietic malignancies[282], and recently the 
list of examples in solid tumours is on the increase as well[283-289]. Both the canonical 
mechanism of Bcl-2 to prevent the outer mitochondrial membrane permeabilization[124, 126, 
137, 152, 155, 156] as well as its non-canonical property as a redox regulator[70, 123, 203, 
204], contribute towards chemoresistance[123, 282-289]. The failure of conventional 
chemotherapeutic drugs to induce apoptosis in Bcl-2-overexpressing cancers has 
urged the need to develop targeted therapy for Bcl-2 specifically in the clinical 
settings. Bearing in mind the heterogeneity and complexity of the disease, a strategy 
that is aimed at targeting the critical circuit that is common and essential would be a 
better choice. With regards to this, the emerging role of Bcl-2 as a redox regulator[70, 
123, 203, 204] as well as the significance of ROS in cell fate decision inevitably 
observed across a plethora of cancers[2, 24-32, 47, 82-110, 112-117, 120-122], have 
highlighted the potential of a novel approach that combines the targeting of pro-
oxidant Bcl-2 with conventional therapies[123, 290]. To that end, a better 
understanding on the molecular mechanisms that govern the role of Bcl-2 in inducing 
a pro-oxidant state will aid in the future therapeutic design.  
 
Here in this study, we demonstrated that Bcl-2-induced pro-oxidant state in the 
mitochondria of cancer cells is mediated through the activation of the small GTPase 
Rac1. Subsequently, a physical interaction between these two proteins at the 
mitochondrial membranes is confirmed and the essential binding domains/residues are 
characterized, namely 1) the geranylgeranylation of Rac1 at the C-terminal cysteine 
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residue, which is important for its membrane localization; 2) the GTP loading of Rac1, 
which turns it on to an active state; 3) the Switch 1 effector loop region (in particular 
the residue 37), which is critical for the interaction of Rac1 with Rac GEFs for 
activation; 4) the BH3 domain groove of Bcl-2; 5) the phosphorylation of the flexible 
loop region (in particular at the residue Ser70) adjacent to BH3 domain, which has 
been reported to stabilize the anti-apoptotic activity of Bcl-2[172-174]. In addition, 
the crosstalk between these parameters where Bcl-2 overexpression is capable of 
inducing Rac1 activation that in turn leads to Bcl-2 phosphorylation at Ser70 through 
JNK and redox changes, suggests a possible positive feedback loop in enhancing the 
interaction levels in human malignancies with aberrant Bcl-2. That this interaction is 
contributing towards Bcl-2-mediated pro-oxidant state and chemoresistance was 
demonstrated later in the follow-up tests on combination therapies aimed at disrupting 
the interaction between Bcl-2 and Rac1 together with conventional drugs. Either the 
pharmacological inhibitor of Rac1 or siRNA-mediated silencing of Rac1 as well as 
the synthetic Bcl-2 BH3 domain peptides successfully compromised the pro-oxidant 
state and sensitized Bcl-2-overexpressing cancer cells to routine chemotherapeutic 
agents including etoposide, vincristine and daunorubicin in chronic myeloid 
leukaemia and cervical cancer models. To further assess the functional relevance of 
this interaction in the cancer context, computer simulation driven predictive 
experiments, in collaboration with ™CELLWORKS Group Inc., confirmed the 
tumorigenic nature of Rac1-Bcl-2 pathway as reflected by enhanced phenotypic 
indices of angiogenesis, proliferation, viability, metastasis and tumor volume as well 
as the pro-oxidant intracellular milieu as indicated by a mild but constitutive elevation 
in the O2.- levels upon Bcl-2 and/or Rac1 overexpression, corroborating our wet lab 
experimental data. Interestingly, the signal transducers and activators of transcription 
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3, STAT3, was identified in a large scale computer simulation screening to positively 
correlate with the expression levels of Rac1 and Bcl-2. Indeed, subsequent 
preliminary wet lab experiments hinted that STAT3 activation could be a functional 
readout for Rac1-Bcl-2 interaction leading to transcription of downstream target genes 
involved in proliferation and survival. Our findings that STAT3 activation, as marked 
by phosphorylation at Tyr705, could be induced by Bcl-2-overexpression (mediated 
through Rac1 activation and O2.- production), have opened doors for future 
exploration on STAT3 as a therapeutic target to overcome Bcl-2-mediated 
chemoresistance, in addition to inhibition of Rac1 activity and blockage of Bcl-2 BH3 
domain groove. The schematic diagram of the working model is shown in Figure 49. 
 
Unlike the conventional chemotherapies that have evolved for more than half a 
century[6], the development of targeted therapies is still in its infant stage[2]. Our data 
presented here in the pilot study, revealed for the first time, that the physical 
interaction between Rac1 and Bcl-2 is the culprit in inducing a pro-oxidant and 
chemoresistant milieu in human malignancies with Bcl-2-overexpression. We also 
provided evidence that by disrupting the interaction, the apoptotic execution 
machinery could be re-activated in those cancer cells upon triggers from clinically 
available chemotherapeutic agents. These novel findings pave the way for future 
therapeutic development that combines targeted therapy with conventional drugs, 
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